# What's Actually Known — complete dataset # Source: ClinicalTrials.gov | Last checked: 2026-08-05 # Interventional human studies only. No medical judgment applied. # https://www.whatsactuallyknown.com ## Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide · PNB-0408) URL: https://www.whatsactuallyknown.com/compounds/dihexa Registered human trials: 0 Currently recruiting or running: 0 FDA approved: No Furthest stage reached: none Marketed for: Cognitive enhancement; Memory; Neuroprotection Answer: Dihexa has no registered human trials in the registries we track. Trials on record: none. No registered interventional human study found. --- ## IGF-1 LR3 (Long R3 IGF-1 · LongR3) URL: https://www.whatsactuallyknown.com/compounds/igf-1-lr3 Registered human trials: 0 Currently recruiting or running: 0 FDA approved: No Furthest stage reached: none Marketed for: Muscle growth; Recovery; Nutrient partitioning Answer: IGF-1 LR3 has no registered human trials in the registries we track. Trials on record: none. No registered interventional human study found. --- ## KPV (Lysine-Proline-Valine · alpha-MSH 11-13) URL: https://www.whatsactuallyknown.com/compounds/kpv Registered human trials: 0 Currently recruiting or running: 0 FDA approved: No Furthest stage reached: none Marketed for: Gut inflammation; Skin healing; Immune modulation Answer: KPV has no registered human trials in the registries we track. Trials on record: none. No registered interventional human study found. --- ## Hexarelin (Examorelin) URL: https://www.whatsactuallyknown.com/compounds/hexarelin Registered human trials: 0 Currently recruiting or running: 0 FDA approved: No Furthest stage reached: none Marketed for: Muscle growth; Cardiac protection; Anti-aging Answer: Hexarelin has no registered human trials in the registries we track. Trials on record: none. No registered interventional human study found. --- ## Semax (ACTH(4-10) analogue) URL: https://www.whatsactuallyknown.com/compounds/semax Registered human trials: 0 Currently recruiting or running: 0 FDA approved: No Furthest stage reached: none Marketed for: Cognitive enhancement; Focus & memory; Stroke recovery; Anxiety Answer: Semax has no registered human trials in the registries we track. Trials on record: none. No registered interventional human study found. --- ## Epitalon (Epithalon · Epithalamin) URL: https://www.whatsactuallyknown.com/compounds/epitalon Registered human trials: 0 Currently recruiting or running: 0 FDA approved: No Furthest stage reached: none Marketed for: Telomere lengthening; Longevity / lifespan extension; Sleep & circadian repair Answer: Epitalon has no registered human trials in the registries we track. Trials on record: none. No registered interventional human study found. --- ## Thymalin (Thymus peptide extract) URL: https://www.whatsactuallyknown.com/compounds/thymalin Registered human trials: 0 Currently recruiting or running: 0 FDA approved: No Furthest stage reached: none Marketed for: Immune support; Anti-aging; Longevity Answer: Thymalin has no registered human trials in the registries we track. Trials on record: none. No registered interventional human study found. --- ## GHRP-6 (Growth Hormone Releasing Peptide-6) URL: https://www.whatsactuallyknown.com/compounds/ghrp-6 Registered human trials: 0 Currently recruiting or running: 0 FDA approved: No Furthest stage reached: none Marketed for: Muscle growth; Fat loss; Recovery; Appetite / bulking Answer: GHRP-6 has no registered human trials in the registries we track. Trials on record: none. No registered interventional human study found. --- ## PEG-MGF (Mechano Growth Factor · IGF-1Ec · MGF) URL: https://www.whatsactuallyknown.com/compounds/peg-mgf Registered human trials: 0 Currently recruiting or running: 0 FDA approved: No Furthest stage reached: none Marketed for: Muscle growth; Recovery; Injury repair Answer: PEG-MGF has no registered human trials in the registries we track. Trials on record: none. No registered interventional human study found. --- ## Selank (Tuftsin analogue) URL: https://www.whatsactuallyknown.com/compounds/selank Registered human trials: 0 Currently recruiting or running: 0 FDA approved: No Furthest stage reached: none Marketed for: Anxiety; Cognitive enhancement; Focus; Stress resilience Answer: Selank has no registered human trials in the registries we track. Trials on record: none. No registered interventional human study found. --- ## 5-Amino-1MQ (NNMT inhibitor) URL: https://www.whatsactuallyknown.com/compounds/5-amino-1mq Registered human trials: 0 Currently recruiting or running: 0 FDA approved: No Furthest stage reached: none Marketed for: Fat loss; Metabolic health; Longevity; Muscle preservation Answer: 5-Amino-1MQ has no registered human trials in the registries we track. Trials on record: none. No registered interventional human study found. --- ## Sermorelin (GHRH (1-29)) URL: https://www.whatsactuallyknown.com/compounds/sermorelin Registered human trials: 0 Currently recruiting or running: 0 FDA approved: No — Was FDA-approved for pediatric growth hormone deficiency; withdrawn from the US market in 2008 for commercial reasons, not safety. Furthest stage reached: none Marketed for: Anti-aging; Muscle & body composition; Sleep; Energy Answer: Sermorelin has no registered human trials in the registries we track. Trials on record: none. No registered interventional human study found. --- ## Adipotide (FTPP · Prohibitin-TP01) URL: https://www.whatsactuallyknown.com/compounds/adipotide Registered human trials: 0 Currently recruiting or running: 0 FDA approved: No Furthest stage reached: none Marketed for: Fat loss; Weight management Answer: Adipotide has no registered human trials in the registries we track. Trials on record: none. No registered interventional human study found. --- ## DSIP (Delta Sleep-Inducing Peptide · Emideltide) URL: https://www.whatsactuallyknown.com/compounds/dsip Registered human trials: 0 Currently recruiting or running: 0 FDA approved: No Furthest stage reached: none Marketed for: Sleep quality; Stress & cortisol; Withdrawal support; Pain Answer: DSIP has no registered human trials in the registries we track. Trials on record: none. No registered interventional human study found. --- ## GHRP-2 (Growth Hormone Releasing Peptide-2 · Pralmorelin) URL: https://www.whatsactuallyknown.com/compounds/ghrp-2 Registered human trials: 0 Currently recruiting or running: 0 FDA approved: No Furthest stage reached: none Marketed for: Muscle growth; Fat loss; Sleep quality; Anti-aging Answer: GHRP-2 has no registered human trials in the registries we track. Trials on record: none. No registered interventional human study found. --- ## Melanotan II (MT-2) URL: https://www.whatsactuallyknown.com/compounds/melanotan-2 Registered human trials: 1 Currently recruiting or running: 1 FDA approved: No Furthest stage reached: phase2 Marketed for: Tanning without sun; Libido; Appetite suppression Answer: Melanotan II has 1 registered human trial. Trials on record: - NCT07437560 | Phase 2 | RECRUITING | enrolled 60 Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo Conditions: NonSegmental Vitiligo, Nonsegmental Vitiligo (Stable) https://clinicaltrials.gov/study/NCT07437560 --- ## TB-500 (Thymosin Beta-4 fragment) URL: https://www.whatsactuallyknown.com/compounds/tb-500 Registered human trials: 1 Currently recruiting or running: 1 FDA approved: No Furthest stage reached: phase2 Marketed for: Soft-tissue & tendon recovery; Injury healing; Hair growth Answer: TB-500 has 1 registered human trial. Trials on record: - NCT07487363 | Phase 2 | RECRUITING | enrolled 80 TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD Conditions: Atherosclerotic Cardiovascular Diseases, Endothelial Dysfunction https://clinicaltrials.gov/study/NCT07487363 --- ## CJC-1295 (Modified GRF (1-29) · DAC:GRF) URL: https://www.whatsactuallyknown.com/compounds/cjc-1295 Registered human trials: 1 Currently recruiting or running: 0 FDA approved: No Furthest stage reached: phase2 Marketed for: Muscle growth; Fat loss; Anti-aging via growth hormone; Sleep quality Answer: CJC-1295 has 1 registered human trial. Trials on record: - NCT00267527 | Phase 2 | TERMINATED | enrolled 120 A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity Conditions: Obesity, HIV Infections https://clinicaltrials.gov/study/NCT00267527 --- ## MOTS-c (Mitochondrial ORF of the 12S rRNA type-c) URL: https://www.whatsactuallyknown.com/compounds/mots-c Registered human trials: 1 Currently recruiting or running: 1 FDA approved: No Furthest stage reached: phase2 Marketed for: Metabolic health; Endurance & performance; Longevity Answer: MOTS-c has 1 registered human trial. Trials on record: - NCT07505745 | Phase 2 | RECRUITING | enrolled 120 MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity Conditions: Prediabetes, Insulin Resistance, Overweight/Obesity https://clinicaltrials.gov/study/NCT07505745 --- ## GHK-Cu (Copper peptide) URL: https://www.whatsactuallyknown.com/compounds/ghk-cu Registered human trials: 2 Currently recruiting or running: 2 FDA approved: No Furthest stage reached: phase2 Marketed for: Skin repair & anti-aging; Hair growth; Wound healing Answer: GHK-Cu has 2 registered human trials. Trials on record: - NCT07706361 | Not phased | NOT_YET_RECRUITING | enrolled 100 Two-Part Study of the Effects of the X39 Patch on Circulating GHK and GHK-Cu Levels in Healthy Adults Conditions: GHK and GHK-Cu Blood Levels https://clinicaltrials.gov/study/NCT07706361 - NCT07437586 | Phase 2 | RECRUITING | enrolled 60 Topical GHK-Cu Gel for Acute Skin Wound Healing Conditions: Acute Standardized Cutaneous Wounds (Punch-biopsy Wounds) https://clinicaltrials.gov/study/NCT07437586 --- ## Ipamorelin (Growth hormone secretagogue) URL: https://www.whatsactuallyknown.com/compounds/ipamorelin Registered human trials: 2 Currently recruiting or running: 0 FDA approved: No Furthest stage reached: phase2 Marketed for: Muscle gain; Fat loss; Recovery & sleep; Anti-aging Answer: Ipamorelin has 2 registered human trials. Trials on record: - NCT01280344 | Phase 2 | COMPLETED | enrolled 320 Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function Conditions: Gastrointestinal Dysmotility https://clinicaltrials.gov/study/NCT01280344 - NCT00672074 | Phase 2 | COMPLETED | enrolled 117 Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus Conditions: Ileus https://clinicaltrials.gov/study/NCT00672074 --- ## BPC-157 (Body Protection Compound 157 · Pentadecapeptide) URL: https://www.whatsactuallyknown.com/compounds/bpc-157 Registered human trials: 2 Currently recruiting or running: 1 FDA approved: No Furthest stage reached: phase2 Marketed for: Tendon & ligament repair; Gut healing / "leaky gut"; Systemic anti-aging; Injury recovery Answer: BPC-157 has 2 registered human trials. Trials on record: - NCT07437547 | Phase 2 | RECRUITING | enrolled 120 BPC 157 for Acute Hamstring Muscle Strain Repair Conditions: Hamstring Muscle Strain, Skeletal Muscle Injury https://clinicaltrials.gov/study/NCT07437547 - NCT02637284 | Phase 1 | UNKNOWN | enrolled 42 PCO-02 - Safety and Pharmacokinetics Trial Conditions: Healthy Volunteers https://clinicaltrials.gov/study/NCT02637284 --- ## LL-37 (Cathelicidin · hCAP18 fragment) URL: https://www.whatsactuallyknown.com/compounds/ll-37 Registered human trials: 2 Currently recruiting or running: 0 FDA approved: No Furthest stage reached: phase2 Marketed for: Wound healing; Antimicrobial; Immune support; Skin Answer: LL-37 has 2 registered human trials. Trials on record: - NCT04098562 | Phase 2 | UNKNOWN | enrolled 40 Efficacy of LL-37 Cream on Bacteria Colonization, Inflammation Response and Healing Rate of Diabetic Foot Ulcers Conditions: Diabetic Foot Ulcer https://clinicaltrials.gov/study/NCT04098562 - NCT02225366 | Phase 2 | COMPLETED | enrolled 4 Intratumoral Injections of LL37 for Melanoma Conditions: Melanoma https://clinicaltrials.gov/study/NCT02225366 --- ## AOD-9604 (Anti-Obesity Drug 9604 · HGH fragment 176-191) URL: https://www.whatsactuallyknown.com/compounds/aod-9604 Registered human trials: 3 Currently recruiting or running: 0 FDA approved: No Furthest stage reached: phase2 Marketed for: Fat loss; Weight management; Cartilage repair Answer: AOD-9604 has 3 registered human trials. Trials on record: - NCT03865953 | Phase 2 | COMPLETED | enrolled 53 Oral LAT8881 in Neuropathic Pain Conditions: Neuropathic Pain, Diabetic Peripheral Neuropathy (DPN), Post Herpetic Neuralgia (PHN) https://clinicaltrials.gov/study/NCT03865953 - NCT05298306 | Phase 1 | COMPLETED | enrolled 26 A Two-part Proof-of-Concept Study Assessing the Safety and Efficacy of LAT8881 in Lumbar Radicular Pain Conditions: Radiculopathy Lumbar https://clinicaltrials.gov/study/NCT05298306 - NCT04153409 | Phase 2 | COMPLETED | enrolled 21 A Proof of Concept Study of the Efficacy and Safety of Oral LAT8881 in Acute Migraine Conditions: Acute Migraine https://clinicaltrials.gov/study/NCT04153409 --- ## ACE-031 (Ramatercept · ActRIIB-IgG1) URL: https://www.whatsactuallyknown.com/compounds/ace-031 Registered human trials: 4 Currently recruiting or running: 0 FDA approved: No — Not FDA-approved. Development was discontinued. Furthest stage reached: phase2 Marketed for: Muscle growth; Strength Answer: ACE-031 has 4 registered human trials. Trials on record: - NCT00755638 | Phase 1 | COMPLETED | enrolled 48 A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 (ActRIIB-IgG1)in Healthy Postmenopausal Volunteers Conditions: Muscle Loss https://clinicaltrials.gov/study/NCT00755638 - NCT00952887 | Phase 1 | COMPLETED | enrolled 70 A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 in Healthy Postmenopausal Women Conditions: Muscular Atrophy https://clinicaltrials.gov/study/NCT00952887 - NCT01239758 | Phase 2 | TERMINATED | enrolled 11 Extension Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy Conditions: Duchenne Muscular Dystrophy https://clinicaltrials.gov/study/NCT01239758 - NCT01099761 | Phase 2 | TERMINATED | enrolled 24 Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy Conditions: Duchenne Muscular Dystrophy https://clinicaltrials.gov/study/NCT01099761 --- ## PT-141 (Bremelanotide · Vyleesi) URL: https://www.whatsactuallyknown.com/compounds/pt-141 Registered human trials: 10 Currently recruiting or running: 1 FDA approved: Yes — FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women. Grey-market "PT-141" is not the approved product. Furthest stage reached: phase4 Marketed for: Libido / sexual function; Erectile function; Energy Answer: PT-141 has 10 registered human trials. Trials on record: - NCT00425256 | Phase 2 | COMPLETED | enrolled not posted Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD) Conditions: Sexual Arousal Disorder https://clinicaltrials.gov/study/NCT00425256 - NCT04943068 | Phase 3 | COMPLETED | enrolled 193 A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal) Conditions: Hypoactive Sexual Desire Disorder https://clinicaltrials.gov/study/NCT04943068 - NCT06867835 | Phase 4 | COMPLETED | enrolled 10 Single Dose of Vyleesi in Lactating Female Subjects to Measure the Concentration of Bremelanotide in Breast Milk Conditions: Lactating Mother https://clinicaltrials.gov/study/NCT06867835 - NCT02338960 | Phase 3 | COMPLETED | enrolled 714 2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder Conditions: Hypoactive Sexual Desire Disorder https://clinicaltrials.gov/study/NCT02338960 - NCT01382719 | Phase 2 | COMPLETED | enrolled 612 Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder Conditions: Female Sexual Arousal Disorder, Hypoactive Sexual Desire Disorder https://clinicaltrials.gov/study/NCT01382719 - NCT03973047 | Phase 1 | COMPLETED | enrolled 228 Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran Conditions: Nausea https://clinicaltrials.gov/study/NCT03973047 - NCT02333071 | Phase 3 | COMPLETED | enrolled 723 1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder Conditions: Hypoactive Sexual Desire Disorder https://clinicaltrials.gov/study/NCT02333071 - NCT05709444 | Phase 2 | COMPLETED | enrolled 16 A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease Conditions: Kidney Disease https://clinicaltrials.gov/study/NCT05709444 - NCT06565611 | Phase 2 | ACTIVE_NOT_RECRUITING | enrolled 108 A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity Conditions: Obesity https://clinicaltrials.gov/study/NCT06565611 - NCT04179734 | Phase 4 | COMPLETED | enrolled 40 Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder Conditions: Hypoactive Sexual Desire Disorder https://clinicaltrials.gov/study/NCT04179734 --- ## Tesofensine (NS 2330) URL: https://www.whatsactuallyknown.com/compounds/tesofensine Registered human trials: 13 Currently recruiting or running: 0 FDA approved: No — Not FDA-approved. A marketing application has been under review by Mexico's COFEPRIS since 2019; a favourable technical opinion in 2023 was explicitly not an authorisation, and approval had not been granted as of the most recent company disclosure. Furthest stage reached: phase2 Marketed for: Weight loss; Appetite suppression Answer: Tesofensine has 13 registered human trials. Trials on record: - NCT00153010 | Phase 2 | COMPLETED | enrolled 430 An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type Conditions: Alzheimer Disease https://clinicaltrials.gov/study/NCT00153010 - NCT00428415 | Phase 2 | COMPLETED | enrolled 32 Effect of Tesofensine on Energy Balance in Humans. Conditions: Obesity https://clinicaltrials.gov/study/NCT00428415 - NCT03149445 | Phase 2 | COMPLETED | enrolled 18 Co-administration of Tesofensine/Metoprolol in Subjects With Prader-Willi Syndrome (PWS) Conditions: Confirmed Genetic Diagnosis of Prader-Willi Syndrome https://clinicaltrials.gov/study/NCT03149445 - NCT00394667 | Phase 2 | COMPLETED | enrolled 200 Effect of Tesofensine on Weight Reduction in Patients With Obesity. Conditions: Obesity https://clinicaltrials.gov/study/NCT00394667 - NCT05198362 | Phase 2 | WITHDRAWN | enrolled 0 Study of Tesomet With Open-label Extension in Subjects With Prader-Willi Syndrome Conditions: Prader-Willi Syndrome https://clinicaltrials.gov/study/NCT05198362 - NCT05147415 | Phase 2 | WITHDRAWN | enrolled 0 Study of Tesomet With Open-label Extension in Subjects With Hypothalamic Obesity (HO) Conditions: Hypothalamic Obesity https://clinicaltrials.gov/study/NCT05147415 - NCT03488719 | Phase 1 | COMPLETED | enrolled 37 A Study to Examine the Effect of Tesofensine and Metoprolol on the 24-hour Mean Heart Rate Conditions: Phase 1 https://clinicaltrials.gov/study/NCT03488719 - NCT03845075 | Phase 2 | COMPLETED | enrolled 21 48 Weeks, Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO) Conditions: Hypothalamic Injury-induced Obesity (HIO) https://clinicaltrials.gov/study/NCT03845075 - NCT02737891 | Phase 2 | COMPLETED | enrolled 60 Safety and Efficacy Study of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes Mellitus Conditions: Type 2 Diabetes Mellitus https://clinicaltrials.gov/study/NCT02737891 - NCT03286829 | Phase 1 | COMPLETED | enrolled 60 Study to Investigate the Pharmacokinetic Profile Conditions: Healthy Male Subjects https://clinicaltrials.gov/study/NCT03286829 - NCT00148512 | Phase 2 | COMPLETED | enrolled 254 A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Study of NS 2330 (Tesofensine) (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations Conditions: Parkinson Disease https://clinicaltrials.gov/study/NCT00148512 - NCT00481104 | Phase 2 | COMPLETED | enrolled 140 Evaluation of Long Term Safety of Tesofensine in Patients With Obesity Conditions: Obesity https://clinicaltrials.gov/study/NCT00481104 - NCT00148486 | Phase 2 | COMPLETED | enrolled 261 A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE) Conditions: Parkinson Disease https://clinicaltrials.gov/study/NCT00148486 --- ## Ibutamoren (MK-677 · MK-0677 · LUM-201 · Nutrobal) URL: https://www.whatsactuallyknown.com/compounds/ibutamoren Registered human trials: 13 Currently recruiting or running: 4 FDA approved: No — Not FDA-approved for any indication. Furthest stage reached: phase3 Marketed for: Muscle growth; Sleep quality; Appetite; Anti-aging Answer: Ibutamoren has 13 registered human trials. Trials on record: - NCT01343641 | Phase 2 | WITHDRAWN | enrolled 0 Growth Hormone Secretagogue MK-0677's Effect on Lean Body Mass in Chronic Kidney Disease Stage 4/5 Subjects Conditions: Chronic Kidney Disease, Kidney Disease https://clinicaltrials.gov/study/NCT01343641 - NCT06948214 | Phase 3 | RECRUITING | enrolled 150 Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency Conditions: Growth Hormone Deficiency (GHD) https://clinicaltrials.gov/study/NCT06948214 - NCT04614337 | Phase 2 | COMPLETED | enrolled 104 Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial) Conditions: Growth Hormone Deficiency https://clinicaltrials.gov/study/NCT04614337 - NCT00474279 | Phase 2 | COMPLETED | enrolled 72 Effects of an Oral GH Secretagogue (MK-677) on Body Composition and Functional Ability of Older Adults Conditions: Aging https://clinicaltrials.gov/study/NCT00474279 - NCT00074529 | Phase 2 | COMPLETED | enrolled 512 Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED) Conditions: Alzheimer's Disease https://clinicaltrials.gov/study/NCT00074529 - NCT05364684 | Phase 2 | COMPLETED | enrolled 12 The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease Conditions: NAFLD, Nonalcoholic Fatty Liver, NASH - Nonalcoholic Steatohepatitis https://clinicaltrials.gov/study/NCT05364684 - NCT05796440 | Phase 2 | ENROLLING_BY_INVITATION | enrolled 60 A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211) Conditions: Growth Hormone Deficiency https://clinicaltrials.gov/study/NCT05796440 - NCT05250063 | Phase 2 | COMPLETED | enrolled 15 Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213) Conditions: Growth Hormone Deficiency https://clinicaltrials.gov/study/NCT05250063 - NCT07129759 | Phase 3 | NOT_YET_RECRUITING | enrolled 150 Phase 3 Long Term Safety Extension Study of LUM-201 in Children With Growth Hormone Deficiency Conditions: Growth Hormone Deficiency (GHD) https://clinicaltrials.gov/study/NCT07129759 - NCT00116129 | Phase 2 | COMPLETED | enrolled 64 Efficacy and Safety of an Oral Growth Hormone Drug in the Treatment of Fibromyalgia Conditions: Fibromyalgia https://clinicaltrials.gov/study/NCT00116129 - NCT00128115 | Phase 2 | TERMINATED | enrolled 83 Treatment of Sarcopenia in Post-Hip Fracture Patients (0677-032) Conditions: Hip Fracture https://clinicaltrials.gov/study/NCT00128115 - NCT04806854 | Phase 2 | ACTIVE_NOT_RECRUITING | enrolled 24 PK and PD Study of LUM-201 in Children With Idiopathic Growth Hormone Deficiency: (OraGrowtH212) Conditions: Growth Hormone Deficiency https://clinicaltrials.gov/study/NCT04806854 - NCT00395291 | Not phased | COMPLETED | enrolled 49 Growth Hormone Secretagogue MK-0677 Effect on IGF-1 Levels in ESRD Patients Conditions: Chronic Kidney Disease, End Stage Renal Disease https://clinicaltrials.gov/study/NCT00395291 --- ## Tesamorelin (Egrifta) URL: https://www.whatsactuallyknown.com/compounds/tesamorelin Registered human trials: 16 Currently recruiting or running: 3 FDA approved: Yes — FDA-approved for HIV-associated lipodystrophy. Furthest stage reached: phase4 Marketed for: Visceral fat loss; Anti-aging; Cognition Answer: Tesamorelin has 16 registered human trials. Trials on record: - NCT00608023 | Phase 3 | COMPLETED | enrolled 263 TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy Conditions: Lipodystrophy, HIV Infections https://clinicaltrials.gov/study/NCT00608023 - NCT07481734 | Phase 2 | RECRUITING | enrolled 120 Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study) Conditions: Metabolic Associated Steatotic Liver Disease, Nonalcoholic Steatohepatitis, Hepatic Steatosis https://clinicaltrials.gov/study/NCT07481734 - NCT02553603 | Phase 1 | COMPLETED | enrolled 22 The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment Conditions: Mild Cognitive Impairment https://clinicaltrials.gov/study/NCT02553603 - NCT03226821 | Phase 4 | TERMINATED | enrolled 6 Body Composition and Adipose Tissue in HIV Conditions: HIV Lipodystrophy Syndrome, Growth Hormone Deficiency, Body Composition https://clinicaltrials.gov/study/NCT03226821 - NCT00850564 | Not phased | COMPLETED | enrolled 15 Effect of Short Term Growth Hormone Releasing Hormone in Healthy Men Conditions: Healthy Volunteers https://clinicaltrials.gov/study/NCT00850564 - NCT03150511 | Phase 2 | RECRUITING | enrolled 36 Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury Conditions: Peripheral Nerve Injuries https://clinicaltrials.gov/study/NCT03150511 - NCT01591902 | Phase 4 | TERMINATED | enrolled 129 Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA® Conditions: Diabetic Retinopathy, HIV https://clinicaltrials.gov/study/NCT01591902 - NCT02012556 | Phase 1 | COMPLETED | enrolled 18 Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients Conditions: HIV https://clinicaltrials.gov/study/NCT02012556 - NCT01388920 | Phase 2 | TERMINATED | enrolled 3 Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting Conditions: Chronic Obstructive Pulmonary Disease (COPD) https://clinicaltrials.gov/study/NCT01388920 - NCT03375788 | Phase 2 | COMPLETED | enrolled 51 Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk Conditions: Non-Alcoholic Fatty Liver Disease, Obesity, Obesity, Abdominal, Liver Fat, Fatty Liver https://clinicaltrials.gov/study/NCT03375788 - NCT01263717 | Not phased | COMPLETED | enrolled 54 Effects of Growth Hormone Releasing Hormone in HIV Conditions: HIV, HIV Lipodystrophy https://clinicaltrials.gov/study/NCT01263717 - NCT01632592 | Not phased | WITHDRAWN | enrolled 0 Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone Analogue Conditions: Abdominal Obesity https://clinicaltrials.gov/study/NCT01632592 - NCT02196831 | Not phased | COMPLETED | enrolled 61 Tesamorelin Effects on Liver Fat and Histology in HIV Conditions: Human Immunodeficiency Virus (HIV), Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH) https://clinicaltrials.gov/study/NCT02196831 - NCT06554717 | Phase 2 | RECRUITING | enrolled 100 Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV Conditions: HIV-1-infection, Frailty, Impaired Physical Function, Abdominal Obesity, Aging https://clinicaltrials.gov/study/NCT06554717 - NCT02572323 | Phase 2 | COMPLETED | enrolled 73 Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons Conditions: Mild Cognitive Impairment https://clinicaltrials.gov/study/NCT02572323 - NCT02931474 | Phase 2 | WITHDRAWN | enrolled 0 Impact of GHRH on Sleep Promotion and Endocrine Regulation in Service Members Who Sustained a Traumatic Brain Injury and Have Current Insomnia Conditions: Sleep Disorder, Traumatic Brain Injury https://clinicaltrials.gov/study/NCT02931474 --- ## Kisspeptin-10 (Kisspeptin 112-121 · Metastin 45-54 · KP-10) URL: https://www.whatsactuallyknown.com/compounds/kisspeptin-10 Registered human trials: 17 Currently recruiting or running: 3 FDA approved: No Furthest stage reached: phase3 Marketed for: Testosterone support; Fertility; Libido Answer: Kisspeptin-10 has 17 registered human trials. Trials on record: - NCT07224490 | Phase 1 | RECRUITING | enrolled 40 Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease Conditions: Reproductive Disorder, Neurodegeneration, SARS-CoV 2, Long COVID https://clinicaltrials.gov/study/NCT07224490 - NCT00914823 | Phase 1 | COMPLETED | enrolled 256 Kisspeptin Administration in the Adult Conditions: Hypogonadotropic Hypogonadism, Kallmann Syndrome, GnRH Deficiency, PCOS, Polycystic Ovarian Syndrome, Hyperprolactinemia https://clinicaltrials.gov/study/NCT00914823 - NCT03771326 | Phase 3 | COMPLETED | enrolled 14 KP-10 and Insulin Secretion in Men Conditions: Kisspeptin Action on Insulin in Healthy Normal Men, Kisspeptin Action on Insulin in Obese Diabetic Men https://clinicaltrials.gov/study/NCT03771326 - NCT03315325 | Phase 3 | COMPLETED | enrolled 15 Age-dependent Changes in the Responsiveness of Hypothalamic Pituitary Gonadal Axis in Men Conditions: Sterility, Reproductive https://clinicaltrials.gov/study/NCT03315325 - NCT02956447 | Phase 2 | COMPLETED | enrolled 36 Administration of Kisspeptin in Patients With Hyperprolactinemia Conditions: Hyperprolactinemia, Hypogonadism https://clinicaltrials.gov/study/NCT02956447 - NCT03286517 | Phase 3 | COMPLETED | enrolled 30 Link Between the Sensitivity of Kisspeptin Signalling and Pubertal Onset in Boys. Conditions: Reproductive Physiological Phenomena https://clinicaltrials.gov/study/NCT03286517 - NCT01952782 | Phase 1 | COMPLETED | enrolled 61 Neuropeptides in Human Reproduction Conditions: Hypogonadotropic Hypogonadism https://clinicaltrials.gov/study/NCT01952782 - NCT07224438 | Phase 2 | RECRUITING | enrolled 20 Kisspeptin Administration Subcutaneously to Patients With Hypothalamic Amenorrhea Conditions: Hypothalamic Amenorrhea, Hypogonadotropic Hypogonadism https://clinicaltrials.gov/study/NCT07224438 - NCT05901467 | Phase 1 | TERMINATED | enrolled 16 Recall by Genotype: Neuropeptide Stimulation Conditions: Reproductive Disorder https://clinicaltrials.gov/study/NCT05901467 - NCT05971849 | Phase 1 | COMPLETED | enrolled 8 Dampening the Reproductive Axis With Continuous Kisspeptin Conditions: Reproductive Disorder, PCOS, Polycystic Ovary Syndrome https://clinicaltrials.gov/study/NCT05971849 - NCT05633966 | Phase 1 | COMPLETED | enrolled 13 Kisspeptin Administration Subcutaneously to Patients With Reproductive Disorders Conditions: Hypothalamic Amenorrhea, Hypogonadotropic Hypogonadism https://clinicaltrials.gov/study/NCT05633966 - NCT04648969 | Phase 2 | COMPLETED | enrolled 18 Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism Conditions: Hypogonadotropic Hypogonadism https://clinicaltrials.gov/study/NCT04648969 - NCT05896293 | Phase 2 | RECRUITING | enrolled 36 Kisspeptin Administration Subcutaneously to Patients With IHH Conditions: Hypogonadotropic Hypogonadism https://clinicaltrials.gov/study/NCT05896293 - NCT01438073 | Phase 1 | COMPLETED | enrolled 96 Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling Conditions: Hypogonadotropic Hypogonadism, Healthy Postmenopausal Women, Agonadism https://clinicaltrials.gov/study/NCT01438073 - NCT01438034 | Phase 1 | COMPLETED | enrolled 24 Kisspeptin in the Evaluation of Delayed Puberty Conditions: Delayed Puberty, Kallmann Syndrome, Hypogonadotropic Hypogonadism, GnRH Deficiency https://clinicaltrials.gov/study/NCT01438034 - NCT04532801 | Phase 1 | WITHDRAWN | enrolled 0 Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Physiologic Mixed Meal Tolerance Conditions: Insulin, Glucose, Healthy Volunteers, Women, Pregnancy https://clinicaltrials.gov/study/NCT04532801 - NCT05456854 | Phase 1 | WITHDRAWN | enrolled 0 Evaluation of Kisspeptin Stimulated Insulin Secretion With Hyperglycemic Clamp Conditions: Metabolic Disease https://clinicaltrials.gov/study/NCT05456854 --- ## Thymosin β4 (Tβ4 · TB4 full protein) URL: https://www.whatsactuallyknown.com/compounds/thymosin-beta-4 Registered human trials: 18 Currently recruiting or running: 3 FDA approved: No Furthest stage reached: phase3 Marketed for: Tissue repair; Wound healing; Hair growth; Cardiac recovery Answer: Thymosin β4 has 18 registered human trials. Trials on record: - NCT00743769 | Phase 1 | WITHDRAWN | enrolled 0 A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy Volunteers Conditions: Myocardial Infarction, Myocardial Ischemia https://clinicaltrials.gov/study/NCT00743769 - NCT00382174 | Phase 2 | COMPLETED | enrolled 72 Study of Thymosin Beta 4 in Patients With Pressure Ulcers Conditions: Pressure Ulcers https://clinicaltrials.gov/study/NCT00382174 - NCT07487363 | Phase 2 | RECRUITING | enrolled 80 TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD Conditions: Atherosclerotic Cardiovascular Diseases, Endothelial Dysfunction https://clinicaltrials.gov/study/NCT07487363 - NCT02974907 | Phase 3 | COMPLETED | enrolled 601 Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2 Conditions: Dry Eye Syndrome https://clinicaltrials.gov/study/NCT02974907 - NCT01311518 | Phase 2 | WITHDRAWN | enrolled 0 A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction Conditions: Acute Myocardial Infarction, ST Elevation Myocardial Infarction, STEMI https://clinicaltrials.gov/study/NCT01311518 - NCT04555824 | Phase 1 | COMPLETED | enrolled 54 A Phase 1a Study of Thymosin Beta 4 in Healthy Volunteers Conditions: Healthy https://clinicaltrials.gov/study/NCT04555824 - NCT05984134 | Phase 2 | COMPLETED | enrolled 90 Efficacy and Safety Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction Conditions: Acute Myocardial Infarction https://clinicaltrials.gov/study/NCT05984134 - NCT04555850 | Phase 1 | COMPLETED | enrolled 30 A Phase 1b Study of Thymosin Beta 4 in Healthy Volunteers Conditions: Healthy https://clinicaltrials.gov/study/NCT04555850 - NCT00832091 | Phase 2 | COMPLETED | enrolled 72 Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers Conditions: Venous Stasis Ulcers https://clinicaltrials.gov/study/NCT00832091 - NCT03937882 | Phase 3 | COMPLETED | enrolled 700 Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3 Conditions: Dry Eye Syndromes, Dry Eye https://clinicaltrials.gov/study/NCT03937882 - NCT02597803 | Phase 3 | COMPLETED | enrolled 317 Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1 Conditions: Dry Eye Syndrome https://clinicaltrials.gov/study/NCT02597803 - NCT05555589 | Phase 3 | RECRUITING | enrolled 70 Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2 Conditions: Neurotrophic Keratopathy https://clinicaltrials.gov/study/NCT05555589 - NCT05485818 | Phase 2 | COMPLETED | enrolled 62 Safety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.Infarction Conditions: Acute Myocardial Infarction https://clinicaltrials.gov/study/NCT05485818 - NCT01387347 | Phase 2 | COMPLETED | enrolled 72 Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry Eye Conditions: Dry Eye Syndrome, Dry Eye https://clinicaltrials.gov/study/NCT01387347 - NCT01393132 | Phase 2 | COMPLETED | enrolled 9 Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye Conditions: Dry Eye, Sjogren's Syndrome, Graft vs. Host Disease https://clinicaltrials.gov/study/NCT01393132 - NCT00311766 | Phase 2 | TERMINATED | enrolled 30 A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa Conditions: Epidermolysis Bullosa https://clinicaltrials.gov/study/NCT00311766 - NCT00598871 | Phase 2 | TERMINATED | enrolled 12 A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal Wounds Conditions: Diabetes https://clinicaltrials.gov/study/NCT00598871 - NCT07586865 | Phase 2 | NOT_YET_RECRUITING | enrolled 189 Recombinant Human Thymosin Beta 4 for Injection(NL005) for Acute Myocardial Infarction Conditions: Acute Myocardial Infarction (AMI), Acute Myocardial Infarction of Anterior Wall, Acute Myocardial Infarction With ST Elevation, Acute Myocardial Infarction of Left Ventricle, Acute Myocardial Infarction With ST Segment Elevation https://clinicaltrials.gov/study/NCT07586865 --- ## Retatrutide (LY3437943 · triple agonist) URL: https://www.whatsactuallyknown.com/compounds/retatrutide Registered human trials: 19 Currently recruiting or running: 11 FDA approved: No — Not FDA-approved. Still in clinical development — grey-market sale is happening ahead of any approval. Furthest stage reached: phase3 Marketed for: Weight loss; Blood sugar control; Metabolic health Answer: Retatrutide has 19 registered human trials. Trials on record: - NCT05929079 | Phase 3 | COMPLETED | enrolled 1152 A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight Conditions: Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea https://clinicaltrials.gov/study/NCT05929079 - NCT07467447 | Phase 2 | RECRUITING | enrolled 300 Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight Conditions: Obesity https://clinicaltrials.gov/study/NCT07467447 - NCT05882045 | Phase 3 | COMPLETED | enrolled 1946 A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease Conditions: Obesity, Cardiovascular Diseases https://clinicaltrials.gov/study/NCT05882045 - NCT07035093 | Phase 3 | ACTIVE_NOT_RECRUITING | enrolled 586 A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain Conditions: Obesity, Overweight, Chronic Low Back Pain (CLBP) https://clinicaltrials.gov/study/NCT07035093 - NCT07165028 | Phase 3 | RECRUITING | enrolled 4500 A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease https://clinicaltrials.gov/study/NCT07165028 - NCT05931367 | Phase 3 | COMPLETED | enrolled 445 A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee Conditions: Obesity, Overweight, Osteo Arthritis Knee https://clinicaltrials.gov/study/NCT05931367 - NCT06662383 | Phase 3 | ACTIVE_NOT_RECRUITING | enrolled 800 A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity Conditions: Obesity https://clinicaltrials.gov/study/NCT06662383 - NCT06383390 | Phase 3 | ACTIVE_NOT_RECRUITING | enrolled 10000 The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD) https://clinicaltrials.gov/study/NCT06383390 - NCT06260722 | Phase 3 | ACTIVE_NOT_RECRUITING | enrolled 1250 Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT06260722 - NCT07232719 | Phase 3 | ACTIVE_NOT_RECRUITING | enrolled 250 A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight Conditions: Obesity, Overweight https://clinicaltrials.gov/study/NCT07232719 - NCT06808802 | Phase 1 | COMPLETED | enrolled 30 To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants Conditions: Healthy https://clinicaltrials.gov/study/NCT06808802 - NCT06859268 | Phase 3 | ACTIVE_NOT_RECRUITING | enrolled 643 A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity Conditions: Obesity https://clinicaltrials.gov/study/NCT06859268 - NCT06982859 | Phase 1 | ACTIVE_NOT_RECRUITING | enrolled 95 A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus Conditions: Diabetes Mellitus, Insulin Sensitivity https://clinicaltrials.gov/study/NCT06982859 - NCT06297603 | Phase 3 | ACTIVE_NOT_RECRUITING | enrolled 320 Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3) Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT06297603 - NCT05936151 | Phase 2 | COMPLETED | enrolled 146 A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes Conditions: Overweight or Obesity, CKD, Type 2 Diabetes https://clinicaltrials.gov/study/NCT05936151 - NCT06354660 | Phase 3 | COMPLETED | enrolled 537 Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1) Conditions: Diabetes Type 2 https://clinicaltrials.gov/study/NCT06354660 - NCT05929066 | Phase 3 | COMPLETED | enrolled 2335 A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight Conditions: Obesity, Overweight, Osteoarthritis, Knee, Obstructive Sleep Apnea https://clinicaltrials.gov/study/NCT05929066 - NCT07357415 | Phase 3 | ACTIVE_NOT_RECRUITING | enrolled 600 A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight Conditions: Obesity, Overweight https://clinicaltrials.gov/study/NCT07357415 - NCT06982846 | Phase 1 | COMPLETED | enrolled 80 A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia Conditions: Type 2 Diabetes Mellitus https://clinicaltrials.gov/study/NCT06982846 --- ## Afamelanotide (Scenesse · Melanotan-1 · Melanotan I) URL: https://www.whatsactuallyknown.com/compounds/afamelanotide Registered human trials: 22 Currently recruiting or running: 1 FDA approved: Yes — FDA-approved (Scenesse, 2019) to increase pain-free light exposure in adults with erythropoietic protoporphyria. Not approved for tanning. Furthest stage reached: phase3 Marketed for: Tanning; Photoprotection; Skin pigmentation Answer: Afamelanotide has 22 registered human trials. Trials on record: - NCT00979745 | Phase 3 | COMPLETED | enrolled 74 Phase III Confirmatory Study in Erythropoietic Protoporphyria (EPP) Conditions: Erythropoietic Protoporphyria https://clinicaltrials.gov/study/NCT00979745 - NCT04525157 | Phase 2 | COMPLETED | enrolled 21 Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Phototherapy in the Treatment of Nonsegmental Vitiligo (NSV) Conditions: Vitiligo https://clinicaltrials.gov/study/NCT04525157 - NCT01382589 | Phase 2 | COMPLETED | enrolled 15 Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo Conditions: Vitiligo https://clinicaltrials.gov/study/NCT01382589 - NCT06388642 | Phase 2 | COMPLETED | enrolled 28 Pharmacokinetics of Afamelanotide in Erythropoietic Protoporphyria Patients Conditions: Erythropoietic Protoporphyria https://clinicaltrials.gov/study/NCT06388642 - NCT00829192 | Phase 2 | UNKNOWN | enrolled 200 Phase II AK Study in Organ Transplant Patients Conditions: Actinic Keratoses, Carcinoma, Squamous Cell, Organ Transplant Recipients https://clinicaltrials.gov/study/NCT00829192 - NCT03634137 | Phase 1 | COMPLETED | enrolled 24 Implant Pharmacokinetic and Pharmacodynamic Study Conditions: Healthy https://clinicaltrials.gov/study/NCT03634137 - NCT01097044 | Phase 2 | COMPLETED | enrolled 77 Phase II Confirmatory Study in Erythropoietic Protoporphyria (EPP) Conditions: Erythropoietic Protoporphyria https://clinicaltrials.gov/study/NCT01097044 - NCT04053270 | Phase 3 | COMPLETED | enrolled 100 Multicentre Phase III Erythropoietic Protoporphyria Study Conditions: Erythropoietic Protoporphyria https://clinicaltrials.gov/study/NCT04053270 - NCT01430195 | Phase 1 | COMPLETED | enrolled 56 Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo (NSV) Conditions: Vitiligo https://clinicaltrials.gov/study/NCT01430195 - NCT04943159 | Phase 2 | COMPLETED | enrolled 3 Afamelanotide in Patients Suffering With Acne Vulgaris Conditions: Acne Vulgaris https://clinicaltrials.gov/study/NCT04943159 - NCT04578496 | Phase 3 | COMPLETED | enrolled 16 A Safety Extension Study in Patients With Erythropoietic Protoporphyria (EPP) Conditions: Erythropoietic Protoporphyria https://clinicaltrials.gov/study/NCT04578496 - NCT04704713 | Phase 3 | COMPLETED | enrolled 31 Afamelanotide in Patients Suffering From Polymorphic Light Eruption (PLE) Conditions: Polymorphic Light Eruption https://clinicaltrials.gov/study/NCT04704713 - NCT05854784 | Phase 2 | COMPLETED | enrolled 6 Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Variegate Porphyria (VP) Conditions: Variegate Porphyria https://clinicaltrials.gov/study/NCT05854784 - NCT05368857 | Phase 1 | COMPLETED | enrolled 10 DNA Repair Capacity of Afamelanotide on Ultraviolet Radiation-induced DNA Damage in Healthy Volunteers Conditions: Afamelanotide Evaluated as Skin DNA Repair Therapy in Healthy Volunteers https://clinicaltrials.gov/study/NCT05368857 - NCT04962503 | Phase 2 | COMPLETED | enrolled 6 A Proof of Concept Study to Evaluate the Safety of Afamelanotide in Patients With Acute Arterial Ischaemic Stroke (AIS) Conditions: Arterial Ischemic Stroke https://clinicaltrials.gov/study/NCT04962503 - NCT06109649 | Phase 3 | ACTIVE_NOT_RECRUITING | enrolled 200 A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo Conditions: Vitiligo https://clinicaltrials.gov/study/NCT06109649 - NCT04425746 | Phase 2 | COMPLETED | enrolled 16 Afamelanotide as Adjunctive Therapy in Patients Undergoing Photodynamic Therapy (PDT) Utilising Porfimer Sodium Conditions: Patients Undergoing Photodynamic Therapy Using Porfimer Sodium https://clinicaltrials.gov/study/NCT04425746 - NCT05159752 | Phase 2 | UNKNOWN | enrolled 6 A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum (XP) Conditions: Xeroderma Pigmentosum https://clinicaltrials.gov/study/NCT05159752 - NCT01605136 | Phase 3 | COMPLETED | enrolled 93 Phase III Confirmatory Study in Erythropoietic Protoporphyria Conditions: Erythropoietic Protoporphyria https://clinicaltrials.gov/study/NCT01605136 - NCT05370235 | Phase 2 | UNKNOWN | enrolled 6 A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum C and V Conditions: Xeroderma Pigmentosum https://clinicaltrials.gov/study/NCT05370235 - NCT00859534 | Phase 2 | COMPLETED | enrolled 5 Phase II Solar Urticaria (SU) Pilot Study Conditions: Solar Urticaria https://clinicaltrials.gov/study/NCT00859534 - NCT05210582 | Phase 2 | UNKNOWN | enrolled 6 A Study to Assess the Changes in Pigmentation and Safety of Afamelanotide in Patients With Vitiligo on the Face Conditions: Vitiligo https://clinicaltrials.gov/study/NCT05210582 --- ## Elamipretide (SS-31 · MTP-131 · Bendavia · Forzinity) URL: https://www.whatsactuallyknown.com/compounds/elamipretide Registered human trials: 29 Currently recruiting or running: 3 FDA approved: Yes — FDA-approved (Forzinity, accelerated approval) to improve muscle strength in Barth syndrome, an ultra-rare mitochondrial disease. Approval does not extend to general anti-aging use. Furthest stage reached: phase4 Marketed for: Mitochondrial function; Anti-aging; Energy; Muscle performance Answer: Elamipretide has 29 registered human trials. Trials on record: - NCT05162768 | Phase 3 | COMPLETED | enrolled 102 Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD) Conditions: Mitochondrial Myopathies, Mitochondrial Pathology, Mitochondrial DNA Mutation, Mitochondrial Diseases, Mitochondrial DNA Deletion, Mitochondrial DNA Depletion, Mitochondrial Metabolism Defect, Mitochondrial Complex I Deficiency https://clinicaltrials.gov/study/NCT05162768 - NCT01754818 | Phase 1 | COMPLETED | enrolled 30 A Phase 1 Study Examining the Pharmacokinetics and Tolerability of a Single Oral Dose of Bendavia (MTP-131) Conditions: Healthy https://clinicaltrials.gov/study/NCT01754818 - NCT02653391 | Phase 2 | COMPLETED | enrolled 22 A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED) Conditions: Fuchs' Corneal Endothelial Dystrophy (FCED) https://clinicaltrials.gov/study/NCT02653391 - NCT02805790 | Phase 2 | COMPLETED | enrolled 30 Safety, Tolerability, Efficacy of MTP-131 for Treatment of Mitochondrial Disease in Subjects From the MMPOWER Study Conditions: Primary Mitochondrial Disease https://clinicaltrials.gov/study/NCT02805790 - NCT02693119 | Phase 2 | COMPLETED | enrolled 12 A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for Treatment of Leber's Hereditary Optic Neuropathy Conditions: Leber's Hereditary Optic Neuropathy https://clinicaltrials.gov/study/NCT02693119 - NCT02976038 | Phase 2 | TERMINATED | enrolled 28 Open-Label Extension Trial to Characterize the Long-term Safety and Tolerability of Elamipretide in Subjects With Genetically Confirmed Primary Mitochondrial Myopathy (PMM) Conditions: Primary Mitochondrial Disease https://clinicaltrials.gov/study/NCT02976038 - NCT01572909 | Phase 2 | COMPLETED | enrolled 300 Evaluation of Myocardial Effects of MTP-131 for Reducing Reperfusion Injury in Patients With Acute Coronary Events Conditions: Reperfusion Injury, STEMI https://clinicaltrials.gov/study/NCT01572909 - NCT01755858 | Phase 2 | TERMINATED | enrolled 16 Effects of Intravenous Bendavia™ on Reperfusion Injury in Patients Undergoing Angioplasty of the Renal Artery Conditions: Renal Artery Obstruction, Hypertension, Renovascular, Ischemia Reperfusion Injury https://clinicaltrials.gov/study/NCT01755858 - NCT03891875 | Phase 2 | COMPLETED | enrolled 176 ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA Conditions: Age-related Macular Degeneration https://clinicaltrials.gov/study/NCT03891875 - NCT02436447 | Phase 1 | COMPLETED | enrolled 23 A Phase 1 Study Investigating the Safety and Pharmacokinetics of Repeat-dose Intravenous Infusion of MTP-131 in Subjects With Impaired Renal Function Conditions: Normal and Impaired Renal Function https://clinicaltrials.gov/study/NCT02436447 - NCT03098797 | Phase 3 | COMPLETED | enrolled 12 A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome Conditions: Barth Syndrome https://clinicaltrials.gov/study/NCT03098797 - NCT02848313 | Phase 1 | COMPLETED | enrolled 40 An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration Conditions: Age-Related Macular Degeneration https://clinicaltrials.gov/study/NCT02848313 - NCT02245620 | Phase 2 | COMPLETED | enrolled 41 A Phase 2 Study to Evaluate the Impact of MTP-131 (Bendavia™) on Skeletal Muscle Function in Elderly Conditions: Skeletal Muscle Mitochondrial Dysfunction in the Elderly https://clinicaltrials.gov/study/NCT02245620 - NCT05168774 | Phase 2 | COMPLETED | enrolled 20 FRDA Investigator Initiated Study (IIS) With Elamipretide Conditions: Friedreich Ataxia https://clinicaltrials.gov/study/NCT05168774 - NCT02388464 | Phase 1 | COMPLETED | enrolled 36 A Study Investigating the Safety, Tolerability, and Pharmacokinetics of MTP-131 in Subjects With Congestive Heart Failure Conditions: Congestive Heart Failure https://clinicaltrials.gov/study/NCT02388464 - NCT01115920 | Phase 1 | COMPLETED | enrolled 40 Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of Intravenous (IV) Infusion of MTP-131 (Bendavia™) in Healthy Adults Conditions: Healthy https://clinicaltrials.gov/study/NCT01115920 - NCT02788747 | Phase 2 | COMPLETED | enrolled 71 Effect of Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection Fraction Conditions: Heart Failure https://clinicaltrials.gov/study/NCT02788747 - NCT07531251 | Phase 4 | RECRUITING | enrolled 48 Clinical Trial in Patients With Barth Syndrome- 4TAZPower Conditions: Barth Syndrome https://clinicaltrials.gov/study/NCT07531251 - NCT02388529 | Phase 1 | WITHDRAWN | enrolled 0 A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Bendavia™ (MTP-131) in Patients With Heart Failure Conditions: Heart Failure https://clinicaltrials.gov/study/NCT02388529 - NCT01513200 | Phase 1 | COMPLETED | enrolled 12 Study to Assess the Pharmacodynamic Effects of Unfractionated Heparin (UFH) in Healthy Volunteers With and Without Bendavia Conditions: Healthy Volunteers https://clinicaltrials.gov/study/NCT01513200 - NCT02314299 | Phase 2 | COMPLETED | enrolled 20 A Study of MTP-131 Topical Ophthalmic Solution in Subjects With Diabetic Macular Edema and Non-Exudative Intermediate Age-related Macular Degeneration Conditions: Diabetic Macular Edema, Age-related Macular Degeneration https://clinicaltrials.gov/study/NCT02314299 - NCT02914665 | Phase 2 | COMPLETED | enrolled 308 A Phase 2 Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Due to Heart Failure Conditions: Heart Failure https://clinicaltrials.gov/study/NCT02914665 - NCT03323749 | Phase 3 | TERMINATED | enrolled 218 A Trial to Evaluate Safety and Efficacy of Elamipretide Primary Mitochondrial Myopathy Followed by Open-Label Extension Conditions: Primary Mitochondrial Myopathy https://clinicaltrials.gov/study/NCT03323749 - NCT01518985 | Phase 1 | COMPLETED | enrolled 6 The Impact of Intravenous Bendavia™ on Endothelial Reactivity Dysfunction in Cigarette Smoking Conditions: Healthy Volunteers https://clinicaltrials.gov/study/NCT01518985 - NCT06373731 | Phase 3 | ACTIVE_NOT_RECRUITING | enrolled 313 ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD) Conditions: Age Related Macular Degeneration (ARMD) https://clinicaltrials.gov/study/NCT06373731 - NCT02367014 | Phase 2 | COMPLETED | enrolled 36 Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial Myopathy Conditions: Mitochondrial Myopathy https://clinicaltrials.gov/study/NCT02367014 - NCT01786915 | Phase 1 | COMPLETED | enrolled 30 Safety and Pharmacokinetic (PK) Study of Oral Bendavia Administered for 7 Days Conditions: Healthy Volunteers https://clinicaltrials.gov/study/NCT01786915 - NCT02814097 | Phase 2 | COMPLETED | enrolled 46 A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction Conditions: Chronic Heart Failure https://clinicaltrials.gov/study/NCT02814097 - NCT07275424 | Phase 2 | RECRUITING | enrolled 30 Study of Healthy Aging and Physical Function With Elamipretide Conditions: Aging, Healthy https://clinicaltrials.gov/study/NCT07275424 --- ## Survodutide (BI 456906) URL: https://www.whatsactuallyknown.com/compounds/survodutide Registered human trials: 31 Currently recruiting or running: 6 FDA approved: No — Not FDA-approved. Investigational, with fast-track designation for MASH. Furthest stage reached: phase3 Marketed for: Weight loss; Metabolic health; Liver fat Answer: Survodutide has 31 registered human trials. Trials on record: - NCT06352424 | Phase 1 | COMPLETED | enrolled 23 A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity Conditions: Obesity https://clinicaltrials.gov/study/NCT06352424 - NCT07206290 | Phase 2 | NOT_YET_RECRUITING | enrolled 120 Albuminuria Reduction Study With Survodutide Treatment in Kidney Disease Conditions: Chronic Kidney Disease https://clinicaltrials.gov/study/NCT07206290 - NCT05751226 | Phase 1 | COMPLETED | enrolled 88 A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906 Conditions: Healthy, Obesity https://clinicaltrials.gov/study/NCT05751226 - NCT06772532 | Phase 1 | COMPLETED | enrolled 30 A Study in Healthy People to Compare How 3 Different Formulations of Survodutide Are Taken up in the Body Conditions: Healthy https://clinicaltrials.gov/study/NCT06772532 - NCT05896384 | Phase 1 | COMPLETED | enrolled 32 A Study in Women With Overweight or Obesity to Test Whether Different Doses of BI 456906 Influence the Amount of a Contraceptive in the Blood Conditions: Healthy https://clinicaltrials.gov/study/NCT05896384 - NCT06492135 | Phase 1 | COMPLETED | enrolled 30 A Study in Chinese People With Overweight or Obesity to Test How Different Doses of Survodutide Are Taken up in the Body Conditions: Overweight, Obesity https://clinicaltrials.gov/study/NCT06492135 - NCT04771273 | Phase 2 | COMPLETED | enrolled 295 A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3) Conditions: Non-alcoholic Steatohepatitis (NASH) https://clinicaltrials.gov/study/NCT04771273 - NCT06632457 | Phase 3 | RECRUITING | enrolled 1590 LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis Conditions: Metabolic Dysfunction Associated Steatohepatitis https://clinicaltrials.gov/study/NCT06632457 - NCT06214741 | Phase 3 | COMPLETED | enrolled 307 A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight Conditions: Obesity, Overweight https://clinicaltrials.gov/study/NCT06214741 - NCT06176365 | Phase 3 | COMPLETED | enrolled 274 A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease Conditions: Obesity https://clinicaltrials.gov/study/NCT06176365 - NCT06066515 | Phase 3 | COMPLETED | enrolled 726 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight Conditions: Obesity https://clinicaltrials.gov/study/NCT06066515 - NCT03591718 | Phase 1 | COMPLETED | enrolled 131 A Study to Test Different Doses of BI 456906 in Patients With Obesity Conditions: Obesity https://clinicaltrials.gov/study/NCT03591718 - NCT05296733 | Phase 1 | COMPLETED | enrolled 82 A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906 Conditions: Healthy, Liver Diseases, Obesity https://clinicaltrials.gov/study/NCT05296733 - NCT06632444 | Phase 3 | RECRUITING | enrolled 1800 LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis Conditions: Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis https://clinicaltrials.gov/study/NCT06632444 - NCT04384081 | Phase 1 | COMPLETED | enrolled 37 A Study to Test How Different Doses of BI 456906 Are Tolerated in Japanese Men With a Body Mass Index (BMI) Between 23 and 40 kg/m2 Conditions: Healthy https://clinicaltrials.gov/study/NCT04384081 - NCT06564441 | Phase 1 | COMPLETED | enrolled 34 A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity Conditions: Overweight, Obesity https://clinicaltrials.gov/study/NCT06564441 - NCT04667377 | Phase 2 | COMPLETED | enrolled 387 A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight Conditions: Obesity https://clinicaltrials.gov/study/NCT04667377 - NCT06745284 | Phase 1 | ACTIVE_NOT_RECRUITING | enrolled 64 A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity Conditions: Obesity https://clinicaltrials.gov/study/NCT06745284 - NCT05202353 | Phase 1 | ACTIVE_NOT_RECRUITING | enrolled 29 A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver Conditions: Obesity https://clinicaltrials.gov/study/NCT05202353 - NCT06309992 | Phase 3 | COMPLETED | enrolled 218 A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD) Conditions: Obesity, Non-Alcoholic SteatoHepatitis (NASH) https://clinicaltrials.gov/study/NCT06309992 - NCT07407348 | Phase 1 | RECRUITING | enrolled 80 A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body Conditions: Healthy, Obesity, Overweight https://clinicaltrials.gov/study/NCT07407348 - NCT05421338 | Phase 1 | COMPLETED | enrolled 6 A Study in Healthy Men to Test How BI 456906 is Processed in the Body Conditions: Healthy https://clinicaltrials.gov/study/NCT05421338 - NCT06077864 | Phase 3 | COMPLETED | enrolled 5531 A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) Conditions: Obesity https://clinicaltrials.gov/study/NCT06077864 - NCT07221591 | Phase 1 | COMPLETED | enrolled 100 A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body Conditions: Healthy https://clinicaltrials.gov/study/NCT07221591 - NCT06352411 | Phase 1 | COMPLETED | enrolled 42 A Study to Test How BI 456906 is Taken up in the Blood of People With and Without Kidney Problems Conditions: Healthy, Renal Impairment https://clinicaltrials.gov/study/NCT06352411 - NCT07071974 | Phase 1 | COMPLETED | enrolled 16 A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body Conditions: Healthy https://clinicaltrials.gov/study/NCT07071974 - NCT06200467 | Phase 1 | COMPLETED | enrolled 110 A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or Obesity Conditions: Overweight, Obesity https://clinicaltrials.gov/study/NCT06200467 - NCT04153929 | Phase 2 | COMPLETED | enrolled 413 A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes. Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT04153929 - NCT06066528 | Phase 3 | COMPLETED | enrolled 755 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight Conditions: Obesity, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT06066528 - NCT07413913 | Phase 1 | COMPLETED | enrolled 56 A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-like Injector Conditions: Healthy, Obesity https://clinicaltrials.gov/study/NCT07413913 - NCT03175211 | Phase 1 | COMPLETED | enrolled 20 Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 456906 in Healthy Male Volunteers Conditions: Healthy https://clinicaltrials.gov/study/NCT03175211 --- ## Cerebrolysin (Porcine brain peptide preparation) URL: https://www.whatsactuallyknown.com/compounds/cerebrolysin Registered human trials: 37 Currently recruiting or running: 8 FDA approved: No — Not FDA-approved for any indication. Approved in Russia, China, Austria and other countries for stroke and dementia — a different regulatory system with different evidence standards. Furthest stage reached: phase4 Marketed for: Cognitive enhancement; Brain recovery; Neuroprotection; Anti-aging Answer: Cerebrolysin has 37 registered human trials. Trials on record: - NCT02149875 | Phase 2 | COMPLETED | enrolled 84 Dl-3-n-butylphthalide and Cerebrolysin Treatment in Acute Ischemic Stroke Conditions: Acute Cerebral Stroke Within 12 Hours for the First Time https://clinicaltrials.gov/study/NCT02149875 - NCT04913831 | Phase 4 | UNKNOWN | enrolled 30 Effects of Cerebrolysin on Level of Consciousness and Brain Metabolism in Disorder of Consciousness After Stroke: Single Center Randomized Controlled Study Conditions: Stroke https://clinicaltrials.gov/study/NCT04913831 - NCT06677502 | Not phased | ENROLLING_BY_INVITATION | enrolled 500 Cerebrolysin in Critically Ill Patients With Delirium Conditions: Cognitive Impairment https://clinicaltrials.gov/study/NCT06677502 - NCT03506841 | Phase 1 | COMPLETED | enrolled 60 Cerebrolysin and Neurodevelopment in Preterm Infants Conditions: Infant Development, Cerebral Palsy, Preterm Infant https://clinicaltrials.gov/study/NCT03506841 - NCT01388738 | Phase 3 | COMPLETED | enrolled 30 Navigation Brain Stimulation for Evaluation of the Neuroprotective Drug Efficiency in Patients After Ischemic Stroke. Conditions: Stroke https://clinicaltrials.gov/study/NCT01388738 - NCT01059461 | Phase 2 | COMPLETED | enrolled 40 Study of Cerebrolysin for Treatment of Infants With History of Neonatal Hypoxic Ischemic Encephalopathy Conditions: Hypoxic-Ischemic Encephalopathy https://clinicaltrials.gov/study/NCT01059461 - NCT01787123 | Phase 3 | COMPLETED | enrolled 50 Randomized, Double-blind, Placebo-controlled Trial to Investigate Safety and Efficacy of Cerebrolysin™ in Patients With Aneurysmal Subarachnoid Hemorrhage Conditions: Subarachnoid Hemorrhage, Intracranial Aneurysm, Delayed Cerebral Ischemia, Delayed Ischemic Neurological Deficit https://clinicaltrials.gov/study/NCT01787123 - NCT04904341 | Phase 3 | UNKNOWN | enrolled 50 Efficacy of Cerebrolysin Treatment as an add-on Therapy to Mechanical Thrombectomy in Acute Ischemic Stroke. Conditions: Stroke, Ischemic, Stroke, Acute, Stroke Sequelae https://clinicaltrials.gov/study/NCT04904341 - NCT04427241 | Phase 4 | RECRUITING | enrolled 12 Efficacy and Safety of Cerebrolysin on Prolonged Disorders of Consciousness Conditions: Disorder of Consciousness, Hemorrhagic Stroke https://clinicaltrials.gov/study/NCT04427241 - NCT06489925 | Phase 1 | UNKNOWN | enrolled 20 Cerebrolysin as an Add-On Therapy to Standard Treatment of Basilar Artery Occlusion Conditions: Basilar Artery Occlusion, Posterior Circulation Brain Infarction https://clinicaltrials.gov/study/NCT06489925 - NCT06899464 | Phase 4 | NOT_YET_RECRUITING | enrolled 30 Safety and Feasibility of Using Cerebrolysin in the Treatment of Primary Intracerebral Hemorrhage - a Prospective Randomized Open Blinded End-point Trial Conditions: Intracerebral Hemorrhage, Hemorrhagic Stroke, Intracerebral, Hemorrhagic Stroke, Stroke https://clinicaltrials.gov/study/NCT06899464 - NCT04751136 | Phase 2 | COMPLETED | enrolled 64 the Effect of Cerebrolysin on Physical and Mental Functions of Down Syndrome Conditions: Down Syndrome https://clinicaltrials.gov/study/NCT04751136 - NCT00868283 | Phase 4 | COMPLETED | enrolled 1071 The Safety and Efficacy of Cerebrolysin in Patients With Acute Ischemic Stroke Conditions: Ischemic Stroke https://clinicaltrials.gov/study/NCT00868283 - NCT06208540 | Phase 4 | COMPLETED | enrolled 160 Clinical Characteristics and Treatment of Anosmia and Ageusia Due to SARS-CoV2 Variants Conditions: Post-covid-19 Persistent Smell and Taste Disorders https://clinicaltrials.gov/study/NCT06208540 - NCT06078215 | Phase 4 | UNKNOWN | enrolled 350 CERebrolysine Effect on Blood-brain Barrier in acUte Ischemic Stroke Conditions: Acute Ischemic Stroke https://clinicaltrials.gov/study/NCT06078215 - NCT02768571 | Phase 4 | COMPLETED | enrolled 80 Effects of Cerebrolysin Combined With Rehabilitation on Motor Recovery in Stroke Conditions: Stroke https://clinicaltrials.gov/study/NCT02768571 - NCT02581371 | Phase 4 | UNKNOWN | enrolled 30 Comprehensive Reparative Therapy in Ischemic Stroke COMplex Repair in Ischemic Stroke-Arm Conditions: Ischemic Stroke https://clinicaltrials.gov/study/NCT02581371 - NCT06897176 | Phase 4 | RECRUITING | enrolled 40 Effects of Cerebrolysin on Language Ability in Non-fluent Aphasia Patients After Stroke: A Randomized, Placebo-controlled, Double-blinded, Single Center Study Conditions: Stroke https://clinicaltrials.gov/study/NCT06897176 - NCT05288465 | Not phased | COMPLETED | enrolled 5 Hair Repigmentation During Cerebrolysin Therapy Conditions: Hair Problems https://clinicaltrials.gov/study/NCT05288465 - NCT06339411 | Phase 1 | NOT_YET_RECRUITING | enrolled 100 Exploring Cerebrolysin in Late Thrombectomy for Stroke: Blood-brain Barrier Biomarkers and Imaging Insights Conditions: Acute Ischemic Stroke https://clinicaltrials.gov/study/NCT06339411 - NCT00840671 | Phase 3 | COMPLETED | enrolled 119 Combined Treatment With Alteplase (Rt-PA) and Cerebrolysin® in Acute Ischemic Hemispheric Stroke Conditions: Stroke https://clinicaltrials.gov/study/NCT00840671 - NCT05864677 | Not phased | UNKNOWN | enrolled 100 Cerebrolysin in Prevention of Postoperative Delirium in Cardiac Surgery Conditions: Neurocognitive Disorders, Surgery-Complications, Critical Illness, Brain Damage, Cardiac Disease https://clinicaltrials.gov/study/NCT05864677 - NCT02116348 | Phase 2 | UNKNOWN | enrolled 100 Cerebrolysin Neural Repair Therapy in Children With Traumatic Brain Injury and Cerebral Palsy Conditions: Cerebral Palsy Children, Children With Traumatic Brain Injury, Mental Handicap, Delayed Speech Development https://clinicaltrials.gov/study/NCT02116348 - NCT06273020 | Phase 4 | UNKNOWN | enrolled 60 Effect of Cerebrolysin on the Blood Brain Barrier in Patients With Diabetes and Ischemic Stroke Conditions: Ischemic Stroke, Acute, Diabetes Mellitus, Type 2, Blood Brain Barrier https://clinicaltrials.gov/study/NCT06273020 - NCT01996761 | Phase 4 | COMPLETED | enrolled 71 Effects of Cerebrolysin on Motor Recovery in Patients With Subacute Stroke Conditions: Cerebrolysin https://clinicaltrials.gov/study/NCT01996761 - NCT05124353 | Phase 3 | UNKNOWN | enrolled 100 Early Administration of Cerebrolysin on the Outcome of Patients With Acute Stroke Undergoing EVT Conditions: Stroke, Acute, Ischemic https://clinicaltrials.gov/study/NCT05124353 - NCT00947531 | Phase 4 | COMPLETED | enrolled 242 A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia Conditions: Vascular Dementia https://clinicaltrials.gov/study/NCT00947531 - NCT05755997 | Phase 2 | ACTIVE_NOT_RECRUITING | enrolled 30 CERebrolysin In CADASIL Conditions: Cadasil https://clinicaltrials.gov/study/NCT05755997 - NCT06052787 | Phase 3 | COMPLETED | enrolled 150 Combined Cerebrolysin and Amantadine Sulfate Administration for Patients With Traumatic Brain Injury in the ICU Conditions: Traumatic Brain Injury https://clinicaltrials.gov/study/NCT06052787 - NCT07043686 | Not phased | RECRUITING | enrolled 30 Cerebrolysin in Early Stroke Rehabilitation - Tertiary Study Conditions: Ischemic Stroke, Acute, Rehabilitation Outcome, Cerebrolysin https://clinicaltrials.gov/study/NCT07043686 - NCT01606111 | Phase 4 | TERMINATED | enrolled 46 The CAPTAIN Trial: Cerebrolysin Asian Pacific Trial in Acute Brain Injury and Neurorecovery Conditions: Traumatic Brain Injury https://clinicaltrials.gov/study/NCT01606111 - NCT00911807 | Phase 2 | COMPLETED | enrolled 217 Comparative Study to Test Safety and Efficacy of Neurotrophic and Cholinergic Treatment of Alzheimer's Disease Conditions: Alzheimer Disease https://clinicaltrials.gov/study/NCT00911807 - NCT01822951 | Phase 4 | WITHDRAWN | enrolled 0 Cerebrolysin Compared to Donepezil in Patients With Mild to Moderate Dementia of Alzheimer's Type (DAT) Conditions: Alzheimer Disease https://clinicaltrials.gov/study/NCT01822951 - NCT04124367 | Phase 2 | TERMINATED | enrolled 4 IMPULSE - StIMulation of Brain Plasticity to Improve Upper Limb Recovery After StrokE Conditions: Chronic Stroke, Subacute Stroke https://clinicaltrials.gov/study/NCT04124367 - NCT06070753 | Not phased | UNKNOWN | enrolled 30 A Prospective, Trial About Safety and Efficacy of Combined Treatment With Cerebrolysin in Acute Ischemic Hemispheric Stroke Patients Undergoing EndoVascular Treatment (EVT) Conditions: Acute Ischemic Stroke https://clinicaltrials.gov/study/NCT06070753 - NCT04830943 | Phase 3 | COMPLETED | enrolled 250 Cerebrolycin for Treatment of Covid-related Anosmia and Ageusia Conditions: Covid19 Related Anosmia and Aguesia https://clinicaltrials.gov/study/NCT04830943 - NCT05821075 | Phase 2 | RECRUITING | enrolled 90 Efficacy of Prednisolone Versus Cerebrolysin in the Treatment of Bell's Palsy Conditions: Bell Palsy https://clinicaltrials.gov/study/NCT05821075 --- ## Mazdutide (IBI362 · LY3305677) URL: https://www.whatsactuallyknown.com/compounds/mazdutide Registered human trials: 37 Currently recruiting or running: 19 FDA approved: No — Not FDA-approved. Approved by China's NMPA for obesity; not filed with the FDA or EMA. Furthest stage reached: phase4 Marketed for: Weight loss; Blood sugar control; Metabolic health Answer: Mazdutide has 37 registered human trials. Trials on record: - NCT06124807 | Phase 2 | COMPLETED | enrolled 179 A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight Conditions: Obesity, Overweight and Obesity https://clinicaltrials.gov/study/NCT06124807 - NCT04904913 | Phase 2 | COMPLETED | enrolled 328 A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects Conditions: Overweight/ Obesity https://clinicaltrials.gov/study/NCT04904913 - NCT07517042 | Not phased | RECRUITING | enrolled 420 ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management Conditions: Obesity, Weight Control https://clinicaltrials.gov/study/NCT07517042 - NCT07135141 | Not phased | NOT_YET_RECRUITING | enrolled 256 Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity Conditions: Severe Obesity https://clinicaltrials.gov/study/NCT07135141 - NCT05607680 | Phase 3 | COMPLETED | enrolled 610 A Study of IBI362 in Participants With Obesity or Overweight Conditions: Obesity Or Overweight https://clinicaltrials.gov/study/NCT05607680 - NCT02972645 | Phase 1 | COMPLETED | enrolled 66 A Study of LY3305677 in Healthy Participants Conditions: Healthy https://clinicaltrials.gov/study/NCT02972645 - NCT07713992 | Not phased | NOT_YET_RECRUITING | enrolled 72 Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide Conditions: Type 2 Diabetes Mellitus (T2DM), Nonalcoholic Fatty Liver Disease (NAFLD) With History of Diabetes Melitus https://clinicaltrials.gov/study/NCT07713992 - NCT04773977 | Phase 1 | COMPLETED | enrolled 24 Clinical Study of IBI362 in Healthy Chinese Male Subjects Conditions: Overweight/Obesity https://clinicaltrials.gov/study/NCT04773977 - NCT06931028 | Phase 3 | RECRUITING | enrolled 260 A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2 Conditions: Sleep Apnea, Obstructive, Obesity https://clinicaltrials.gov/study/NCT06931028 - NCT07718126 | Phase 3 | NOT_YET_RECRUITING | enrolled 60 Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME) Conditions: Metabolic Dysfunction-Associated Steatohepatitis, Hepatic Steatosis, Living Liver Donors https://clinicaltrials.gov/study/NCT07718126 - NCT06817356 | Phase 2 | COMPLETED | enrolled 308 A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder Conditions: Alcohol Use Disorder https://clinicaltrials.gov/study/NCT06817356 - NCT07000955 | Phase 2 | ACTIVE_NOT_RECRUITING | enrolled 98 Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity Conditions: Obesity https://clinicaltrials.gov/study/NCT07000955 - NCT06536023 | Phase 1 | COMPLETED | enrolled 36 This is a Study to Evaluate the Pharmacokinetics and Safety of IBI362 in Chinese Adolescents With Obesity Conditions: Adolescents With Obesity https://clinicaltrials.gov/study/NCT06536023 - NCT06143956 | Phase 2 | RECRUITING | enrolled 1481 A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight Conditions: Obesity, Overweight https://clinicaltrials.gov/study/NCT06143956 - NCT07417306 | Phase 3 | NOT_YET_RECRUITING | enrolled 912 A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT07417306 - NCT07083154 | Phase 3 | RECRUITING | enrolled 420 GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study) Conditions: Dementia, Mild, Mild Cognitive Impairment, Type 2 Diabetes https://clinicaltrials.gov/study/NCT07083154 - NCT06937749 | Phase 2 | RECRUITING | enrolled 165 A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) Conditions: Metabolic Dysfunction-associated Steatohepatitis (MASH) https://clinicaltrials.gov/study/NCT06937749 - NCT05623839 | Phase 1 | COMPLETED | enrolled 32 A Study of LY3305677 in Participants With Obesity Or Overweight Conditions: Overweight, Obesity https://clinicaltrials.gov/study/NCT05623839 - NCT05606913 | Phase 3 | COMPLETED | enrolled 731 A Study of IBI362 in Participants With Type 2 Diabetes Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT05606913 - NCT03928379 | Phase 1 | COMPLETED | enrolled 24 A Study of LY3305677 in Participants With Type 2 Diabetes Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT03928379 - NCT07469800 | Phase 3 | RECRUITING | enrolled 336 Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity Conditions: Overweight, Obesity, Hypertensive https://clinicaltrials.gov/study/NCT07469800 - NCT05815680 | Phase 1 | COMPLETED | enrolled 48 A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects Conditions: Overweight Subjects, Obese Subjects https://clinicaltrials.gov/study/NCT05815680 - NCT07633639 | Not phased | RECRUITING | enrolled 200 GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity Conditions: Obesity https://clinicaltrials.gov/study/NCT07633639 - NCT07657676 | Phase 4 | NOT_YET_RECRUITING | enrolled 116 Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity Conditions: Obesity & Overweight, Coronary Heart Disease https://clinicaltrials.gov/study/NCT07657676 - NCT06164873 | Phase 3 | ACTIVE_NOT_RECRUITING | enrolled 462 A Study of IBI362 9 mg in Chinese Adults With Obesity Conditions: Obesity https://clinicaltrials.gov/study/NCT06164873 - NCT06519656 | Phase 2 | RECRUITING | enrolled 50 Efficacy of Mazdutide for Treating PCOS Conditions: Polycystic Ovary Syndrome https://clinicaltrials.gov/study/NCT06519656 - NCT07255209 | Phase 3 | RECRUITING | enrolled 180 A Study of IBI362 in Chinese Adolescents With Obesity or Overweight Conditions: Adolescents With Obesity or Overweight With Weight-Related Comorbidities https://clinicaltrials.gov/study/NCT07255209 - NCT04440345 | Phase 2 | COMPLETED | enrolled 60 Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects Conditions: Overweight or Obesity https://clinicaltrials.gov/study/NCT04440345 - NCT07654062 | Phase 4 | NOT_YET_RECRUITING | enrolled 150 Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE) Conditions: Prediabetes, Impaired Fasting Glucose, Impaired Glucose Tolerance (Prediabetes) https://clinicaltrials.gov/study/NCT07654062 - NCT05628311 | Phase 3 | COMPLETED | enrolled 319 A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT05628311 - NCT06862908 | Phase 2 | RECRUITING | enrolled 141 A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity Conditions: Obesity, Heart Failure With Preserved Ejection Fraction (HFPEF), Heart Failure With Mildly Reduced Ejection Fraction https://clinicaltrials.gov/study/NCT06862908 - NCT06184568 | Phase 3 | COMPLETED | enrolled 349 A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity Conditions: Type 2 Diabetes, Obesity https://clinicaltrials.gov/study/NCT06184568 - NCT04466904 | Phase 2 | COMPLETED | enrolled 42 Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT04466904 - NCT06884293 | Phase 3 | ACTIVE_NOT_RECRUITING | enrolled 479 A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD） Conditions: Overweight, Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) https://clinicaltrials.gov/study/NCT06884293 - NCT03325387 | Phase 1 | COMPLETED | enrolled 56 A Study of Multiple Doses of LY3305677 in Healthy Participants Conditions: Healthy https://clinicaltrials.gov/study/NCT03325387 - NCT05793450 | Phase 1 | COMPLETED | enrolled 20 Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment Conditions: Renal Impairment https://clinicaltrials.gov/study/NCT05793450 - NCT04965506 | Phase 2 | COMPLETED | enrolled 252 A Study of IBI362 in Chinese Patients With Type 2 Diabetes Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT04965506 --- ## Cagrilintide (AM833 · NNC0174-1213) URL: https://www.whatsactuallyknown.com/compounds/cagrilintide Registered human trials: 40 Currently recruiting or running: 19 FDA approved: No Furthest stage reached: phase3 Marketed for: Weight loss; Appetite suppression; Metabolic health Answer: Cagrilintide has 40 registered human trials. Trials on record: - NCT05804162 | Phase 1 | COMPLETED | enrolled 107 A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy Participants Conditions: Obesity https://clinicaltrials.gov/study/NCT05804162 - NCT06409130 | Phase 2 | COMPLETED | enrolled 270 Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease Conditions: Alcohol-related Liver Disease https://clinicaltrials.gov/study/NCT06409130 - NCT07605052 | Phase 1 | ACTIVE_NOT_RECRUITING | enrolled 50 A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight Conditions: Overweight, Obesity https://clinicaltrials.gov/study/NCT07605052 - NCT05813925 | Phase 3 | COMPLETED | enrolled 331 A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight Conditions: Obesity or Overweight https://clinicaltrials.gov/study/NCT05813925 - NCT07184086 | Phase 1 | RECRUITING | enrolled 80 A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet Conditions: Obesity https://clinicaltrials.gov/study/NCT07184086 - NCT07745504 | Phase 3 | NOT_YET_RECRUITING | enrolled 285 A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight Conditions: Overweight, Obesity https://clinicaltrials.gov/study/NCT07745504 - NCT06534411 | Phase 3 | COMPLETED | enrolled 1023 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT06534411 - NCT07253285 | Phase 3 | RECRUITING | enrolled 460 A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight Conditions: Overweight, Obesity https://clinicaltrials.gov/study/NCT07253285 - NCT05996848 | Phase 3 | COMPLETED | enrolled 300 A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight Conditions: Obesity or Overweight https://clinicaltrials.gov/study/NCT05996848 - NCT07011667 | Phase 3 | ACTIVE_NOT_RECRUITING | enrolled 609 A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term Conditions: Obesity https://clinicaltrials.gov/study/NCT07011667 - NCT07411560 | Phase 1 | RECRUITING | enrolled 100 A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese Conditions: Overweight, Obese https://clinicaltrials.gov/study/NCT07411560 - NCT06797869 | Phase 2 | ACTIVE_NOT_RECRUITING | enrolled 142 A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy Conditions: Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy https://clinicaltrials.gov/study/NCT06797869 - NCT06131372 | Phase 2 | COMPLETED | enrolled 626 A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo Conditions: Chronic Kidney Disease, Type 2 Diabetes, Obesity https://clinicaltrials.gov/study/NCT06131372 - NCT06719011 | Phase 1 | RECRUITING | enrolled 177 A Study on How NNC0174-1213 Works in People With Overweight or Obesity. Conditions: Obesity, Overweight https://clinicaltrials.gov/study/NCT06719011 - NCT05564104 | Phase 1 | COMPLETED | enrolled 32 A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Works in Participants With Reduced Liver Function and in Healthy Participants With Normal Liver Function and How Cagrilintide is Absorbed and Used by the Body Conditions: Hepatic Impairment, Healthy Volunteers https://clinicaltrials.gov/study/NCT05564104 - NCT06131437 | Phase 3 | COMPLETED | enrolled 809 A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight Conditions: Obesity https://clinicaltrials.gov/study/NCT06131437 - NCT05567796 | Phase 3 | ACTIVE_NOT_RECRUITING | enrolled 3400 A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight Conditions: Obesity https://clinicaltrials.gov/study/NCT05567796 - NCT06716307 | Phase 1 | COMPLETED | enrolled 18 A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity Conditions: Obesity https://clinicaltrials.gov/study/NCT06716307 - NCT07607587 | Phase 1 | RECRUITING | enrolled 114 Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events Conditions: Obesity, Overweight https://clinicaltrials.gov/study/NCT07607587 - NCT06289504 | Phase 1 | COMPLETED | enrolled 34 A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight Conditions: Obesity https://clinicaltrials.gov/study/NCT06289504 - NCT06780449 | Phase 3 | ACTIVE_NOT_RECRUITING | enrolled 400 A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity Conditions: Obesity https://clinicaltrials.gov/study/NCT06780449 - NCT05394519 | Phase 3 | COMPLETED | enrolled 1200 A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight Conditions: Overweight, Obesity, Type 2 Diabetes Mellitus https://clinicaltrials.gov/study/NCT05394519 - NCT07597018 | Phase 1 | RECRUITING | enrolled 234 A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity Conditions: Obesity, Overweight https://clinicaltrials.gov/study/NCT07597018 - NCT04940078 | Phase 1 | COMPLETED | enrolled 40 A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity Conditions: Obesity & Overweight https://clinicaltrials.gov/study/NCT04940078 - NCT07010432 | Phase 1 | RECRUITING | enrolled 144 The Role of the Amylin Analogue Cagrilintide in Bone Metabolism Conditions: Obesity https://clinicaltrials.gov/study/NCT07010432 - NCT04982575 | Phase 2 | COMPLETED | enrolled 92 Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT04982575 - NCT06267092 | Phase 1 | COMPLETED | enrolled 164 A Study of How CagriSema Works on Appetite in People With Excess Body Weight Conditions: Overweight, Obesity https://clinicaltrials.gov/study/NCT06267092 - NCT06388187 | Phase 3 | COMPLETED | enrolled 300 A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight Conditions: Obesity https://clinicaltrials.gov/study/NCT06388187 - NCT07220642 | Phase 3 | ACTIVE_NOT_RECRUITING | enrolled 300 Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide Conditions: Obesity, Overweight https://clinicaltrials.gov/study/NCT07220642 - NCT06207877 | Phase 1 | COMPLETED | enrolled 62 A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight Conditions: Obesity https://clinicaltrials.gov/study/NCT06207877 - NCT06221969 | Phase 3 | COMPLETED | enrolled 1024 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT06221969 - NCT07282613 | Phase 3 | NOT_YET_RECRUITING | enrolled 80 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT07282613 - NCT06403761 | Phase 1 | COMPLETED | enrolled 158 Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT06403761 - NCT06323174 | Phase 3 | COMPLETED | enrolled 189 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT06323174 - NCT07527195 | Phase 1 | RECRUITING | enrolled 100 Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health) Conditions: Obesity https://clinicaltrials.gov/study/NCT07527195 - NCT06065540 | Phase 3 | COMPLETED | enrolled 2734 A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor Conditions: Type 2 Diabetes Mellitus https://clinicaltrials.gov/study/NCT06065540 - NCT06323161 | Phase 3 | COMPLETED | enrolled 274 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT06323161 - NCT07557953 | Phase 1 | RECRUITING | enrolled 120 A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity Conditions: Overweight, Obesity https://clinicaltrials.gov/study/NCT07557953 - NCT07220759 | Phase 3 | ACTIVE_NOT_RECRUITING | enrolled 330 Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide Conditions: Overweight, Obesity, Type 2 Diabetes https://clinicaltrials.gov/study/NCT07220759 - NCT05669755 | Phase 3 | ACTIVE_NOT_RECRUITING | enrolled 7101 REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels Conditions: Cardiovascular Disease https://clinicaltrials.gov/study/NCT05669755 --- ## Thymosin α1 (Thymalfasin · Zadaxin · Tα1) URL: https://www.whatsactuallyknown.com/compounds/thymosin-alpha-1 Registered human trials: 53 Currently recruiting or running: 15 FDA approved: No — Not FDA-approved in the United States. Approved in over 30 other countries, mostly for hepatitis B and as a vaccine adjuvant. Furthest stage reached: phase4 Marketed for: Autoimmune conditions; Immune system regulation; Chronic infection; Longevity / immune aging Answer: Thymosin α1 has 53 registered human trials. Trials on record: - NCT00580450 | Phase 2 | UNKNOWN | enrolled 9 Thymosin Alfa 1 in Recipients of Allogeneic Hematopoietic Transplantation for Hematological Malignancies Conditions: Hematological Malignancies https://clinicaltrials.gov/study/NCT00580450 - NCT06056804 | Phase 2 | ACTIVE_NOT_RECRUITING | enrolled 20 Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer Conditions: Locally Advanced Rectal Cancer https://clinicaltrials.gov/study/NCT06056804 - NCT02542930 | Phase 2 | WITHDRAWN | enrolled 0 Abscopal Effect for Metastatic Non-small Cell Lung Cancer. Conditions: Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Radiotherapy, Thymalfasin https://clinicaltrials.gov/study/NCT02542930 - NCT05487469 | Not phased | UNKNOWN | enrolled 200 Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass Conditions: Rheumatic Heart Disease, Cardiopulmonary Bypass, Immunotherapy https://clinicaltrials.gov/study/NCT05487469 - NCT02545751 | Phase 2 | UNKNOWN | enrolled 29 SBRT Combined With Thymalfasin for Metastatic Esophageal Cancer Conditions: Esophageal Cancer, Metastatic Esophageal Cancer, Stereotactic Body Radiation Therapy, Thymalfasin https://clinicaltrials.gov/study/NCT02545751 - NCT04524169 | Phase 4 | UNKNOWN | enrolled 100 Immunotherapy for Elderly Patients With Chronic Osteoporotic Pain Conditions: Osteoporotic Pain https://clinicaltrials.gov/study/NCT04524169 - NCT03082885 | Not phased | COMPLETED | enrolled 120 The Efficacy and Safety of Thymosin-α1 in Patients With HBV-related ACLF Conditions: Liver Failure https://clinicaltrials.gov/study/NCT03082885 - NCT04320238 | Phase 3 | UNKNOWN | enrolled 2944 Experimental Trial of rhIFNα Nasal Drops to Prevent 2019-nCOV in Medical Staff Conditions: 2019 Novel Coronavirus Infection https://clinicaltrials.gov/study/NCT04320238 - NCT07382375 | Not phased | NOT_YET_RECRUITING | enrolled 300 AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection Conditions: Aortic Aneurysm and Dissection https://clinicaltrials.gov/study/NCT07382375 - NCT05086614 | Phase 3 | RECRUITING | enrolled 2500 Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer Conditions: Stage II Colorectal Cancer, Stage III Colorectal Cancer https://clinicaltrials.gov/study/NCT05086614 - NCT04963712 | Phase 1 | COMPLETED | enrolled 20 Zadaxin and HIV-positive Patients With Immune Reconstitution Disorder Conditions: HIV-1-infection https://clinicaltrials.gov/study/NCT04963712 - NCT04487444 | Phase 2 | TERMINATED | enrolled 56 Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection Conditions: Covid19 https://clinicaltrials.gov/study/NCT04487444 - NCT02542137 | Phase 2 | WITHDRAWN | enrolled 0 Abscopal Effect for Metastatic Small Cell Lung Cancer Conditions: Small Cell Lung Cancer, Radiotherapy, Thymalfasin https://clinicaltrials.gov/study/NCT02542137 - NCT02906150 | Phase 2 | UNKNOWN | enrolled 140 Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type Conditions: Non-Small Cell Lung Cancer https://clinicaltrials.gov/study/NCT02906150 - NCT02867267 | Phase 3 | COMPLETED | enrolled 1106 The Efficacy and Safety of Ta1 for Sepsis Conditions: Sepsis https://clinicaltrials.gov/study/NCT02867267 - NCT05790447 | Phase 2 | UNKNOWN | enrolled 60 Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors Conditions: Advanced Solid Tumor, Refractory Tumor https://clinicaltrials.gov/study/NCT05790447 - NCT06178146 | Phase 4 | UNKNOWN | enrolled 40 Thymosin Alpha-1 for irAE Secondary to ICIs Conditions: IrAE https://clinicaltrials.gov/study/NCT06178146 - NCT00711620 | Not phased | COMPLETED | enrolled 366 Efficacy of Thymosin alpha1 for Severe Sepsis Conditions: Severe Sepsis https://clinicaltrials.gov/study/NCT00711620 - NCT00082082 | Phase 2 | COMPLETED | enrolled not posted A Trial of Thymalfasin in Adult Patients With Hepatocellular Carcinoma Conditions: Carcinoma, Hepatocellular https://clinicaltrials.gov/study/NCT00082082 - NCT06598839 | Not phased | RECRUITING | enrolled 40 Immuno-effect of Tα1 for Stage I NSCLC Conditions: Non Small Cell Lung Cancer https://clinicaltrials.gov/study/NCT06598839 - NCT01031966 | Phase 2 | COMPLETED | enrolled 120 A Pilot Study to Evaluate ZADAXIN's® (Thymalfasin) Ability to Enhance Immune Response to the H1N1sw Influenza Vaccine Conditions: END STAGE RENAL DISEASE https://clinicaltrials.gov/study/NCT01031966 - NCT06139419 | Phase 2 | COMPLETED | enrolled 114 The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC Conditions: Non-small Cell Lung Cancer https://clinicaltrials.gov/study/NCT06139419 - NCT01178996 | Phase 3 | COMPLETED | enrolled 552 Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin. Conditions: Chronic Hepatitis C https://clinicaltrials.gov/study/NCT01178996 - NCT00935558 | Phase 2 | WITHDRAWN | enrolled 0 Dendritic Cell Based Therapy for Breast Cancer Patients Conditions: Breast Cancer https://clinicaltrials.gov/study/NCT00935558 - NCT03659578 | Phase 2 | COMPLETED | enrolled 69 Study of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer Conditions: Non-small Cell Lung Cancer https://clinicaltrials.gov/study/NCT03659578 - NCT06573398 | Phase 2 | NOT_YET_RECRUITING | enrolled 20 Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC Conditions: Carcinoma, Pancreatic Ductal https://clinicaltrials.gov/study/NCT06573398 - NCT02646189 | Phase 2 | COMPLETED | enrolled 12 Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients Conditions: Hepatitis B, Chronic https://clinicaltrials.gov/study/NCT02646189 - NCT02366208 | Phase 2 | COMPLETED | enrolled 116 Phase II Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg Positive Chronic Hepatitis B Conditions: Hepatitis B, Chronic https://clinicaltrials.gov/study/NCT02366208 - NCT02787447 | Phase 2 | UNKNOWN | enrolled 46 Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy Conditions: Lung Adenocarcinoma https://clinicaltrials.gov/study/NCT02787447 - NCT04428008 | Phase 2 | COMPLETED | enrolled 189 Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients Conditions: COVID-19 https://clinicaltrials.gov/study/NCT04428008 - NCT06461910 | Phase 2 | RECRUITING | enrolled 30 Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma Conditions: Gastric Cancer, Esophagogastric Junction Adenocarcinoma https://clinicaltrials.gov/study/NCT06461910 - NCT00039962 | Phase 3 | COMPLETED | enrolled 500 Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin Conditions: Hepatitis C, Hepatitis C, Chronic https://clinicaltrials.gov/study/NCT00039962 - NCT00001036 | Phase 1 | COMPLETED | enrolled 12 The Safety and Effectiveness of a Type of Interleukin-2 Plus Zidovudine Plus Thymosin in HIV-Positive Patients With and Without Symptoms of Infection Conditions: HIV Infections https://clinicaltrials.gov/study/NCT00001036 - NCT02976740 | Phase 2 | UNKNOWN | enrolled 48 SBRT Combination With rhGM-CSF and Tα1 for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy Conditions: Lung Cancer Metastatic https://clinicaltrials.gov/study/NCT02976740 - NCT00911443 | Phase 2 | COMPLETED | enrolled 488 Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melanoma Conditions: Malignant Melanoma https://clinicaltrials.gov/study/NCT00911443 - NCT00291616 | Phase 4 | COMPLETED | enrolled 52 Efficacy Study of Thymosin alpha1 & Pegylated Interferon-alpha2a to Treat Chronic Hepatitis B Conditions: Chronic Hepatitis B https://clinicaltrials.gov/study/NCT00291616 - NCT06829355 | Phase 2 | RECRUITING | enrolled 52 "Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer" Conditions: MCRC https://clinicaltrials.gov/study/NCT06829355 - NCT06584006 | Phase 2 | RECRUITING | enrolled 50 Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological Tumors Conditions: Hematological Malignancy, Lymphocytopenia https://clinicaltrials.gov/study/NCT06584006 - NCT06966687 | Not phased | ENROLLING_BY_INVITATION | enrolled 200 Protective Effect of Ulinastatin and Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA XI) Conditions: Aortic Dissection, Aortic Dissection Aneurysm https://clinicaltrials.gov/study/NCT06966687 - NCT02535988 | Phase 2 | WITHDRAWN | enrolled 0 Abscopal Effect for Metastatic Colorectal Cancer Conditions: Colorectal Cancer, Metastatic Colorectal Cancer, Thymalfasin https://clinicaltrials.gov/study/NCT02535988 - NCT06821100 | Phase 1 | RECRUITING | enrolled 75 Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine Conditions: Vaccine Response, COVID-19 Vaccine, Immune Response to Covid 19 Vaccination https://clinicaltrials.gov/study/NCT06821100 - NCT02366247 | Phase 3 | UNKNOWN | enrolled 463 Phase Ⅲ Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg-positive Chronic Hepatitis B Conditions: Hepatitis B, Chronic https://clinicaltrials.gov/study/NCT02366247 - NCT05339529 | Not phased | RECRUITING | enrolled 330 Protective Effect of Thymosin Α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA II) Conditions: Acute Aortic Syndrome, Aortic Dissection Type a https://clinicaltrials.gov/study/NCT05339529 - NCT02906163 | Phase 2 | UNKNOWN | enrolled 188 First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy Conditions: EGFR Mutation Positive Non Small Cell Lung Cancer https://clinicaltrials.gov/study/NCT02906163 - NCT00040027 | Phase 3 | COMPLETED | enrolled 500 Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin Conditions: Hepatitis C, Hepatitis C, Chronic https://clinicaltrials.gov/study/NCT00040027 - NCT02281266 | Phase 4 | UNKNOWN | enrolled 360 Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection Conditions: Curable Hepatitis B Virus-Related Hepatocellular Carcinoma https://clinicaltrials.gov/study/NCT02281266 - NCT07675980 | Phase 3 | RECRUITING | enrolled 136 Thymosin-α1 for Recurrent Implantation Failure Conditions: Recurrent Implantation Faliure https://clinicaltrials.gov/study/NCT07675980 - NCT02473406 | Phase 4 | COMPLETED | enrolled 508 Thymosin Alpha 1 in the Prevention of Pancreatic Infection Following Acute Necrotizing Pancreatitis Conditions: Pancreatitis, Acute Necrotizing https://clinicaltrials.gov/study/NCT02473406 - NCT07644897 | Phase 2 | RECRUITING | enrolled 55 Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma Conditions: Melanoma, Immune-related Adverse Event, Immune Checkpoint Inhibitor https://clinicaltrials.gov/study/NCT07644897 - NCT07277439 | Phase 2 | RECRUITING | enrolled 48 Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma Conditions: Gastric Cancer https://clinicaltrials.gov/study/NCT07277439 - NCT02883595 | Phase 4 | COMPLETED | enrolled 20 Efficacy of Thymosin Alpha 1 on Improving Monocyte Function for Sepsis Conditions: Sepsis https://clinicaltrials.gov/study/NCT02883595 - NCT03448744 | Phase 4 | UNKNOWN | enrolled 240 Efficacy and Safety of Combination Therapy of Thymalfasin and Entecavir in HBeAg-positive ETV-experienced Patients Conditions: Chronic Hepatitis b https://clinicaltrials.gov/study/NCT03448744 - NCT06607926 | Not phased | NOT_YET_RECRUITING | enrolled 40 Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC Conditions: Resectable Non-Small-Cell Lung Cancer https://clinicaltrials.gov/study/NCT06607926 --- ## Tirzepatide (Mounjaro · Zepbound) URL: https://www.whatsactuallyknown.com/compounds/tirzepatide Registered human trials: 209 Currently recruiting or running: 135 FDA approved: Yes — FDA-approved for type 2 diabetes and chronic weight management. Furthest stage reached: phase4 Marketed for: Weight loss; Blood sugar control Answer: Tirzepatide has 209 registered human trials. Trials on record: - NCT07293325 | Not phased | RECRUITING | enrolled 66 Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity Conditions: Adults With Simple Obesity https://clinicaltrials.gov/study/NCT07293325 - NCT07707778 | Phase 4 | ENROLLING_BY_INVITATION | enrolled 60 Tirzepatide's Effects on Epigenetic Aging and Metabolic Restoration in Virally Suppressed People With HIV Conditions: Human Immunodeficiency Virus (HIV), Metabolic Dysfunction Associated Steatotic Liver Disease, Dyslipidaemia, Diabetes Mellitus, Obesity & Overweight, Metabolic Syndrome https://clinicaltrials.gov/study/NCT07707778 - NCT06073184 | Phase 2 | NOT_YET_RECRUITING | enrolled 71 Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium Conditions: Endometrial Cancer, Atypical Hyperplasia https://clinicaltrials.gov/study/NCT06073184 - NCT06657209 | Phase 4 | RECRUITING | enrolled 104 Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide Conditions: Diabetes Mellitus, Type 2, Diabetes, Type 2 Diabetes, Pre Diabetes https://clinicaltrials.gov/study/NCT06657209 - NCT07265752 | Phase 2 | NOT_YET_RECRUITING | enrolled 6 Tirzepatide for the Treatment of Cannabis Use Disorder Conditions: Cannabis Use Disorder https://clinicaltrials.gov/study/NCT07265752 - NCT05912621 | Phase 2 | RECRUITING | enrolled 66 Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity Conditions: Obesity, Overweight and Obesity, Overweight https://clinicaltrials.gov/study/NCT05912621 - NCT07443956 | Not phased | RECRUITING | enrolled 45 Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis Conditions: Psoriatic Arthritis (PsA), Obesity & Overweight https://clinicaltrials.gov/study/NCT07443956 - NCT06582875 | Phase 2 | RECRUITING | enrolled 126 Glucagon-Like Peptide-1 Receptor Agonist in ADPKD Conditions: Autosomal Dominant Polycystic Kidney, Obesity https://clinicaltrials.gov/study/NCT06582875 - NCT07671391 | Phase 2 | NOT_YET_RECRUITING | enrolled 60 A Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of LAE102 Injection in Combination With Tirzepatide on Body in Obese Participants Conditions: Obesity Adult Onset https://clinicaltrials.gov/study/NCT07671391 - NCT05553093 | Phase 4 | RECRUITING | enrolled 150 Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes Conditions: Type 2 Diabetes Mellitus https://clinicaltrials.gov/study/NCT05553093 - NCT07292519 | Phase 2 | NOT_YET_RECRUITING | enrolled 46 Tirzepatide Combined With Cognitive-Behavioural Therapy (CBT) for Adults With Alcohol Use Disorder (AUD) and Overweight/Obesity (OOB) Conditions: Alcohol Use Disorder (AUD), Overweight or Obese, Comorbidities and Coexisting Conditions https://clinicaltrials.gov/study/NCT07292519 - NCT06893211 | Phase 2 | COMPLETED | enrolled 34 Effect of Tirzepatide on Brown Adipose Tissue in Obesity Conditions: Obesity https://clinicaltrials.gov/study/NCT06893211 - NCT06246799 | Phase 3 | RECRUITING | enrolled 256 Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes Conditions: Type 2 Diabetes (Adult Onset) https://clinicaltrials.gov/study/NCT06246799 - NCT06517212 | Phase 2 | RECRUITING | enrolled 48 Tirzepatide Weight Loss for MRD+ Early Breast Cancer Conditions: Breast Cancer, Breast Neoplasms, Breast Cancers https://clinicaltrials.gov/study/NCT06517212 - NCT07154719 | Phase 4 | ACTIVE_NOT_RECRUITING | enrolled 50 GLP-1R Actions on Muscle and the Skeleton Conditions: Musculoskeletal Abnormalities, Obesity, Sarcopenic Obesity, Osteoporosis, Drug Effect https://clinicaltrials.gov/study/NCT07154719 - NCT07354880 | Phase 4 | NOT_YET_RECRUITING | enrolled 30 Effect of Tirzepatide on Cardiovascular and Metabolic Parameters in Obese Adult Patients With Congenital Heart Disease Conditions: Obesity & Overweight, Adult Congenital Heart Disease https://clinicaltrials.gov/study/NCT07354880 - NCT06890611 | Phase 1 | COMPLETED | enrolled 125 A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants Conditions: Healthy https://clinicaltrials.gov/study/NCT06890611 - NCT03482024 | Phase 1 | COMPLETED | enrolled 45 A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney Function Conditions: Renal Insufficiency, End Stage Renal Disease https://clinicaltrials.gov/study/NCT03482024 - NCT05708859 | Phase 4 | RECRUITING | enrolled 120 Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT Conditions: Type II Diabetes, Atherosclerosis https://clinicaltrials.gov/study/NCT05708859 - NCT07693608 | Phase 2 | NOT_YET_RECRUITING | enrolled 45 An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use Disorder Conditions: Obesity, Methamphetamine Use Disorder, Cocaine Use Disorder, Stimulant Use Disorders https://clinicaltrials.gov/study/NCT07693608 - NCT04255433 | Phase 3 | COMPLETED | enrolled 13299 A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes Conditions: Type 2 Diabetes Mellitus https://clinicaltrials.gov/study/NCT04255433 - NCT06400615 | Phase 2 | COMPLETED | enrolled 40 Study That Tests AD109 in Patients Taking GLP-1 Drugs Conditions: OSA https://clinicaltrials.gov/study/NCT06400615 - NCT05822830 | Phase 3 | COMPLETED | enrolled 751 A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities Conditions: Obesity, Overweight https://clinicaltrials.gov/study/NCT05822830 - NCT06801015 | Phase 4 | ACTIVE_NOT_RECRUITING | enrolled 30 Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions Conditions: Obesity https://clinicaltrials.gov/study/NCT06801015 - NCT06191848 | Phase 4 | RECRUITING | enrolled 352 Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA) Conditions: Obesity, Knee Osteoarthritis, Osteoarthritis, Knee https://clinicaltrials.gov/study/NCT06191848 - NCT07706088 | Phase 4 | NOT_YET_RECRUITING | enrolled 40 Effect of Tirzepatide on Diabetic Peripheral Sensorimotor Neuropathy Conditions: Neuropathy, Small Fiber, Diabete Mellitus https://clinicaltrials.gov/study/NCT07706088 - NCT05260021 | Phase 3 | COMPLETED | enrolled 99 A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both Conditions: Type2 Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, T2D, T2DM (Type 2 Diabetes Mellitus), Glucose Metabolism Disorders, Endocrine System Diseases, Metabolic Disease https://clinicaltrials.gov/study/NCT05260021 - NCT06047548 | Phase 3 | COMPLETED | enrolled 441 A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities Conditions: Overweight, Obesity https://clinicaltrials.gov/study/NCT06047548 - NCT07738276 | Phase 3 | NOT_YET_RECRUITING | enrolled 60 Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity Conditions: Heart Failure and Reduced Ejection Fraction, Obesity & Overweight, Tirzepatide https://clinicaltrials.gov/study/NCT07738276 - NCT07574723 | Not phased | RECRUITING | enrolled 68 Tirzepatide Titration to Reduce Side Effects in Individuals With Obesity Conditions: Obesity https://clinicaltrials.gov/study/NCT07574723 - NCT07423247 | Phase 4 | RECRUITING | enrolled 30 Tirzepatide (Spartina) in Obese Kidney Transplant Recipients Conditions: Tirzepatide https://clinicaltrials.gov/study/NCT07423247 - NCT07228741 | Phase 2 | RECRUITING | enrolled 20 Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity Conditions: Acute Lymphoblastic Leukemia, Obesity https://clinicaltrials.gov/study/NCT07228741 - NCT05691712 | Phase 3 | COMPLETED | enrolled 257 A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes Conditions: Diabetes Type 2, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases https://clinicaltrials.gov/study/NCT05691712 - NCT06534411 | Phase 3 | COMPLETED | enrolled 1023 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT06534411 - NCT06009653 | Phase 4 | WITHDRAWN | enrolled 0 Effects of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity Conditions: Obesity, Metabolic Disease https://clinicaltrials.gov/study/NCT06009653 - NCT04184622 | Phase 3 | COMPLETED | enrolled 2539 A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight Conditions: Overweight, Obesity https://clinicaltrials.gov/study/NCT04184622 - NCT07483801 | Phase 4 | NOT_YET_RECRUITING | enrolled 112 DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies Conditions: Cardiovascular Diseases https://clinicaltrials.gov/study/NCT07483801 - NCT07685834 | Not phased | ACTIVE_NOT_RECRUITING | enrolled 30 Evaluation of Facial and Neck Skin Laxity With SofWave Treatment in Adults Initiating Tirzepatide for Weight Loss Conditions: Lax Skin https://clinicaltrials.gov/study/NCT07685834 - NCT07373834 | Not phased | RECRUITING | enrolled 30 Tirzepatide and Muscle Outcomes in Obesity Conditions: Obesity (Disorder) https://clinicaltrials.gov/study/NCT07373834 - NCT06635057 | Phase 4 | COMPLETED | enrolled 166 A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT06635057 - NCT04004988 | Phase 1 | COMPLETED | enrolled 47 A Study of Tirzepatide Administered by Two Different Devices in Healthy Participants Conditions: Healthy https://clinicaltrials.gov/study/NCT04004988 - NCT07740291 | Not phased | RECRUITING | enrolled 27 Tirzepatide Impact Assessment Study Conditions: Obesity & Overweight, Cardiometabolic Health Indicators, Addiction, Eating Disorders, Mental Health https://clinicaltrials.gov/study/NCT07740291 - NCT07602699 | Phase 2 | RECRUITING | enrolled 300 Multi-Site Trial of Tirzepatide for Smoking Cessation Conditions: Smoking Cessation, Smoking Behaviors https://clinicaltrials.gov/study/NCT07602699 - NCT07165028 | Phase 3 | RECRUITING | enrolled 4500 A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease https://clinicaltrials.gov/study/NCT07165028 - NCT05963022 | Phase 3 | COMPLETED | enrolled 206 A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO) Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT05963022 - NCT06037252 | Phase 2 | ACTIVE_NOT_RECRUITING | enrolled 414 A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity Conditions: Type 2 Diabetes, Obesity https://clinicaltrials.gov/study/NCT06037252 - NCT07573163 | Phase 2 | RECRUITING | enrolled 34 Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion Conditions: Mild Autonomous Cortisol Secretion (MACS), Adrenalectomy; Status https://clinicaltrials.gov/study/NCT07573163 - NCT06857942 | Phase 4 | RECRUITING | enrolled 200 A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO) Conditions: Psoriasis, Overweight or Obesity https://clinicaltrials.gov/study/NCT06857942 - NCT07078838 | Phase 2 | NOT_YET_RECRUITING | enrolled 40 Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer Conditions: Endometrial Cancer, Endometrial Intraepithelial Neoplasia, Grade 1 Endometrial Endometrioid Carcinoma https://clinicaltrials.gov/study/NCT07078838 - NCT03882970 | Phase 3 | COMPLETED | enrolled 1444 A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes Conditions: Type 2 Diabetes Mellitus https://clinicaltrials.gov/study/NCT03882970 - NCT06515418 | Phase 2 | TERMINATED | enrolled 204 Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over Conditions: Obesity https://clinicaltrials.gov/study/NCT06515418 - NCT07382024 | Not phased | NOT_YET_RECRUITING | enrolled 200 Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation Conditions: Atrial Fibrillation Ablation, Persistent Atrial Fibrillation, Obesity & Overweight https://clinicaltrials.gov/study/NCT07382024 - NCT04407234 | Phase 1 | COMPLETED | enrolled 36 A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide Conditions: Overweight, Obesity, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT04407234 - NCT07555730 | Phase 4 | NOT_YET_RECRUITING | enrolled 400 AI-assisted Multi-domain Lifestyle Versus Tirzepatide for Weight Loss Maintenance in Adults With Type 2 Diabetes (AIM-MAINTAIN) Conditions: Overweight or Obesity; Type 2 Diabetes, Weight Loss Maintenance https://clinicaltrials.gov/study/NCT07555730 - NCT04657016 | Phase 3 | COMPLETED | enrolled 579 A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program Conditions: Obesity, Overweight https://clinicaltrials.gov/study/NCT04657016 - NCT07676331 | Phase 2 | NOT_YET_RECRUITING | enrolled 168 Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA Trial Conditions: Hormone-receptor-positive Breast Cancer, Early Breast Cancer https://clinicaltrials.gov/study/NCT07676331 - NCT06737042 | Phase 2 | COMPLETED | enrolled 326 Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants Conditions: Obesity and Overweight https://clinicaltrials.gov/study/NCT06737042 - NCT03311724 | Phase 2 | COMPLETED | enrolled 111 A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT03311724 - NCT07000955 | Phase 2 | ACTIVE_NOT_RECRUITING | enrolled 98 Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity Conditions: Obesity https://clinicaltrials.gov/study/NCT07000955 - NCT04311424 | Phase 1 | COMPLETED | enrolled 6 Study of Tirzepatide in Healthy Participants Conditions: Healthy https://clinicaltrials.gov/study/NCT04311424 - NCT06373146 | Phase 2 | COMPLETED | enrolled 392 A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity Conditions: Obesity https://clinicaltrials.gov/study/NCT06373146 - NCT07468552 | Phase 2 | NOT_YET_RECRUITING | enrolled 100 Trial of Tirzepatide for the Treatment of Cannabis Use Disorder Conditions: Cannabis Use Disorder https://clinicaltrials.gov/study/NCT07468552 - NCT06131437 | Phase 3 | COMPLETED | enrolled 809 A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight Conditions: Obesity https://clinicaltrials.gov/study/NCT06131437 - NCT06976853 | Phase 2 | RECRUITING | enrolled 60 Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease Conditions: Crohn Disease (CD) https://clinicaltrials.gov/study/NCT06976853 - NCT03940742 | Phase 1 | COMPLETED | enrolled 32 A Study of Tirzepatide in Participants With Impaired Liver Function Conditions: Hepatic Insufficiency https://clinicaltrials.gov/study/NCT03940742 - NCT06588296 | Phase 3 | COMPLETED | enrolled 279 Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight Conditions: Psoriatic Arthritis, Obesity https://clinicaltrials.gov/study/NCT06588296 - NCT05556512 | Phase 3 | ACTIVE_NOT_RECRUITING | enrolled 15374 A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity Conditions: Obesity, Overweight https://clinicaltrials.gov/study/NCT05556512 - NCT07046819 | Phase 2 | RECRUITING | enrolled 120 Tirzepatide in MetALD Conditions: Metabolic Alcohol-associated Liver Disease, Alcohol Use Disorder https://clinicaltrials.gov/study/NCT07046819 - NCT05696847 | Phase 1 | COMPLETED | enrolled 28 A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity Conditions: Obesity https://clinicaltrials.gov/study/NCT05696847 - NCT05536804 | Phase 2 | ACTIVE_NOT_RECRUITING | enrolled 140 A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes Conditions: Overweight, Obesity, Chronic Kidney Disease, Type 2 Diabetes, T2D https://clinicaltrials.gov/study/NCT05536804 - NCT06901349 | Phase 2 | WITHDRAWN | enrolled 0 A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes Conditions: Obesity, Overweight https://clinicaltrials.gov/study/NCT06901349 - NCT04657003 | Phase 3 | COMPLETED | enrolled 938 A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight Conditions: Type 2 Diabetes, Overweight, Obesity https://clinicaltrials.gov/study/NCT04657003 - NCT06734273 | Phase 1 | RECRUITING | enrolled 42 Randomized Control Trial of Sleeve Gastrectomy With Tirzepatide in Maximizing Weight Loss Conditions: Obesity and Obesity-related Medical Conditions https://clinicaltrials.gov/study/NCT06734273 - NCT06885736 | Not phased | RECRUITING | enrolled 232 LEAN Mass Preservation With Resistance Exercise and Protein During Semaglutide/Tirzepatide Therapy Conditions: Obesity https://clinicaltrials.gov/study/NCT06885736 - NCT03954834 | Phase 3 | COMPLETED | enrolled 478 A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone Conditions: Type 2 Diabetes Mellitus https://clinicaltrials.gov/study/NCT03954834 - NCT04844918 | Phase 3 | COMPLETED | enrolled 267 A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease Conditions: Obesity https://clinicaltrials.gov/study/NCT04844918 - NCT04050553 | Phase 1 | COMPLETED | enrolled 42 A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus Conditions: Diabetes Mellitus, Type 2, Hypoglycemia https://clinicaltrials.gov/study/NCT04050553 - NCT07630454 | Phase 4 | NOT_YET_RECRUITING | enrolled 602 Tirzepatide on Atrial Fibrillation Recurrence After Catheter Ablation in Patients With Obesity and HFpEF Conditions: Atrial Fibrillation, Heart Failure With Preserved Ejection Fraction (HFpEF), Tirzepatide https://clinicaltrials.gov/study/NCT07630454 - NCT06700538 | Phase 2 | RECRUITING | enrolled 180 A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus Conditions: Obesity https://clinicaltrials.gov/study/NCT06700538 - NCT06143956 | Phase 2 | RECRUITING | enrolled 1481 A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight Conditions: Obesity, Overweight https://clinicaltrials.gov/study/NCT06143956 - NCT06937099 | Phase 3 | RECRUITING | enrolled 290 Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight Conditions: Crohn's Disease, Obesity or Overweight https://clinicaltrials.gov/study/NCT06937099 - NCT07303556 | Not phased | ACTIVE_NOT_RECRUITING | enrolled 120 Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs Conditions: Heart Failure, Diabete Type 2, Arterial Hypertension https://clinicaltrials.gov/study/NCT07303556 - NCT07257484 | Phase 4 | RECRUITING | enrolled 30 Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors Conditions: Obesity (Disorder), Breast Cancer https://clinicaltrials.gov/study/NCT07257484 - NCT03861039 | Phase 3 | COMPLETED | enrolled 443 A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Conditions: Type 2 Diabetes Mellitus https://clinicaltrials.gov/study/NCT03861039 - NCT06811324 | Phase 2 | RECRUITING | enrolled 20 Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults Conditions: Obesity Prevention, Sarcopenia in Elderly, Cardiovascular Function, GLP - 1, Weight Loss https://clinicaltrials.gov/study/NCT06811324 - NCT06662383 | Phase 3 | ACTIVE_NOT_RECRUITING | enrolled 800 A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity Conditions: Obesity https://clinicaltrials.gov/study/NCT06662383 - NCT05706506 | Phase 4 | COMPLETED | enrolled 152 A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2) Conditions: Type 2 Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT05706506 - NCT07298915 | Phase 3 | NOT_YET_RECRUITING | enrolled 24 The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED) Conditions: Obesity & Overweight https://clinicaltrials.gov/study/NCT07298915 - NCT04311411 | Phase 1 | COMPLETED | enrolled 114 A Study of Tirzepatide in Overweight and Very Overweight Participants Conditions: Obesity, Overweight https://clinicaltrials.gov/study/NCT04311411 - NCT07734870 | Phase 2 | NOT_YET_RECRUITING | enrolled 20 Tirzepatide for Treatment of CCCA Conditions: Central Centrifugal Cicatricial Alopecia (CCCA) https://clinicaltrials.gov/study/NCT07734870 - NCT07284511 | Phase 3 | RECRUITING | enrolled 105 A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar Conditions: Type 1 Diabetes, Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes Mellitus https://clinicaltrials.gov/study/NCT07284511 - NCT06965413 | Phase 2 | ACTIVE_NOT_RECRUITING | enrolled 285 A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity Conditions: Obesity, Overweight, Overweight With One Weight Related Comorbidity https://clinicaltrials.gov/study/NCT06965413 - NCT07326111 | Phase 4 | RECRUITING | enrolled 198 A Clincial Study Testing Tirzepatide on Reproductive Function and Metabolic Health in Women With PCOS Who Are Overweight or Obese Conditions: Polycystic Ovary Syndrome (PCOS), Obesity & Overweight https://clinicaltrials.gov/study/NCT07326111 - NCT07319975 | Not phased | NOT_YET_RECRUITING | enrolled 48 Effect of Semaglutide and Tirzepatide Combined With Exercise in Obesity Conditions: Obesity https://clinicaltrials.gov/study/NCT07319975 - NCT07728318 | Not phased | NOT_YET_RECRUITING | enrolled 52 Efficacy, Safety, and Treatment Satisfaction of Once-Weekly Tirzepatide in Obese Type 2 Diabetic Patients Conditions: Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight https://clinicaltrials.gov/study/NCT07728318 - NCT07715929 | Phase 4 | NOT_YET_RECRUITING | enrolled 710 Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients Conditions: Atrial Fibrillation, Obesity & Overweight, Catheter Ablation https://clinicaltrials.gov/study/NCT07715929 - NCT07734792 | Phase 3 | NOT_YET_RECRUITING | enrolled 430 Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial Conditions: Acute Ischemic Stroke (AIS) https://clinicaltrials.gov/study/NCT07734792 - NCT04847557 | Phase 3 | COMPLETED | enrolled 731 A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial Conditions: Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF) https://clinicaltrials.gov/study/NCT04847557 - NCT07065552 | Phase 1 | RECRUITING | enrolled 20 Tirzepatide in Obesity-Driven Endometrial Cancer Conditions: Endometrial Cancer, Obesity https://clinicaltrials.gov/study/NCT07065552 - NCT07179120 | Phase 2 | NOT_YET_RECRUITING | enrolled 180 Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health Conditions: Obesity-related Male Infertility https://clinicaltrials.gov/study/NCT07179120 - NCT06937086 | Phase 3 | RECRUITING | enrolled 350 Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study Conditions: Ulcerative Colitis, Obesity or Overweight https://clinicaltrials.gov/study/NCT06937086 - NCT06847399 | Phase 2 | RECRUITING | enrolled 105 Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder Conditions: Obesity and Overweight, Binge Eating Disorder https://clinicaltrials.gov/study/NCT06847399 - NCT06962280 | Phase 3 | ACTIVE_NOT_RECRUITING | enrolled 465 A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight Conditions: Type 1 Diabetes, Obesity, Overweight https://clinicaltrials.gov/study/NCT06962280 - NCT04039503 | Phase 3 | COMPLETED | enrolled 475 A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT04039503 - NCT06648031 | Phase 1 | COMPLETED | enrolled 148 Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants Conditions: Type2diabetes https://clinicaltrials.gov/study/NCT06648031 - NCT06820281 | Phase 2 | NOT_YET_RECRUITING | enrolled 44 Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes Conditions: Type 1 Diabetes Mellitus https://clinicaltrials.gov/study/NCT06820281 - NCT07697391 | Phase 4 | NOT_YET_RECRUITING | enrolled 285 AI-Assisted Lifestyle Intervention Versus Tirzepatide for Obesity and Newly Diagnosed Type 2 Diabetes Conditions: Obesity, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT07697391 - NCT03861052 | Phase 3 | COMPLETED | enrolled 636 A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT03861052 - NCT07633639 | Not phased | RECRUITING | enrolled 200 GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity Conditions: Obesity https://clinicaltrials.gov/study/NCT07633639 - NCT07438444 | Phase 4 | RECRUITING | enrolled 344 A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity Conditions: Diabetes Mellitus, Type 2, Obesity, Overweight https://clinicaltrials.gov/study/NCT07438444 - NCT06651177 | Phase 2 | RECRUITING | enrolled 310 Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder Conditions: Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe https://clinicaltrials.gov/study/NCT06651177 - NCT07605247 | Phase 2 | NOT_YET_RECRUITING | enrolled 30 Tirzepatide in the Treatment of Endometrial Cancer Conditions: Endometrial Cancer https://clinicaltrials.gov/study/NCT07605247 - NCT06518837 | Phase 2 | RECRUITING | enrolled 40 Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer Conditions: Hormone Receptor-Positive Breast Cancer, HER2-Negative Breast Cancer https://clinicaltrials.gov/study/NCT06518837 - NCT06745128 | Phase 2 | ACTIVE_NOT_RECRUITING | enrolled 45 Tirzepatide for Obesity and Meth Use Disorder Conditions: Obesity, Methamphetamine Use Disorder https://clinicaltrials.gov/study/NCT06745128 - NCT07521631 | Phase 2 | RECRUITING | enrolled 372 Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes Conditions: Obesity https://clinicaltrials.gov/study/NCT07521631 - NCT06721507 | Phase 4 | RECRUITING | enrolled 50 2024 Tirzepatide-Bariatric Surgery Conditions: Obesity and Obesity-related Medical Conditions, Bariatric Surgery https://clinicaltrials.gov/study/NCT06721507 - NCT06916065 | Phase 1 | COMPLETED | enrolled 188 A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity Conditions: Overweight, Obesity https://clinicaltrials.gov/study/NCT06916065 - NCT07091734 | Phase 2 | RECRUITING | enrolled 32 Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024 Conditions: Lipodystrophy, Partial https://clinicaltrials.gov/study/NCT07091734 - NCT03951753 | Phase 1 | COMPLETED | enrolled 117 A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM) Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT03951753 - NCT07671248 | Phase 3 | NOT_YET_RECRUITING | enrolled 15 Tirzepatide in the Treatment of Cannabis Use Disorder Conditions: Cannabis Use Disorder, Moderate, Cannabis Use Disorder, Severe https://clinicaltrials.gov/study/NCT07671248 - NCT07095517 | Phase 1 | RECRUITING | enrolled 20 Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors Conditions: Colorectal Cancer Prevention, Colorectal Adenoma https://clinicaltrials.gov/study/NCT07095517 - NCT07247084 | Phase 4 | RECRUITING | enrolled 3000 A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK) Conditions: Obesity https://clinicaltrials.gov/study/NCT07247084 - NCT07554638 | Phase 4 | NOT_YET_RECRUITING | enrolled 50 Incretin Therapies in Obesity-related HFpEF Conditions: Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Obesity https://clinicaltrials.gov/study/NCT07554638 - NCT06439277 | Phase 3 | RECRUITING | enrolled 300 A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2) Conditions: Obesity, Weight Gain https://clinicaltrials.gov/study/NCT06439277 - NCT07245771 | Phase 2 | RECRUITING | enrolled 104 Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity Conditions: Obesity &Amp; Overweight https://clinicaltrials.gov/study/NCT07245771 - NCT06180616 | Phase 2 | NOT_YET_RECRUITING | enrolled 40 Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity Conditions: Type 1 Diabetes Mellitus, Overweight and Obesity https://clinicaltrials.gov/study/NCT06180616 - NCT07202247 | Phase 2 | RECRUITING | enrolled 60 Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial Conditions: Prostate Carcinoma, Recurrent Prostate Carcinoma https://clinicaltrials.gov/study/NCT07202247 - NCT04235959 | Phase 1 | COMPLETED | enrolled 24 A Study of Tirzepatide in Chinese Participants With Type 2 Diabetes Mellitus Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT04235959 - NCT06533527 | Phase 4 | COMPLETED | enrolled 69 Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy Conditions: Diabetes Mellitus, Type 2, Obesity, Gastroparesis https://clinicaltrials.gov/study/NCT06533527 - NCT06802081 | Phase 2 | RECRUITING | enrolled 100 TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation Conditions: Atrial Fibrillation, Obesity https://clinicaltrials.gov/study/NCT06802081 - NCT06914895 | Phase 3 | ACTIVE_NOT_RECRUITING | enrolled 905 A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight Conditions: Type 1 Diabetes, Obesity, Overweight https://clinicaltrials.gov/study/NCT06914895 - NCT06484114 | Not phased | ACTIVE_NOT_RECRUITING | enrolled 315 Evaluation of the Safety and Efficacy of Revita® DMR on Body Weight Maintenance in Subjects With Obesity Who Have Achieved at Least 15% Weight Loss on Tirzepatide Conditions: Obesity, Weight Change Trajectory, Weight Change, Body https://clinicaltrials.gov/study/NCT06484114 - NCT06326060 | Phase 2 | COMPLETED | enrolled 354 A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight Conditions: Obesity https://clinicaltrials.gov/study/NCT06326060 - NCT07635953 | Phase 3 | NOT_YET_RECRUITING | enrolled 296 New Triple Combination Therapy in Newly Diagnosed Type 2 Diabetes Conditions: Diabetes Mellitus https://clinicaltrials.gov/study/NCT07635953 - NCT06727331 | Phase 2 | RECRUITING | enrolled 20 Study of Tirzepatide for Recovery and Alcohol Use Management Conditions: Alcohol Use Disorder (AUD) https://clinicaltrials.gov/study/NCT06727331 - NCT03375463 | Phase 1 | COMPLETED | enrolled 52 A Study of Tirzepatide (LY3298176) in Healthy Participants Conditions: Healthy https://clinicaltrials.gov/study/NCT03375463 - NCT04660643 | Phase 3 | COMPLETED | enrolled 783 A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss Conditions: Obesity, Overweight https://clinicaltrials.gov/study/NCT04660643 - NCT06911203 | Phase 2 | RECRUITING | enrolled 90 A Study of BGM0504 in Participants With Obesity Conditions: Obesity https://clinicaltrials.gov/study/NCT06911203 - NCT04172987 | Phase 1 | COMPLETED | enrolled 40 A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants Conditions: Healthy https://clinicaltrials.gov/study/NCT04172987 - NCT05564039 | Phase 4 | COMPLETED | enrolled 282 A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT05564039 - NCT06897475 | Phase 2 | RECRUITING | enrolled 240 A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT06897475 - NCT05933499 | Phase 2 | RECRUITING | enrolled 63 Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity Conditions: Obesity https://clinicaltrials.gov/study/NCT05933499 - NCT07387796 | Not phased | RECRUITING | enrolled 40 Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation Conditions: Drug Discontinuation, Substance Use Disorders, Eating Behavior Changes, Tirzepatide https://clinicaltrials.gov/study/NCT07387796 - NCT06934642 | Phase 1 | RECRUITING | enrolled 8 Effect of Tirzepatide on Markers of MASLD in Patients With Obesity Conditions: MASLD, Obesity https://clinicaltrials.gov/study/NCT06934642 - NCT06345066 | Phase 1 | COMPLETED | enrolled 96 A Study of LY3841136 in Overweight and Obese Participants Conditions: Obesity, Overweight https://clinicaltrials.gov/study/NCT06345066 - NCT06565611 | Phase 2 | ACTIVE_NOT_RECRUITING | enrolled 108 A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity Conditions: Obesity https://clinicaltrials.gov/study/NCT06565611 - NCT05024032 | Phase 3 | COMPLETED | enrolled 210 A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN) Conditions: Obesity, Overweight, Metabolism and Nutrition Disorder https://clinicaltrials.gov/study/NCT05024032 - NCT03987919 | Phase 3 | COMPLETED | enrolled 1879 A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT03987919 - NCT06640972 | Phase 2 | COMPLETED | enrolled 68 Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists Conditions: Triglycerides, Weight Gain Trajectory, Cholesterol, Elevated https://clinicaltrials.gov/study/NCT06640972 - NCT06575738 | Phase 1 | RECRUITING | enrolled 40 Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents Conditions: Obesity, Adolescent Obesity, Body-Weight Trajectory, Weight Loss Trajectory, Bariatric Surgery, Anti-obesity Agents https://clinicaltrials.gov/study/NCT06575738 - NCT06901245 | Phase 4 | RECRUITING | enrolled 36 Tirzepatide in PWS, HO and GNSO Conditions: Prader-Willi Syndrome, Hypothalamic Obesity, Obesity/Therapy https://clinicaltrials.gov/study/NCT06901245 - NCT06759701 | Phase 1 | RECRUITING | enrolled 30 Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study Conditions: Diabetes, Prostate Cancer https://clinicaltrials.gov/study/NCT06759701 - NCT06221969 | Phase 3 | COMPLETED | enrolled 1024 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT06221969 - NCT06803888 | Phase 4 | ACTIVE_NOT_RECRUITING | enrolled 125 Bariatric Surgery vs. Semaglutide vs. Tirzepatide Conditions: Obesity and Obesity-related Medical Conditions https://clinicaltrials.gov/study/NCT06803888 - NCT07299084 | Phase 1 | ACTIVE_NOT_RECRUITING | enrolled 40 A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus Conditions: Diabetes Mellitus, Type 2, Overweight, Obesity https://clinicaltrials.gov/study/NCT07299084 - NCT07559500 | Phase 1 | RECRUITING | enrolled 176 Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD) Conditions: Alcohol Use Disorder (AUD) https://clinicaltrials.gov/study/NCT07559500 - NCT06606821 | Phase 4 | RECRUITING | enrolled 124 The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease Conditions: Coronary Artery Disease, Coronary Microvascular Dysfunction, Overweight or Obesity, Stable Angina Pectoris, Chronic Coronary Artery Disease, Atherosclerosis Cardiovascular Disease https://clinicaltrials.gov/study/NCT06606821 - NCT06603571 | Phase 2 | ACTIVE_NOT_RECRUITING | enrolled 367 A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes Conditions: Obesity, Overweight https://clinicaltrials.gov/study/NCT06603571 - NCT07527910 | Phase 2 | RECRUITING | enrolled 204 A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) https://clinicaltrials.gov/study/NCT07527910 - NCT07191873 | Phase 4 | NOT_YET_RECRUITING | enrolled 60 Tirzepatide in Idiopathic Intracranial Hypertension Trial Conditions: Idiopathic Intracranial Hypertension (IIH) https://clinicaltrials.gov/study/NCT07191873 - NCT07588438 | Phase 4 | RECRUITING | enrolled 160 Efficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay. Conditions: Obesity, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT07588438 - NCT05659368 | Phase 2 | UNKNOWN | enrolled 10 Tirzepatide Monotherapy in Patients With Wolfram Syndrome Type 1 Conditions: Wolfram Syndrome https://clinicaltrials.gov/study/NCT05659368 - NCT03131687 | Phase 2 | COMPLETED | enrolled 318 A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus Conditions: Type 2 Diabetes Mellitus https://clinicaltrials.gov/study/NCT03131687 - NCT06751589 | Phase 1 | RECRUITING | enrolled 36 A Study of a Weight Loss Intervention in People With Endometrial Cancer Conditions: Endometrial Cancer https://clinicaltrials.gov/study/NCT06751589 - NCT06994338 | Phase 2 | RECRUITING | enrolled 42 Tirzepatide for Alcohol Use Disorder Conditions: Alcohol Use Disorder, Obesity and Overweight, Alcohol https://clinicaltrials.gov/study/NCT06994338 - NCT07589322 | Not phased | RECRUITING | enrolled 120 Comparative Observation of Metabolic and Pharmacologic Adipose Remodeling With Enhanced Incretin AgonisTs Conditions: Obesity and Metabolic Syndrome https://clinicaltrials.gov/study/NCT07589322 - NCT06297616 | Phase 1 | COMPLETED | enrolled 128 A Study of LY3841136 in Japanese Participants With Obesity or Overweight Conditions: Obesity, Overweight https://clinicaltrials.gov/study/NCT06297616 - NCT07457437 | Not phased | RECRUITING | enrolled 60 Function and Lean Mass Preservation With Resistance Exercise During a GLP-1RA Treatment Conditions: Muscle Mass and Strength, Obesity & Overweight, Physical Function https://clinicaltrials.gov/study/NCT07457437 - NCT07057310 | Phase 4 | ENROLLING_BY_INVITATION | enrolled 30 Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women Conditions: Obesity, Menopause https://clinicaltrials.gov/study/NCT07057310 - NCT04050670 | Phase 1 | COMPLETED | enrolled 54 A Study of Tirzepatide at Different Injection Sites in Participants With Different Body Sizes Conditions: Healthy https://clinicaltrials.gov/study/NCT04050670 - NCT07176663 | Not phased | NOT_YET_RECRUITING | enrolled 15 Efficacy and Safety of Tirzepatide (Spartina) in Chronic Kidney Failure Conditions: Obesity https://clinicaltrials.gov/study/NCT07176663 - NCT05810597 | Phase 1 | COMPLETED | enrolled 65 A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection Devices Conditions: Healthy https://clinicaltrials.gov/study/NCT05810597 - NCT02759107 | Phase 1 | COMPLETED | enrolled 142 A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM) Conditions: Healthy, Type 2 Diabetes Mellitus (T2DM) https://clinicaltrials.gov/study/NCT02759107 - NCT05433584 | Phase 4 | ACTIVE_NOT_RECRUITING | enrolled 780 A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT05433584 - NCT06861439 | Phase 4 | ACTIVE_NOT_RECRUITING | enrolled 40 GLP-1s to Enhance Lasting Optimal Weight Conditions: Obesity https://clinicaltrials.gov/study/NCT06861439 - NCT06445075 | Phase 2 | COMPLETED | enrolled 102 Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese Conditions: Overweight and Obesity https://clinicaltrials.gov/study/NCT06445075 - NCT06075667 | Phase 3 | ACTIVE_NOT_RECRUITING | enrolled 160 A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities Conditions: Obesity, Overweight https://clinicaltrials.gov/study/NCT06075667 - NCT07481747 | Phase 3 | RECRUITING | enrolled 2539 Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1) Conditions: Obesity, Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities https://clinicaltrials.gov/study/NCT07481747 - NCT06605703 | Phase 4 | COMPLETED | enrolled 226 A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial) Conditions: Obesity, Overweight https://clinicaltrials.gov/study/NCT06605703 - NCT03730662 | Phase 3 | COMPLETED | enrolled 2002 A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk Conditions: Type 2 Diabetes Mellitus https://clinicaltrials.gov/study/NCT03730662 - NCT05582096 | Phase 1 | COMPLETED | enrolled 38 A Study of LY3457263 in Obese Participants Conditions: Overweight, Obesity https://clinicaltrials.gov/study/NCT05582096 - NCT06939088 | Phase 2 | RECRUITING | enrolled 108 Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder Conditions: Alcohol Use Disorder, Alcohol Abuse/Dependence, Alcohol Dependence, Alcoholism, Schizophrenia Disorders, Schizophrenia and Disorders With Psychotic Features, Schizophrenia and Schizophrenia Spectrum Psychosis, Schizophrenia https://clinicaltrials.gov/study/NCT06939088 - NCT06630585 | Phase 3 | RECRUITING | enrolled 42 GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes Conditions: Type 1 Diabetes (T1D) https://clinicaltrials.gov/study/NCT06630585 - NCT05412004 | Phase 3 | COMPLETED | enrolled 469 Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea Conditions: Obstructive Sleep Apnea, Obesity https://clinicaltrials.gov/study/NCT05412004 - NCT04093752 | Phase 3 | COMPLETED | enrolled 917 A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo) Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT04093752 - NCT06732245 | Phase 2 | NOT_YET_RECRUITING | enrolled 224 Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese Conditions: Obesity and Overweight https://clinicaltrials.gov/study/NCT06732245 - NCT07349641 | Phase 2 | NOT_YET_RECRUITING | enrolled 55 A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer Conditions: Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma https://clinicaltrials.gov/study/NCT07349641 - NCT05990374 | Not phased | UNKNOWN | enrolled 100 Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years Conditions: Diabetes https://clinicaltrials.gov/study/NCT05990374 - NCT07364175 | Not phased | RECRUITING | enrolled 60 A Trial Within Cohort Feasibility Study Design Comparing Standard of Care Versus Weight Loss (Achieved Through Tirzepatide) for Obesity-related Hypertension in Young Adults Conditions: Hypertension, Obesity & Overweight https://clinicaltrials.gov/study/NCT07364175 - NCT06935838 | Phase 2 | COMPLETED | enrolled 12 Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV Conditions: Obesity and Overweight, HIV, Chronic Inflammation https://clinicaltrials.gov/study/NCT06935838 - NCT04537923 | Phase 3 | COMPLETED | enrolled 1428 A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT04537923 - NCT07218445 | Phase 4 | RECRUITING | enrolled 40 The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity Conditions: Obesity, Menopause Hot Flashes https://clinicaltrials.gov/study/NCT07218445 - NCT05978713 | Phase 1 | COMPLETED | enrolled 11 A Study of Tirzepatide (LY3298176) in Healthy Lactating Females Conditions: Healthy https://clinicaltrials.gov/study/NCT05978713 - NCT06301256 | Not phased | UNKNOWN | enrolled 20 Evaluate the Efficacy of TIRZEPATIDE for the Treatment of Moderate to Severe HS Hidradenitis Suppurativa Conditions: Hidradenitis Suppurativa https://clinicaltrials.gov/study/NCT06301256 - NCT07128082 | Phase 2 | ACTIVE_NOT_RECRUITING | enrolled 1000 The Long COVID Treatment Trial Conditions: Long COVID https://clinicaltrials.gov/study/NCT07128082 - NCT06918405 | Phase 3 | ACTIVE_NOT_RECRUITING | enrolled 440 Efficacy and Safety of Tirzepatide for Weight Management Conditions: Obesity and Obesity-related Medical Conditions https://clinicaltrials.gov/study/NCT06918405 - NCT06588283 | Phase 3 | COMPLETED | enrolled 281 Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight Conditions: Psoriasis, Obesity https://clinicaltrials.gov/study/NCT06588283 - NCT04166773 | Phase 2 | COMPLETED | enrolled 190 A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH) Conditions: Nonalcoholic Steatohepatitis https://clinicaltrials.gov/study/NCT04166773 - NCT06643728 | Phase 2 | ACTIVE_NOT_RECRUITING | enrolled 252 A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight Conditions: Obesity, Overweight https://clinicaltrials.gov/study/NCT06643728 - NCT05822544 | Phase 1 | RECRUITING | enrolled 564 Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes Conditions: Healthy Subjects, Obesity, Type 2 Diabetes https://clinicaltrials.gov/study/NCT05822544 - NCT06162715 | Phase 3 | ACTIVE_NOT_RECRUITING | enrolled 30 GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial Conditions: Severe Obesity, Obesity, BMI Greater Than 30 https://clinicaltrials.gov/study/NCT06162715 - NCT03322631 | Phase 1 | COMPLETED | enrolled 48 A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 Diabetes Conditions: Type 2 Diabetes Mellitus https://clinicaltrials.gov/study/NCT03322631 - NCT06864026 | Phase 4 | RECRUITING | enrolled 200 A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA) Conditions: Psoriatic Arthritis, Overweight or Obesity https://clinicaltrials.gov/study/NCT06864026 - NCT07619989 | Not phased | RECRUITING | enrolled 24 Transcutaneous Auricular Vagus Nerve Stimulation for Poor Weight-Loss Response to Incretin Receptor Agonists Conditions: Obesity & Overweight https://clinicaltrials.gov/study/NCT07619989 - NCT06774079 | Phase 4 | RECRUITING | enrolled 24 Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients Conditions: Crohn Disease https://clinicaltrials.gov/study/NCT06774079 - NCT07463846 | Phase 2 | RECRUITING | enrolled 156 A Study to Evaluate ALN-2232 in Participants With Obesity Conditions: Obesity https://clinicaltrials.gov/study/NCT07463846 - NCT07096908 | Phase 4 | RECRUITING | enrolled 60 Tirzepatide Use in People With Obesity and Type 1 Diabetes Conditions: Type1diabetes, Obesity https://clinicaltrials.gov/study/NCT07096908 - NCT04081337 | Phase 1 | COMPLETED | enrolled 55 A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide Conditions: Obesity https://clinicaltrials.gov/study/NCT04081337 - NCT07220473 | Phase 2 | RECRUITING | enrolled 90 Tirzepatide to Slow Biological Aging Conditions: Aging, LONGEVITY 1 https://clinicaltrials.gov/study/NCT07220473 --- ## Liraglutide (Victoza · Saxenda · NN2211) URL: https://www.whatsactuallyknown.com/compounds/liraglutide Registered human trials: 419 Currently recruiting or running: 23 FDA approved: Yes — FDA-approved as Victoza for type 2 diabetes in patients 10 and older, and as Saxenda for chronic weight management. Two products, two separate indications. Furthest stage reached: phase4 Marketed for: Weight loss; Blood sugar control Answer: Liraglutide has 419 registered human trials. Trials on record: - NCT01592279 | Phase 4 | UNKNOWN | enrolled 124 GLP-1 Analogue Treatment in Uncontrolled Type 1 Diabetic Patients Conditions: Uncontrolled Type 1 Diabetic Patients https://clinicaltrials.gov/study/NCT01592279 - NCT02100475 | Phase 3 | COMPLETED | enrolled 31 A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT02100475 - NCT02298192 | Phase 3 | COMPLETED | enrolled 420 A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT02298192 - NCT05767255 | Phase 3 | UNKNOWN | enrolled 66 Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin Plus GLP-1 Analogue Conditions: Diabetes Mellitus, Type 2 Treated With Insulin https://clinicaltrials.gov/study/NCT05767255 - NCT04324229 | Not phased | ACTIVE_NOT_RECRUITING | enrolled 80 Liraglutide in the Prevention of Type 2 Diabetes After Gestational Diabetes Conditions: Gestational Diabetes https://clinicaltrials.gov/study/NCT04324229 - NCT00983021 | Phase 1 | COMPLETED | enrolled 24 Safety and Tolerability of NN9068 in Healthy Male Volunteers Conditions: Diabetes, Healthy https://clinicaltrials.gov/study/NCT00983021 - NCT01511185 | Phase 1 | COMPLETED | enrolled 20 Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT01511185 - NCT07590219 | Phase 4 | ACTIVE_NOT_RECRUITING | enrolled 30 Use of Liraglutide in Children Aged 6 to 12 Years With Severe Obesity Conditions: Severe Obesity, Cardiovascular Function, Liraglutide, Childhood Obesity, Echocardiography, Speckle Tracking https://clinicaltrials.gov/study/NCT07590219 - NCT01722266 | Phase 3 | COMPLETED | enrolled 72 Liraglutide in the Treatment of Type 1 Diabetes Mellitus Conditions: Type 1 Diabetes https://clinicaltrials.gov/study/NCT01722266 - NCT01800968 | Phase 2 | COMPLETED | enrolled 300 Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT) Conditions: Acute Heart Failure https://clinicaltrials.gov/study/NCT01800968 - NCT03500484 | Phase 1 | TERMINATED | enrolled 13 Effect of Liraglutide on Neural Responses to High Fructose Corn Syrup in Individuals With Obesity. Conditions: Obesity, Childhood, Neural Development https://clinicaltrials.gov/study/NCT03500484 - NCT02584582 | Phase 3 | UNKNOWN | enrolled 10 The Effect of GLP-1 on Postprandial Glucagon Secretion Independent of The Gastric Emptying Rate Conditions: Type 1 Diabetes https://clinicaltrials.gov/study/NCT02584582 - NCT01319240 | Phase 1 | COMPLETED | enrolled 24 Safety and Tolerability of Insulin Degludec/Liraglutide (A3) in Healthy Subjects Conditions: Diabetes, Healthy https://clinicaltrials.gov/study/NCT01319240 - NCT01499108 | Phase 4 | COMPLETED | enrolled 32 Time Course of the Blood Pressure Lowering Effect of Liraglutide Therapy in Type 2 Diabetes Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT01499108 - NCT07325435 | Phase 4 | ACTIVE_NOT_RECRUITING | enrolled 60 Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists Conditions: Type 2 Diabetes (T2DM) https://clinicaltrials.gov/study/NCT07325435 - NCT02351232 | Phase 3 | COMPLETED | enrolled 44 The Lira Pump Trial Conditions: Type 1 Diabetes https://clinicaltrials.gov/study/NCT02351232 - NCT01856790 | Phase 1 | COMPLETED | enrolled 15 Effect of Liraglutide on Automated Closed-loop Glucose Control in Type 1 Diabetes Conditions: Type 1 Diabetes https://clinicaltrials.gov/study/NCT01856790 - NCT00518882 | Phase 3 | COMPLETED | enrolled 467 Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT00518882 - NCT04839237 | Phase 2 | WITHDRAWN | enrolled 0 The Effect and the Pharmacogenomics Study of Liraglutide in Obese Patients Conditions: Obesity https://clinicaltrials.gov/study/NCT04839237 - NCT03191396 | Phase 3 | COMPLETED | enrolled 577 Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT03191396 - NCT00781937 | Phase 3 | COMPLETED | enrolled 422 Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance Conditions: Metabolism and Nutrition Disorder, Obesity https://clinicaltrials.gov/study/NCT00781937 - NCT01761318 | Phase 4 | COMPLETED | enrolled 50 Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients Conditions: Diabetes Mellitus Type 2, Metabolic Syndrome, Cardiovascular Disease, Diastolic Dysfunction, Fatty Liver https://clinicaltrials.gov/study/NCT01761318 - NCT02905864 | Phase 4 | COMPLETED | enrolled 150 Liraglutide 3 mg for Knee Osteoarthritis Conditions: Osteoarthritis, Obesity https://clinicaltrials.gov/study/NCT02905864 - NCT01388361 | Phase 3 | COMPLETED | enrolled 413 Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT01388361 - NCT01508806 | Phase 1 | COMPLETED | enrolled 30 Safety and Tolerability of Liraglutide in Subjects With Impaired Kidney Function and in Subjects With Normal Kidney Function Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT01508806 - NCT02674893 | Phase 4 | TERMINATED | enrolled 48 Effect of Victoza on Dietary Preferences and Habit in Patients With Type 2 Diabetes Conditions: Type 2 Diabetes, Overweight https://clinicaltrials.gov/study/NCT02674893 - NCT05294536 | Phase 1 | COMPLETED | enrolled 50 A Pharmacokinetic Study Comparing the Liraglutide Injection (RD12014) and Victoza® in Healthy Chinese Subjects Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT05294536 - NCT00154401 | Phase 2 | COMPLETED | enrolled 177 Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT00154401 - NCT01451905 | Not phased | UNKNOWN | enrolled 12 GLP-1 Receptors in Normal Skin and Skin From Patients With Psoriasis Conditions: Reduction of Psoriasis Following Liraglutide Therapy in Terms of PASI and DLQI https://clinicaltrials.gov/study/NCT01451905 - NCT01785043 | Phase 4 | COMPLETED | enrolled 13 Differences in Endothelial Function Amongst Sitagliptin and Liraglutide Users Conditions: DIABETES Mellitus Type 2 Not Well Controlled https://clinicaltrials.gov/study/NCT01785043 - NCT01664247 | Phase 3 | COMPLETED | enrolled 346 The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT01664247 - NCT01508923 | Phase 2 | COMPLETED | enrolled 17 Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT01508923 - NCT01779362 | Phase 3 | COMPLETED | enrolled 267 RISE Adult Medication Study Conditions: Prediabetes, Type 2 Diabetes https://clinicaltrials.gov/study/NCT01779362 - NCT02417103 | Phase 3 | TERMINATED | enrolled 2 Pretreatment of Patients Expecting Bariatric Surgery With the GLP-1 Analogon Liraglutid Conditions: Obesity https://clinicaltrials.gov/study/NCT02417103 - NCT01392573 | Phase 3 | COMPLETED | enrolled 413 A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT01392573 - NCT01336023 | Phase 3 | COMPLETED | enrolled 1663 Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT01336023 - NCT04190160 | Not phased | COMPLETED | enrolled 35 Quality of Life and Fixed-ratio Combination of Insulin Degludec and Liraglutide (iDegLira) Conditions: Type2 Diabetes https://clinicaltrials.gov/study/NCT04190160 - NCT01744236 | Phase 4 | COMPLETED | enrolled 70 SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT01744236 - NCT01536665 | Phase 1 | COMPLETED | enrolled 45 The Effect of Liraglutide Adjunct to Insulin on Glucagon Response to Hypoglycaemia in Subjects With Type 1 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 1 https://clinicaltrials.gov/study/NCT01536665 - NCT05705388 | Not phased | UNKNOWN | enrolled 50 POSE2.0 With GLP-1 Agonist for Obesity Management Conditions: Obesity https://clinicaltrials.gov/study/NCT05705388 - NCT01593137 | Phase 4 | WITHDRAWN | enrolled 0 A Long-term Trial to Compare the Effects of Liraglutide and Sulphonylurea (Glimepiride) Both in Combination With Metformin on Clinical, Endothelial and Image Markers of Cardiovascular Risk in Patients With Type 2 Diabetes Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT01593137 - NCT01836523 | Phase 3 | COMPLETED | enrolled 1398 The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 1 https://clinicaltrials.gov/study/NCT01836523 - NCT06925334 | Phase 4 | ENROLLING_BY_INVITATION | enrolled 170 A Study Comparing Degu Insulin Liraglutide Injection With Premixed Insulin on the Prognosis of Diabetes Mellitus Conditions: Type 2 Diabetic Patients https://clinicaltrials.gov/study/NCT06925334 - NCT02787551 | Phase 3 | COMPLETED | enrolled 514 Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period Conditions: Type 2 Diabetes Mellitus https://clinicaltrials.gov/study/NCT02787551 - NCT02501161 | Phase 3 | COMPLETED | enrolled 1012 A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT02501161 - NCT03041792 | Phase 1 | COMPLETED | enrolled 61 Methodology Study To Examine 6-Week Food Intake With Liraglutide In Obese Subjects Conditions: Obesity https://clinicaltrials.gov/study/NCT03041792 - NCT01722240 | Phase 3 | COMPLETED | enrolled 69 Liraglutide in Type 1 Diabetes Conditions: Type 1 Diabetes https://clinicaltrials.gov/study/NCT01722240 - NCT02060383 | Phase 4 | COMPLETED | enrolled 249 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Conditions: Cushing's Disease, Acromegaly https://clinicaltrials.gov/study/NCT02060383 - NCT03260881 | Phase 4 | COMPLETED | enrolled 38 Liraglutide Effects on Epicardial Fat Inflammatory Genes Conditions: Type2 Diabetes, Coronary Artery Disease https://clinicaltrials.gov/study/NCT03260881 - NCT03712098 | Phase 2 | COMPLETED | enrolled 40 Daily Liraglutide for Nicotine Dependence Conditions: Smoking Cessation, Weight, Body https://clinicaltrials.gov/study/NCT03712098 - NCT01620463 | Phase 1 | COMPLETED | enrolled 32 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Healthy Japanese Volunteers Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT01620463 - NCT01739049 | Phase 4 | COMPLETED | enrolled 42 Influence of Appetite Related Hormones in Binge Eating Behaviour Among the Overweight and Obese Conditions: Binge Eating Behaviour https://clinicaltrials.gov/study/NCT01739049 - NCT03347890 | Phase 4 | COMPLETED | enrolled 70 Reward Mechanisms in Obesity Conditions: Obesity https://clinicaltrials.gov/study/NCT03347890 - NCT05681299 | Phase 4 | RECRUITING | enrolled 40 Effects of GH and Lirglutide on AgRP Conditions: Healthy, Growth Hormone Deficiency https://clinicaltrials.gov/study/NCT05681299 - NCT00318461 | Phase 3 | COMPLETED | enrolled 1091 To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT00318461 - NCT06400615 | Phase 2 | COMPLETED | enrolled 40 Study That Tests AD109 in Patients Taking GLP-1 Drugs Conditions: OSA https://clinicaltrials.gov/study/NCT06400615 - NCT02721888 | Phase 4 | TERMINATED | enrolled 127 Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT02721888 - NCT01518166 | Phase 1 | COMPLETED | enrolled 70 Effect of Liraglutide on Gastrointestinal Absorption of Several Drugs and Potential Influence of Liraglutide on Intragastric pH Conditions: Diabetes, Healthy https://clinicaltrials.gov/study/NCT01518166 - NCT02963922 | Phase 3 | COMPLETED | enrolled 396 Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin Conditions: Metabolism and Nutrition Disorder, Obesity https://clinicaltrials.gov/study/NCT02963922 - NCT02765399 | Phase 4 | COMPLETED | enrolled 23 The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT02765399 - NCT06865365 | Phase 4 | NOT_YET_RECRUITING | enrolled 72 Preoperative Use of Liraglutide Additionally to Common Dietological Measures as Opposed to Dietological Measures Alone Conditions: Obesity, Adolescent https://clinicaltrials.gov/study/NCT06865365 - NCT02043054 | Phase 3 | COMPLETED | enrolled 90 Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA) Conditions: Type 2 Diabetes Mellitus, Cardiovascular Disease https://clinicaltrials.gov/study/NCT02043054 - NCT06818292 | Not phased | COMPLETED | enrolled 10 Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists Conditions: Healthy https://clinicaltrials.gov/study/NCT06818292 - NCT01794143 | Phase 3 | COMPLETED | enrolled 7850 A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes Conditions: Type 2 Diabetes, Comparative Effectiveness of Glycemia-lowering Medications https://clinicaltrials.gov/study/NCT01794143 - NCT05579249 | Phase 4 | COMPLETED | enrolled 500 A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America Conditions: Obesity https://clinicaltrials.gov/study/NCT05579249 - NCT03856047 | Phase 2 | COMPLETED | enrolled 706 Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity. Conditions: Overweight, Obesity https://clinicaltrials.gov/study/NCT03856047 - NCT01664676 | Phase 4 | COMPLETED | enrolled 11 Effects of Liraglutide on Kidney Function in Type 2 Diabetic Patients Conditions: Type 2 Diabetes Mellitus https://clinicaltrials.gov/study/NCT01664676 - NCT06449703 | Phase 1 | UNKNOWN | enrolled 44 A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide in Healthy Chinese Subjects Conditions: Healthy https://clinicaltrials.gov/study/NCT06449703 - NCT05313529 | Not phased | COMPLETED | enrolled 396 LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes Conditions: Type 2 Diabetes Mellitus, Mild Cognitive Impairment https://clinicaltrials.gov/study/NCT05313529 - NCT02535299 | Phase 4 | UNKNOWN | enrolled 200 Par-4 and Telomere-telomerase System in Type 2 Diabetes Patients Who Received GLP-1 or Metformin Treatment Conditions: GLP-1；Metformin；Telomere-telomerase System；Par-4 https://clinicaltrials.gov/study/NCT02535299 - NCT02686177 | Phase 4 | COMPLETED | enrolled 50 Effect of GLP-1 on Angiogenesis Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT02686177 - NCT02527200 | Phase 3 | COMPLETED | enrolled 56 Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome Conditions: Metabolism and Nutrition Disorder, Obesity https://clinicaltrials.gov/study/NCT02527200 - NCT02207348 | Phase 1 | COMPLETED | enrolled 24 Investigating Bioequivalence Between Single-dose Liraglutide Administered Subcutaneously With Two Different Pen-injectors Conditions: Metabolism and Nutrition Disorder, Obesity https://clinicaltrials.gov/study/NCT02207348 - NCT01654120 | Phase 4 | COMPLETED | enrolled 37 Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics Conditions: Diabetes Mellitus, Type II https://clinicaltrials.gov/study/NCT01654120 - NCT04057261 | Phase 3 | WITHDRAWN | enrolled 0 Effect of Liraglutide on the Metabolic Profile in Patients With Type 2 Diabetes and Cardiovascular Disease Conditions: Type 2 Diabetes, Cardiovascular Diseases https://clinicaltrials.gov/study/NCT04057261 - NCT04046822 | Phase 4 | UNKNOWN | enrolled 70 Effect of Liraglutide on Microbiome in Obesity Conditions: Obesity, Weight Loss, Microbiome https://clinicaltrials.gov/study/NCT04046822 - NCT02001363 | Not phased | UNKNOWN | enrolled 90 Efficacy Study of Glucagonlike Peptide-1 to Treat Reperfusion Injury Conditions: Acute Myocardial Infarction https://clinicaltrials.gov/study/NCT02001363 - NCT04531176 | Phase 4 | TERMINATED | enrolled 74 EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial Conditions: Type 2 Diabetes, Obesity https://clinicaltrials.gov/study/NCT04531176 - NCT00395746 | Phase 3 | COMPLETED | enrolled 264 Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT00395746 - NCT02964247 | Phase 3 | COMPLETED | enrolled 303 LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors. Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT02964247 - NCT01425580 | Phase 2 | COMPLETED | enrolled 62 Liraglutide and Heart Failure in Type 2 Diabetes Conditions: Congestive Heart Failure, Type 2 Diabetes Mellitus https://clinicaltrials.gov/study/NCT01425580 - NCT02910570 | Phase 4 | COMPLETED | enrolled 150 Changes in Skin Autoflouresence Following Weight Loss and Maintenance Using Liraglutide in Knee Osteoarthritis Conditions: Osteoarthritis, Knee https://clinicaltrials.gov/study/NCT02910570 - NCT02650596 | Not phased | UNKNOWN | enrolled 68 Effects of GLP-1 on Chronic Heart Failure Conditions: Heart Failure https://clinicaltrials.gov/study/NCT02650596 - NCT06500130 | Not phased | COMPLETED | enrolled 22 Effects of Liraglutide on Body Surface Gastric Mapping Conditions: Gastroparesis, Functional Dyspepsia, Chronic Nausea and Vomiting Syndrome, Healthy https://clinicaltrials.gov/study/NCT06500130 - NCT02717858 | Phase 1 | COMPLETED | enrolled 52 A Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects. Conditions: Metabolism and Nutrition Disorder, Obesity https://clinicaltrials.gov/study/NCT02717858 - NCT02072096 | Phase 4 | TERMINATED | enrolled 192 A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM) Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT02072096 - NCT02284230 | Phase 2 | WITHDRAWN | enrolled 0 The Effect of Liraglutide in Patients With Prediabetes and Kidney Failure Conditions: Kidney Failure, Chronic, Prediabetic State https://clinicaltrials.gov/study/NCT02284230 - NCT01617434 | Phase 3 | COMPLETED | enrolled 451 The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT01617434 - NCT03466021 | Phase 4 | COMPLETED | enrolled 40 Effects of Liraglutide in Chronic Obstructive Pulmonary Disease Conditions: Pulmonary Disease, Chronic Obstructive https://clinicaltrials.gov/study/NCT03466021 - NCT03374956 | Phase 3 | COMPLETED | enrolled 193 Individualized Obesity Pharmacotherapy Conditions: Obesity https://clinicaltrials.gov/study/NCT03374956 - NCT01272232 | Phase 3 | COMPLETED | enrolled 846 Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes Conditions: Metabolism and Nutrition Disorder, Obesity https://clinicaltrials.gov/study/NCT01272232 - NCT01179048 | Phase 3 | COMPLETED | enrolled 9341 Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT01179048 - NCT06836284 | Not phased | RECRUITING | enrolled 40 The Evira Study: Additional Support During Obesity Treatment Conditions: Childhood Obesity, Treatment Adherence https://clinicaltrials.gov/study/NCT06836284 - NCT02507128 | Not phased | UNKNOWN | enrolled 190 Effects of Glucagon Like Peptide-1 on No-reflow Conditions: Acute ST-segment Elevation Myocardial Infarction https://clinicaltrials.gov/study/NCT02507128 - NCT03523273 | Phase 2 | COMPLETED | enrolled 136 Pilot Study of the Effect of Liraglutide 3.0 mg on Weight Loss and Gastric Functions in Obesity Conditions: Obesity https://clinicaltrials.gov/study/NCT03523273 - NCT01610934 | Phase 3 | COMPLETED | enrolled 15 The Effects of GLP-1 in Maturity-Onset Diabetes of The Young (MODY) Conditions: Maturity-onset Diabetes of the Young https://clinicaltrials.gov/study/NCT01610934 - NCT05390307 | Not phased | COMPLETED | enrolled 60 Obesity Treatment to Improve Diabetes Conditions: Type 1 Diabetes https://clinicaltrials.gov/study/NCT05390307 - NCT02453711 | Phase 2 | COMPLETED | enrolled 957 Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus Conditions: Metabolism and Nutrition Disorder, Obesity https://clinicaltrials.gov/study/NCT02453711 - NCT01472640 | Not phased | COMPLETED | enrolled 240 The Effect of Liraglutide on Left Ventricular Function in Chronic Heart Failure Patients With and Without Type 2 Diabetes Mellitus Conditions: Hyperglycemia, Chronic Heart Failure https://clinicaltrials.gov/study/NCT01472640 - NCT07244003 | Phase 4 | RECRUITING | enrolled 430 Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control Conditions: T2DM (Type 2 Diabetes Mellitus) https://clinicaltrials.gov/study/NCT07244003 - NCT02931383 | Phase 4 | COMPLETED | enrolled 150 Ultrasound of the Knee in Obese Patients With Knee Osteoarthritis; Weight Maintenance Conditions: Osteoarthritis, Obesity https://clinicaltrials.gov/study/NCT02931383 - NCT01512108 | Phase 3 | COMPLETED | enrolled 363 Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT01512108 - NCT01832532 | Phase 2 | COMPLETED | enrolled 34 A Pilot Study of the Effects on Sleep Disordered Breathing (SDB) When Using the Drug Liraglutide for 4 Weeks Conditions: Sleep Apnea, Sleep Disordered Breathing https://clinicaltrials.gov/study/NCT01832532 - NCT03426085 | Phase 2 | UNKNOWN | enrolled 44 The Effects of Liraglutide on Sudomotor Function and Inflammation in Type 2 Diabetes Conditions: Autonomic Nervous System Diseases, Sweat Gland Diseases, Diabetic Neuropathy With Neurologic Complication https://clinicaltrials.gov/study/NCT03426085 - NCT00993304 | Phase 1 | COMPLETED | enrolled 20 A Trial to Assess the Effect of Liraglutide on Blood Triglyceride (Fat) Levels After a Meal in Type 2 Diabetics Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT00993304 - NCT01795248 | Phase 4 | COMPLETED | enrolled 105 The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Pregnancy-induced Diabetes Conditions: Gestational Diabetes Mellitus https://clinicaltrials.gov/study/NCT01795248 - NCT06408532 | Phase 4 | UNKNOWN | enrolled 256 The Efficacy and Safety of Insulin Degludec/Liraglutide Combination (IDegLira) in Patients With Type 2 Diabetes Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT06408532 - NCT01562678 | Phase 4 | COMPLETED | enrolled 28 Liraglutide in Obesity and Diabetes: Identification of CNS Targets Using fMRI Conditions: Diabetes, Effects of Liraglutide Administration on Brain Activity, Weight Loss, Hunger https://clinicaltrials.gov/study/NCT01562678 - NCT01917656 | Phase 4 | COMPLETED | enrolled 343 Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT01917656 - NCT01513525 | Phase 1 | COMPLETED | enrolled 21 Comparison of Liraglutide Injected at Three Different Injection Sites in Healthy Volunteers Conditions: Diabetes, Healthy https://clinicaltrials.gov/study/NCT01513525 - NCT02490176 | Not phased | UNKNOWN | enrolled 50 Effects of Glucagon Like Peptide-1 on Haemodynamic Parameters Conditions: Heart Failure https://clinicaltrials.gov/study/NCT02490176 - NCT00873223 | Phase 1 | COMPLETED | enrolled 33 Examination of the Effects of Liraglutide on the Mode of Action of Insulin Detemir Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT00873223 - NCT03948347 | Not phased | UNKNOWN | enrolled 1708 Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus Conditions: Ischemic Stroke, Transient Ischemic Attack, Type 2 Diabetes Mellitus https://clinicaltrials.gov/study/NCT03948347 - NCT03175120 | Phase 3 | COMPLETED | enrolled 453 A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD) Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT03175120 - NCT01954147 | Phase 2 | UNKNOWN | enrolled 100 Umbilical Cord Mesenchymal Stem Cells and Liraglutide in Diabetes Mellitus Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT01954147 - NCT01516255 | Phase 1 | COMPLETED | enrolled 64 Effect of Liraglutide on Heart Frequency in Healthy Volunteers Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT01516255 - NCT02205528 | Phase 2 | COMPLETED | enrolled 108 A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin Conditions: Diabetes, Diabetes Mellitus Type 2 https://clinicaltrials.gov/study/NCT02205528 - NCT05794581 | Phase 1 | COMPLETED | enrolled 32 A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes Conditions: Type 1 Diabetes https://clinicaltrials.gov/study/NCT05794581 - NCT01558271 | Phase 3 | COMPLETED | enrolled 492 A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus Conditions: Type 2 Diabetes Mellitus https://clinicaltrials.gov/study/NCT01558271 - NCT02617654 | Phase 2 | COMPLETED | enrolled 18 Liraglutide Effect on Beta-cell Function in C-peptide Positive Type 1 Diabetes Conditions: Type 1 Diabetes https://clinicaltrials.gov/study/NCT02617654 - NCT01208012 | Phase 4 | COMPLETED | enrolled 44 Impact of Liraglutide on Endothelial Function and Microvascular Blood Flow in Type 2 Diabetes Mellitus Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT01208012 - NCT06438146 | Phase 4 | UNKNOWN | enrolled 40 LIROH - Liraglutide for Obesity in HIV Conditions: Obesity, HIV Infections https://clinicaltrials.gov/study/NCT06438146 - NCT00700817 | Phase 3 | COMPLETED | enrolled 665 The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT00700817 - NCT02324842 | Not phased | COMPLETED | enrolled 45 Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients Conditions: Type 2 Diabetes Mellitus https://clinicaltrials.gov/study/NCT02324842 - NCT06976619 | Phase 2 | RECRUITING | enrolled 60 The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes Conditions: Type 1 Diabetes, Type 2 Diabetes https://clinicaltrials.gov/study/NCT06976619 - NCT00761540 | Phase 1 | COMPLETED | enrolled 37 To Investigate the Blood Concentration of Liraglutide as Well as the Effects on Glucose and Insulin After 21 Days of Daily Subcutaneous Injections of Liraglutide or Placebo Conditions: Diabetes, Healthy https://clinicaltrials.gov/study/NCT00761540 - NCT01557166 | Phase 3 | COMPLETED | enrolled 359 Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea Conditions: Metabolism and Nutrition Disorder, Obesity, Obstructive Sleep Apnoea https://clinicaltrials.gov/study/NCT01557166 - NCT02344186 | Phase 4 | UNKNOWN | enrolled 12 Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT02344186 - NCT02773368 | Phase 3 | COMPLETED | enrolled 420 A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT02773368 - NCT03862716 | Phase 3 | COMPLETED | enrolled 159 Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira Conditions: Type 2 Diabetes Mellitus https://clinicaltrials.gov/study/NCT03862716 - NCT02518945 | Phase 3 | COMPLETED | enrolled 26 Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes Conditions: Type 1 Diabetes Mellitus https://clinicaltrials.gov/study/NCT02518945 - NCT05952882 | Phase 3 | UNKNOWN | enrolled 188 Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility Conditions: Polycystic Ovary Syndrome, Obesity, Infertility, Female https://clinicaltrials.gov/study/NCT05952882 - NCT03795701 | Not phased | COMPLETED | enrolled 73 To Predict Weight Loss Response to Liraglutide (Saxenda®), From fMRI-based Determination of Food Cue Reactivity Conditions: Obesity https://clinicaltrials.gov/study/NCT03795701 - NCT05268627 | Not phased | UNKNOWN | enrolled 38 Endoscopic Ultrasound Guided Gastric Botulinum Toxin Injections Versus Glucagon Like Peptide 1 Receptor Agonist in Weight Loss Conditions: Obesity https://clinicaltrials.gov/study/NCT05268627 - NCT03642600 | Phase 4 | COMPLETED | enrolled 21 The Gut Microbiome in Women With Polycystic Ovary Syndrome Conditions: PCOS, Obesity, Metabolic Syndrome https://clinicaltrials.gov/study/NCT03642600 - NCT02696148 | Phase 1 | COMPLETED | enrolled 24 A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years Conditions: Metabolism and Nutrition Disorder, Obesity https://clinicaltrials.gov/study/NCT02696148 - NCT02647944 | Phase 2 | COMPLETED | enrolled 40 Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity Conditions: Obesity https://clinicaltrials.gov/study/NCT02647944 - NCT03449654 | Phase 4 | COMPLETED | enrolled 102 Effect of Liraglutide on Vascular Inflammation in Type-2 Diabetes Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT03449654 - NCT01782261 | Phase 2 | COMPLETED | enrolled 15 Incretin Effect on the Immunological Phenotype Conditions: Type 1 Diabetes https://clinicaltrials.gov/study/NCT01782261 - NCT02602600 | Phase 4 | COMPLETED | enrolled 33 Glucagon-like Peptide-1 and Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Coronary Stenosis Conditions: Microvascular Angina https://clinicaltrials.gov/study/NCT02602600 - NCT06171152 | Phase 1 | SUSPENDED | enrolled 30 Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues Conditions: Multiple Sclerosis, Long COVID, Long Covid19, Obese, Obesity, Obesity, Morbid, Acute Leukemia in Remission https://clinicaltrials.gov/study/NCT06171152 - NCT02870231 | Phase 1 | COMPLETED | enrolled 187 Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity Conditions: Metabolism and Nutrition Disorder, Obesity https://clinicaltrials.gov/study/NCT02870231 - NCT01845259 | Phase 2 | UNKNOWN | enrolled 103 Does a GLP-1 Receptor Agonist Change Glucose Tolerance in Antipsychotic-treated Patients? Conditions: Impaired Glucose Tolerance Associated With Drugs https://clinicaltrials.gov/study/NCT01845259 - NCT01517568 | Phase 1 | COMPLETED | enrolled 7 Metabolism and Excretion of Liraglutide in Healthy Male Volunteers Conditions: Diabetes, Healthy https://clinicaltrials.gov/study/NCT01517568 - NCT00993720 | Phase 3 | COMPLETED | enrolled 30 Effect of GLP-1 on Insulin-dose, Risk of Hypoglycemia and Gastric Emptying Rate in Patients With Type 1 Diabetes Conditions: Diabetes Mellitus https://clinicaltrials.gov/study/NCT00993720 - NCT00856986 | Phase 3 | COMPLETED | enrolled 987 The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT00856986 - NCT01620489 | Phase 3 | COMPLETED | enrolled 279 Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT01620489 - NCT07301437 | Phase 4 | NOT_YET_RECRUITING | enrolled 120 RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients. Conditions: Overweight and Obese Adults https://clinicaltrials.gov/study/NCT07301437 - NCT01966978 | Phase 4 | COMPLETED | enrolled 157 The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study Conditions: Diabetes Mellitus, Type 2, Diabetes https://clinicaltrials.gov/study/NCT01966978 - NCT05285397 | Not phased | UNKNOWN | enrolled 60 Effect of Liraglutide on Weight Loss in Patients Who Have Undergone Revisional Bariatric Surgeries. Conditions: Morbid Obesity https://clinicaltrials.gov/study/NCT05285397 - NCT05360537 | Phase 4 | COMPLETED | enrolled 100 Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT05360537 - NCT02516657 | Phase 3 | COMPLETED | enrolled 5 Liraglutide in Adolescents With Type 1 Diabetes Conditions: Type 1 Diabetes https://clinicaltrials.gov/study/NCT02516657 - NCT03034941 | Phase 4 | COMPLETED | enrolled 35 Short Term Weight Loss With Liraglutide and Metformin in Infertile Obese PCOS Patients Conditions: Obesity, PCOS https://clinicaltrials.gov/study/NCT03034941 - NCT02908087 | Phase 2 | COMPLETED | enrolled 13 Incretin-based Therapy in Early Diagnosed Type 1 Diabetes Conditions: Type 1 Diabetes https://clinicaltrials.gov/study/NCT02908087 - NCT02718950 | Phase 3 | UNKNOWN | enrolled 20 Influence of Liraglutide, a GLP-1 Receptor Agonist, on Brown Adipose Tissue (BAT) Activity in Humans Conditions: Obesity, Type 2 Diabetes Mellitus https://clinicaltrials.gov/study/NCT02718950 - NCT01270789 | Phase 3 | COMPLETED | enrolled 63 LIraglutide and Beta-cell RepAir (LIBRA) Study Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT01270789 - NCT01620476 | Phase 1 | COMPLETED | enrolled 24 Safety and Tolerability of Liraglutide in Healthy Japanese Volunteers Conditions: Diabetes, Healthy https://clinicaltrials.gov/study/NCT01620476 - NCT04146155 | Phase 4 | UNKNOWN | enrolled 200 Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease Conditions: Type 2 Diabetes, Peripheral Vascular Disorder Due to Diabetes Mellitus https://clinicaltrials.gov/study/NCT04146155 - NCT04199728 | Phase 2 | COMPLETED | enrolled 27 Use of a GLP-1R Agonist to Treat Opioid Use Disorder Conditions: Opiate Substitution Treatment, Opioid-Related Disorders https://clinicaltrials.gov/study/NCT04199728 - NCT01596504 | Phase 2 | COMPLETED | enrolled 142 Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin Conditions: Type 2 Diabetes Mellitus https://clinicaltrials.gov/study/NCT01596504 - NCT02057172 | Phase 2 | COMPLETED | enrolled 254 Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT02057172 - NCT05225974 | Phase 1 | COMPLETED | enrolled 32 A Randomized Phase 1 Study of Liralutide Injection in Healthy Chinese Subjects Conditions: Therapeutic Equivalency https://clinicaltrials.gov/study/NCT05225974 - NCT06201819 | Phase 4 | COMPLETED | enrolled 37 Liraglutide Effectiveness in Preoperative Weight-loss for Bariatric-metabolic Surgery Conditions: Weight Loss, Bariatric Surgery Candidate, Obesity, Morbid https://clinicaltrials.gov/study/NCT06201819 - NCT02650206 | Phase 1 | COMPLETED | enrolled 56 Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and Blood Conditions: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type II, Diabetes Mellitus, Adult-Onset, Inflammation https://clinicaltrials.gov/study/NCT02650206 - NCT01515553 | Phase 1 | COMPLETED | enrolled 22 Bioequivalence of Two Liraglutide Formulations in Healthy Volunteers Conditions: Diabetes, Healthy https://clinicaltrials.gov/study/NCT01515553 - NCT01879917 | Phase 3 | COMPLETED | enrolled 65 Liraglutide in Newly Onset Type 1 Diabetes. Conditions: Diabetes Mellitus, Type 1 https://clinicaltrials.gov/study/NCT01879917 - NCT02299388 | Phase 4 | COMPLETED | enrolled 11 To Evaluate the Effect of Liraglutide on Ambulatory Blood Pressure-A Pilot Study Conditions: Diabetes Mellitus, Non-Insulin-Dependent, Hypertensive Disease https://clinicaltrials.gov/study/NCT02299388 - NCT02889510 | Phase 3 | COMPLETED | enrolled 76 Study to Assess the Efficacy of Liraglutide in Patients With Type 2 Diabetes Mellitus Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT02889510 - NCT01272219 | Phase 3 | COMPLETED | enrolled 3731 Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes Conditions: Metabolism and Nutrition Disorder, Obesity https://clinicaltrials.gov/study/NCT01272219 - NCT04311411 | Phase 1 | COMPLETED | enrolled 114 A Study of Tirzepatide in Overweight and Very Overweight Participants Conditions: Obesity, Overweight https://clinicaltrials.gov/study/NCT04311411 - NCT04122716 | Phase 4 | UNKNOWN | enrolled 215 Combined Effects of GLP-1 Analogue and Exercise on Maintenance of Weight Loss and Health After Very-low Calorie Diet Conditions: Obesity https://clinicaltrials.gov/study/NCT04122716 - NCT01507272 | Phase 1 | COMPLETED | enrolled 34 Safety and Tolerability of Liraglutide in Healthy Male Volunteers Conditions: Diabetes, Healthy https://clinicaltrials.gov/study/NCT01507272 - NCT03172494 | Phase 3 | COMPLETED | enrolled 720 A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT03172494 - NCT00943501 | Phase 1 | COMPLETED | enrolled 21 Safety of Liraglutide in Pediatric Patients With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT00943501 - NCT03353948 | Phase 4 | COMPLETED | enrolled 30 The Effect of a Liraglutide on IVF in Obese PCOS Conditions: Polycystic Ovary Syndrome, Obesity, Infertility, Female https://clinicaltrials.gov/study/NCT03353948 - NCT01128894 | Phase 3 | COMPLETED | enrolled 841 A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide. Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT01128894 - NCT04605861 | Phase 3 | COMPLETED | enrolled 414 The Efficacy and Safety of Liraglutide on Body Weight Loss in Obese and Overweight Patients Conditions: Obese, Overweight https://clinicaltrials.gov/study/NCT04605861 - NCT01507285 | Phase 1 | COMPLETED | enrolled 24 Safety and Tolerability of Liraglutide in Healthy Volunteers and Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2, Healthy https://clinicaltrials.gov/study/NCT01507285 - NCT02231658 | Phase 1 | TERMINATED | enrolled 109 Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion Conditions: Diabetes Mellitus https://clinicaltrials.gov/study/NCT02231658 - NCT02909933 | Phase 4 | COMPLETED | enrolled 30 Low Dose Liraglutide and Metformin vs. High Dose Liraglutide Alone in Treatment of Obesity Conditions: Polycystic Ovary Syndrome, Obesity https://clinicaltrials.gov/study/NCT02909933 - NCT03036800 | Phase 4 | COMPLETED | enrolled 392 Saxenda in Obesity Services (STRIVE Study) Conditions: Obesity, Weight Loss, Diabetes Mellitus https://clinicaltrials.gov/study/NCT03036800 - NCT04903509 | Phase 1 | COMPLETED | enrolled 95 A Study in Men With Overweight to Test How Well Different Doses of BI 1820237 Are Tolerated When Given as an Injection Alone or in Combination With Liraglutide Conditions: Healthy https://clinicaltrials.gov/study/NCT04903509 - NCT04525300 | Phase 3 | UNKNOWN | enrolled 300 Gut Microbiome Changes Following Liraglutide Treatment in Obese Subjects or Overweight Subjects With Co-morbidities Conditions: Obesity https://clinicaltrials.gov/study/NCT04525300 - NCT01363609 | Not phased | COMPLETED | enrolled 50 Effects of Glucagon Like Peptide-1(GLP-1) and Liraglutide on Brain Satiety and Reward Circuits and Feeding Behavior in Diabetes Conditions: Obesity, Type 2 Diabetes https://clinicaltrials.gov/study/NCT01363609 - NCT03883412 | Phase 4 | UNKNOWN | enrolled 60 Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007) Conditions: Type2 Diabetes https://clinicaltrials.gov/study/NCT03883412 - NCT02292290 | Phase 4 | COMPLETED | enrolled 99 Trial for People With Established Type 2 Diabetes During Ramadan Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT02292290 - NCT01237119 | Phase 2 | COMPLETED | enrolled 52 Liraglutide Efficacy and Action in Non-Alcoholic Steatohepatitis Conditions: Nonalcoholic Steatohepatitis https://clinicaltrials.gov/study/NCT01237119 - NCT02082496 | Phase 2 | COMPLETED | enrolled 50 GLP-1 Response and Effect in Individuals With Obesity Causing Genetic Mutations Conditions: Obesity https://clinicaltrials.gov/study/NCT02082496 - NCT02545738 | Phase 4 | COMPLETED | enrolled 32 Antiproteinuric Effects of Liraglutide Treatment Conditions: Diabetic Kidney Disease https://clinicaltrials.gov/study/NCT02545738 - NCT01509755 | Phase 2 | COMPLETED | enrolled 196 Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT01509755 - NCT03480022 | Phase 3 | COMPLETED | enrolled 88 Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS Conditions: Pre Diabetes, Polycystic Ovary Syndrome, Obesity Android https://clinicaltrials.gov/study/NCT03480022 - NCT01460069 | Not phased | COMPLETED | enrolled 20 The Effect of Glucagon Like Peptide (GLP)-1 in Psoriasis Conditions: Psoriasis https://clinicaltrials.gov/study/NCT01460069 - NCT01787916 | Phase 4 | COMPLETED | enrolled 15 52 Week Trial of Liraglutide in Type 1 Diabetes Conditions: Type 1 Diabetes https://clinicaltrials.gov/study/NCT01787916 - NCT02073929 | Phase 4 | COMPLETED | enrolled 72 LIPT - Liraglutide in Polycystic Ovary Syndrome Conditions: Polycystic Ovary Syndrome, Cardiovascular Disease https://clinicaltrials.gov/study/NCT02073929 - NCT03068065 | Phase 4 | COMPLETED | enrolled 87 Antidiabetic Effects on Intrahepatic Fat Conditions: Non-Alcoholic Fatty Liver Disease, Type2 Diabetes https://clinicaltrials.gov/study/NCT03068065 - NCT02244164 | Not phased | TERMINATED | enrolled 5 Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments. Conditions: Type 2 Diabetes, Incretinomimetics, Pancreas https://clinicaltrials.gov/study/NCT02244164 - NCT01870297 | Phase 1 | COMPLETED | enrolled 72 A Study of LY3025876 in Participants With Diabetes Conditions: Type 2 Diabetes Mellitus https://clinicaltrials.gov/study/NCT01870297 - NCT01755416 | Phase 2 | COMPLETED | enrolled 18 Liraglutide Versus Insulin Mono-therapy in the Closed Loop Setting Conditions: Type 1 Diabetes https://clinicaltrials.gov/study/NCT01755416 - NCT04781998 | Phase 4 | COMPLETED | enrolled 24 Is Saxenda® a Viable Treatment of Obese Patients in Forensic Psychiatry? Conditions: Mental Disorder, Metabolic Disturbance, Feasibility, Overweight and Obesity, Liraglutide https://clinicaltrials.gov/study/NCT04781998 - NCT01740921 | Not phased | COMPLETED | enrolled 39 GLP-1 and Microvascular Function in Type 2 Diabetes Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT01740921 - NCT02472717 | Phase 2 | WITHDRAWN | enrolled 0 Psoriatic Arthritis Treated With Liraglutide Therapy: a QUality of Life and Efficacy Study Conditions: Psoriatic Arthritis, Psoriasis, Impaired Glucose Tolerance, Type 2 Diabetes https://clinicaltrials.gov/study/NCT02472717 - NCT01638260 | Phase 4 | TERMINATED | enrolled 22 GLP-1 and Non-exercise Activity Thermogenesis in RHZ Conditions: Type 2 Diabetes Mellitus https://clinicaltrials.gov/study/NCT01638260 - NCT01117350 | Phase 4 | COMPLETED | enrolled 978 Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT01117350 - NCT03158805 | Phase 2 | COMPLETED | enrolled 60 Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated) Conditions: Bipolar Disorder, Obesity https://clinicaltrials.gov/study/NCT03158805 - NCT05779644 | Not phased | UNKNOWN | enrolled 300 Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus Conditions: Metformin, Obesity, Abdominal, Diabetes Mellitus, Type 2, Abdominal Fat, Non-Alcoholic Fatty Liver Disease, Metabolism Disorder, Glucose, Metabolism Disorder, Lipid https://clinicaltrials.gov/study/NCT05779644 - NCT01755572 | Phase 4 | COMPLETED | enrolled 22 Blood Pressure Outcomes With Liraglutide Therapy Conditions: Type 2 Diabetes, Systolic Hypertension https://clinicaltrials.gov/study/NCT01755572 - NCT01517555 | Phase 1 | COMPLETED | enrolled 18 Effect of Liraglutide on Absorption of Paracetamol in Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT01517555 - NCT02638805 | Phase 3 | COMPLETED | enrolled 136 Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT02638805 - NCT02832999 | Phase 4 | COMPLETED | enrolled 14 Short Term Effect of Liraglutide Versus Vildagliptine on Insulin Secretion and Insulin Sensitivity in Type 2 Diabetes Conditions: Type 2 Diabetes Mellitus https://clinicaltrials.gov/study/NCT02832999 - NCT06742710 | Phase 4 | RECRUITING | enrolled 890 Liraglutide Treatment in Obese Infertile PCOS Women Conditions: PCOS, Obesity, Infertility https://clinicaltrials.gov/study/NCT06742710 - NCT03371862 | Phase 2 | WITHDRAWN | enrolled 0 Liraglutide on Decreasing Parenteral Support in Short Bowel Patients (SLIPS) Conditions: Short Bowel Syndrome https://clinicaltrials.gov/study/NCT03371862 - NCT01206101 | Phase 2 | TERMINATED | enrolled 3 Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation Conditions: Diabetes, Diabetes Mellitus, Type 1 https://clinicaltrials.gov/study/NCT01206101 - NCT02488057 | Phase 4 | COMPLETED | enrolled 360 Improving Beta Cell Function in Mexican American Women With Prediabetes Conditions: Pre-Diabetes https://clinicaltrials.gov/study/NCT02488057 - NCT01595789 | Phase 4 | COMPLETED | enrolled 41 The Effect of Liraglutide on the Treatment of Coronary Artery Disease and Type 2 Diabetes Conditions: Coronary Artery Disease, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT01595789 - NCT02973321 | Phase 2 | COMPLETED | enrolled 296 A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus Conditions: Type 2 Diabetes Mellitus https://clinicaltrials.gov/study/NCT02973321 - NCT02138045 | Not phased | COMPLETED | enrolled 39 Treatment of Diabetic Neuropathy With Liraglutide Conditions: Diabetes Mellitus, Type 1, Type 1 Diabetes Mellitus https://clinicaltrials.gov/study/NCT02138045 - NCT05419856 | Phase 1 | COMPLETED | enrolled 34 Safety, Tolerability and Pharmacokinetics of Intraarticular 4P004 Single Dose in Patient With KL 2-4 Osteoarthritic Knee Conditions: Knee Osteoarthritis https://clinicaltrials.gov/study/NCT05419856 - NCT03341429 | Phase 4 | COMPLETED | enrolled 70 Evaluation of Liraglutide 3.0mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response Conditions: Obesity https://clinicaltrials.gov/study/NCT03341429 - NCT05467514 | Phase 3 | COMPLETED | enrolled 35 Effect of Liraglutide on Subclinical Atherosclerosis in Patients With Type 1 Diabetes Mellitus Conditions: Diabetes Mellitus, Type 1 https://clinicaltrials.gov/study/NCT05467514 - NCT01511692 | Phase 1 | COMPLETED | enrolled 43 Effect of Liraglutide Compared to Glimepiride on Appetite in Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT01511692 - NCT00154414 | Phase 2 | COMPLETED | enrolled 226 Effect of Liraglutide on Blood Glucose Control in Japanese Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT00154414 - NCT01455441 | Phase 4 | COMPLETED | enrolled 40 The Effects of Physical Training and GLP-1 Receptor Agonist Liraglutide Treatment in Patients With Type 2 Diabetes Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT01455441 - NCT02092896 | Phase 3 | COMPLETED | enrolled 40 Liraglutide as add-on to Insulin in Type 1 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 1 https://clinicaltrials.gov/study/NCT02092896 - NCT02008682 | Phase 4 | COMPLETED | enrolled 368 The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT02008682 - NCT04883346 | Phase 2 | COMPLETED | enrolled 34 Liraglutide (Saxenda(R)) in Adolescents With Obesity After Sleeve Gastrectomy Conditions: Obesity, Status Post Sleeve Gastrectomy https://clinicaltrials.gov/study/NCT04883346 - NCT03292185 | Phase 1 | COMPLETED | enrolled 24 A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT03292185 - NCT01514487 | Phase 1 | COMPLETED | enrolled 24 Comparison of Three Liraglutide Formulations in Healthy Volunteers Conditions: Diabetes, Healthy https://clinicaltrials.gov/study/NCT01514487 - NCT01029886 | Phase 3 | COMPLETED | enrolled 912 Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes Conditions: Type 2 Diabetes Mellitus https://clinicaltrials.gov/study/NCT01029886 - NCT01952145 | Phase 3 | COMPLETED | enrolled 557 A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT01952145 - NCT03011021 | Phase 2 | UNKNOWN | enrolled 40 Safety and Efficacy of Umbilical Cord Blood Regulatory T Cells Plus Liraglutide on Autoimmune Diabetes Conditions: Type1 Diabetes Mellitus, Autoimmune Diabetes https://clinicaltrials.gov/study/NCT03011021 - NCT03087032 | Phase 4 | RECRUITING | enrolled 164 Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD) Conditions: Type 2 Diabetes Patients, Overweight and Obesity, Hyperglycaemia (Diabetic) https://clinicaltrials.gov/study/NCT03087032 - NCT04643301 | Not phased | WITHDRAWN | enrolled 0 Liraglutide for Low-responders After Bariatric Surgery Conditions: Obesity, Obesity, Morbid https://clinicaltrials.gov/study/NCT04643301 - NCT03010683 | Not phased | COMPLETED | enrolled 60 Effects of Agonists of Glucagon Like Peptide - 1 Receptors (GLP-1R) on Arterial Stiffness, Endothelial Glycocalyx and Coronary Flow Reserve in Patients With Coronary Artery Disease and Patients With Diabetes Mellitus Conditions: Type 2 Diabetes Mellitus, Coronary Artery Disease https://clinicaltrials.gov/study/NCT03010683 - NCT01518101 | Phase 4 | COMPLETED | enrolled 62 Vildagliptin Versus Liraglutide - Patient Preference After Receiving Both Medications Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT01518101 - NCT03115424 | Phase 3 | COMPLETED | enrolled 46 Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy Conditions: Obesity https://clinicaltrials.gov/study/NCT03115424 - NCT06439056 | Phase 1 | COMPLETED | enrolled 12 Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2D Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT06439056 - NCT07374445 | Phase 4 | COMPLETED | enrolled 100 Research on Timing of Liraglutide Therapy in Patients With Obesity After Metabolic Surgery Conditions: Obesity, Weight Loss, Bariatric Surgery https://clinicaltrials.gov/study/NCT07374445 - NCT04325581 | Phase 3 | COMPLETED | enrolled 16 Laparocopic Sleeve Gastrectomy With or Without Liraglutide in Obese Patients Conditions: Weight Loss https://clinicaltrials.gov/study/NCT04325581 - NCT02928679 | Phase 4 | COMPLETED | enrolled 150 Multi-parametric Imaging of the Knee in Obese Patients With Knee Osteoarthritis; Weight Maintenance Conditions: Osteoarthritis, Obesity https://clinicaltrials.gov/study/NCT02928679 - NCT01296412 | Phase 3 | COMPLETED | enrolled 653 Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403) Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT01296412 - NCT00696657 | Phase 2 | COMPLETED | enrolled 415 A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT00696657 - NCT02730377 | Phase 4 | COMPLETED | enrolled 1991 Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT02730377 - NCT07029009 | Phase 2 | RECRUITING | enrolled 50 Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY) Conditions: Maturity Onset Diabetes of the Young https://clinicaltrials.gov/study/NCT07029009 - NCT02104037 | Not phased | COMPLETED | enrolled 8 Liraglutide in Spinal Fluid Conditions: Liraglutide Blood-brain Transfer https://clinicaltrials.gov/study/NCT02104037 - NCT02918279 | Phase 3 | COMPLETED | enrolled 251 Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity Conditions: Metabolism and Nutrition Disorder, Obesity https://clinicaltrials.gov/study/NCT02918279 - NCT06217848 | Phase 1 | UNKNOWN | enrolled 50 The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study Conditions: Panhypopituitarism, Craniopharyngioma, Hypothalamic Obesity https://clinicaltrials.gov/study/NCT06217848 - NCT02783196 | Not phased | UNKNOWN | enrolled 14 Effect of Liraglutide on Clock Genes Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT02783196 - NCT06533527 | Phase 4 | COMPLETED | enrolled 69 Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy Conditions: Diabetes Mellitus, Type 2, Obesity, Gastroparesis https://clinicaltrials.gov/study/NCT06533527 - NCT01695109 | Phase 4 | COMPLETED | enrolled 16 The Influence of Liraglutide on the Reward Properties of Food: an fMRI Study on Healthy Volunteers Conditions: Healthy Human Male Subjects https://clinicaltrials.gov/study/NCT01695109 - NCT02611232 | Phase 2 | UNKNOWN | enrolled 42 Incretin-based Therapy in Preclinical Type 1 Diabetes in Adults Conditions: Type 1 Diabetes https://clinicaltrials.gov/study/NCT02611232 - NCT04683237 | Phase 3 | WITHDRAWN | enrolled 0 Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia Conditions: Atypical Endometrial Hyperplasia, Obese, Fertility Issues https://clinicaltrials.gov/study/NCT04683237 - NCT01982630 | Phase 1 | COMPLETED | enrolled 87 Study of the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Participants With Type 2 Diabetes Mellitus (MK-8521-003) Conditions: Diabetes Mellitus https://clinicaltrials.gov/study/NCT01982630 - NCT01628445 | Phase 3 | TERMINATED | enrolled 52 Study of Liraglutide in Individuals With Type 2 Diabetes Using Insulin Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT01628445 - NCT02109315 | Phase 1 | WITHDRAWN | enrolled 0 Vitamin C and Liraglutide Effects on Hypoglycemia-induced Oxidative Stress, Inflammation and Endothelial Dysfunction in Type 1 Diabetes. Conditions: Type 1 Diabetes Mellitus https://clinicaltrials.gov/study/NCT02109315 - NCT02963935 | Phase 3 | COMPLETED | enrolled 282 Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting Conditions: Metabolism and Nutrition Disorder, Obesity https://clinicaltrials.gov/study/NCT02963935 - NCT02777073 | Not phased | COMPLETED | enrolled 43 Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes Conditions: Type 1 Diabetes https://clinicaltrials.gov/study/NCT02777073 - NCT04775082 | Phase 3 | ACTIVE_NOT_RECRUITING | enrolled 78 SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity Conditions: Obesity https://clinicaltrials.gov/study/NCT04775082 - NCT02863419 | Phase 3 | COMPLETED | enrolled 711 Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT02863419 - NCT01907854 | Phase 4 | COMPLETED | enrolled 407 Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT01907854 - NCT00393718 | Phase 3 | COMPLETED | enrolled 400 Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT00393718 - NCT04373967 | Phase 3 | UNKNOWN | enrolled 424 Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT04373967 - NCT02911948 | Phase 3 | COMPLETED | enrolled 210 A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT02911948 - NCT01658501 | Phase 2 | COMPLETED | enrolled 593 Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM Conditions: Type 2 Diabetes Mellitus https://clinicaltrials.gov/study/NCT01658501 - NCT01515579 | Phase 1 | COMPLETED | enrolled 22 Comparison of Two Liraglutide Formulations in Healthy Subjects Conditions: Diabetes, Healthy https://clinicaltrials.gov/study/NCT01515579 - NCT03038620 | Phase 4 | COMPLETED | enrolled 235 Impact of Liraglutide 3.0 on Body Fat Distribution Conditions: Obesity, Visceral, Cardiovascular Diseases, Fat Disorder https://clinicaltrials.gov/study/NCT03038620 - NCT03707171 | Phase 3 | COMPLETED | enrolled 30 Effects of Liraglutide on the Cognitive Function in Patients With Type 2 Diabetes Mellitus Conditions: Type 2 Diabetes Mellitus https://clinicaltrials.gov/study/NCT03707171 - NCT04487743 | Phase 3 | UNKNOWN | enrolled 300 Efficacy and Safety of Liraglutide on Body Weight in Obese Subjects or Overweight Subjects With Co-morbidities Conditions: Obesity https://clinicaltrials.gov/study/NCT04487743 - NCT01687582 | Not phased | COMPLETED | enrolled 10 Effect of GLP-1 Analogs on Psoriasis in Type 2 Diabetic Patients Conditions: Type 2 Diabetes, Psoriasis https://clinicaltrials.gov/study/NCT01687582 - NCT01934816 | Not phased | TERMINATED | enrolled 2 Incretin and KATP Channels Conditions: Healthy Subjects https://clinicaltrials.gov/study/NCT01934816 - NCT05268237 | Phase 2 | RECRUITING | enrolled 15 Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus Conditions: Diabete Type 2 https://clinicaltrials.gov/study/NCT05268237 - NCT06501326 | Phase 4 | UNKNOWN | enrolled 102 Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease Conditions: Non-alcoholic Fatty Liver Disease, Obesity https://clinicaltrials.gov/study/NCT06501326 - NCT02041234 | Phase 4 | COMPLETED | enrolled 40 Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment Conditions: Type II Diabetes in Subjects BMI 27 to 32 https://clinicaltrials.gov/study/NCT02041234 - NCT03672812 | Phase 3 | COMPLETED | enrolled 50 The Use of Liraglutide in Brain Death Conditions: Brain Death https://clinicaltrials.gov/study/NCT03672812 - NCT04529278 | Phase 2 | UNKNOWN | enrolled 18 Efficacy and Tolerance of Liraglutide for Weight Loss in Obese Type 2 Diabetic Hemodialysis Patients Conditions: Diabetes Mellitus, Type 2, Hemodialysis, Obese https://clinicaltrials.gov/study/NCT04529278 - NCT02960659 | Phase 2 | COMPLETED | enrolled 24 Title: Therapeutic Targets in African-American Youth With Type 2 Diabetes Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT02960659 - NCT01725126 | Phase 2 | COMPLETED | enrolled 53 To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes Conditions: Obesity https://clinicaltrials.gov/study/NCT01725126 - NCT04535960 | Phase 2 | UNKNOWN | enrolled 36 Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" Trial Conditions: Type 2 Diabetes Mellitus https://clinicaltrials.gov/study/NCT04535960 - NCT05965908 | Phase 3 | COMPLETED | enrolled 150 Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome Conditions: Polycystic Ovary https://clinicaltrials.gov/study/NCT05965908 - NCT03486392 | Phase 2 | COMPLETED | enrolled 474 A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants Conditions: Obesity https://clinicaltrials.gov/study/NCT03486392 - NCT02055014 | Phase 4 | UNKNOWN | enrolled 72 Randomisation to Endobarrier Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity) Conditions: Type 2 Diabetes, Obesity, Diabesity https://clinicaltrials.gov/study/NCT02055014 - NCT01508858 | Phase 1 | COMPLETED | enrolled 21 Influence on the Effect of an Oral Contraceptive Drug After Administration of Liraglutide in Postmenopausal Women Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT01508858 - NCT01722227 | Phase 3 | WITHDRAWN | enrolled 0 Anti-diabetic Effects of Liraglutide in Adolescents and Young Subjects With Type 1 Diabetes Conditions: Type 1 Diabetes https://clinicaltrials.gov/study/NCT01722227 - NCT01615978 | Phase 1 | COMPLETED | enrolled 15 Safety and Tolerability of Liraglutide in Japanese Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT01615978 - NCT02577848 | Not phased | UNKNOWN | enrolled 90 GLP-1 on Non-ST-Segment Elevation Myocardial Infarction Conditions: Myocardial Infarction https://clinicaltrials.gov/study/NCT02577848 - NCT04008290 | Phase 4 | UNKNOWN | enrolled 15 The Effect of Liraglutide on the GIT Conditions: Obesity https://clinicaltrials.gov/study/NCT04008290 - NCT01234649 | Phase 3 | COMPLETED | enrolled 153 Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM) Conditions: Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus, Metabolic Syndrome, Impaired Glucose Tolerance, Disorder of Glucose Regulation https://clinicaltrials.gov/study/NCT01234649 - NCT01790308 | Phase 4 | UNKNOWN | enrolled 100 Effect of Liraglutide Combined With Short-term CSII on Long-term Glycemic Remission and β Cell Function Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT01790308 - NCT02616003 | Phase 4 | COMPLETED | enrolled 50 Preoperative Condition in Giant Obese Patients Conditions: Morbid Obesity, Bariatric Surgery Candidate https://clinicaltrials.gov/study/NCT02616003 - NCT04575194 | Phase 4 | UNKNOWN | enrolled 40 Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Conditions: Obesity, Blood Pressure https://clinicaltrials.gov/study/NCT04575194 - NCT02198209 | Phase 4 | WITHDRAWN | enrolled 0 Liraglutide Actions on the Liver: Effects on Glucose Phosphorylation Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT02198209 - NCT04137328 | Not phased | UNKNOWN | enrolled 60 Clinical Study on the Improvement of Diabetic Neuropathic Pain by Liraglutide Conditions: Diabetic Neuropathic Pain https://clinicaltrials.gov/study/NCT04137328 - NCT03619330 | Phase 4 | COMPLETED | enrolled 30 Testosterone Replacement Therapy and Liraglutide Effects on Weight Loss in Hypogonadism. Conditions: Hypogonadism, Obesity https://clinicaltrials.gov/study/NCT03619330 - NCT04074161 | Phase 3 | COMPLETED | enrolled 338 Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity Conditions: Overweight, Obesity https://clinicaltrials.gov/study/NCT04074161 - NCT06559722 | Phase 3 | NOT_YET_RECRUITING | enrolled 510 A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT06559722 - NCT01624259 | Phase 3 | COMPLETED | enrolled 599 A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT01624259 - NCT03632759 | Phase 1 | COMPLETED | enrolled 16 Targeting Beta Cell Dysfunction With Liraglutide or Golimumab in Longstanding T1D Conditions: Type 1 Diabetes Mellitus https://clinicaltrials.gov/study/NCT03632759 - NCT02503943 | Phase 4 | UNKNOWN | enrolled 90 Effects of Incretin on the Blood Pressure and Lipid in Patients With Overweight or Obese Diabetes Conditions: Type 2 Diabetes, Overweight, Obesity, Masked Hypertension https://clinicaltrials.gov/study/NCT02503943 - NCT02920190 | Phase 4 | WITHDRAWN | enrolled 0 Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat Conditions: Monoclonal Gammopathies, Overweight, Obesity https://clinicaltrials.gov/study/NCT02920190 - NCT02403284 | Phase 4 | COMPLETED | enrolled 97 The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in Humans Conditions: Insulin Resistance https://clinicaltrials.gov/study/NCT02403284 - NCT01919489 | Phase 4 | COMPLETED | enrolled 273 Liraglutide Hospital Discharge Trial Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT01919489 - NCT07225829 | Phase 2 | ACTIVE_NOT_RECRUITING | enrolled 129 A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis Conditions: Knee Osteoarthritis, Synovitis of Knee https://clinicaltrials.gov/study/NCT07225829 - NCT03757130 | Phase 1 | COMPLETED | enrolled 50 Multiple Ascending Dose Study of AMG 598 in Adults With Obesity Conditions: Obesity https://clinicaltrials.gov/study/NCT03757130 - NCT01509742 | Phase 1 | COMPLETED | enrolled 19 Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT01509742 - NCT03955575 | Phase 4 | COMPLETED | enrolled 52 Treatment of Bile Acid Malabsorption With Liraglutide Conditions: Bile Acid Malabsorption https://clinicaltrials.gov/study/NCT03955575 - NCT01911468 | Phase 4 | COMPLETED | enrolled 36 Polycystic Ovary Syndrome and Liraglutide as Add-on Therapy on Metformin Conditions: PCOS, Obesity https://clinicaltrials.gov/study/NCT01911468 - NCT02187250 | Phase 4 | COMPLETED | enrolled 45 PDE-4 Inhibitor Roflumilast and GLP-1 Agonist Liraglutide in Polycystic Ovary Syndrome Conditions: PCOS, Obesity https://clinicaltrials.gov/study/NCT02187250 - NCT01515592 | Phase 1 | COMPLETED | enrolled 24 Safety and Tolerability of Liraglutide in Healthy Japanese Male Volunteers Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT01515592 - NCT03048578 | Phase 4 | COMPLETED | enrolled 132 Clinical Efficacy and Safety of Using 3.0mg Liraglutide to Treat Weight Regain After Roux-en-Y Gastric Bypass Surgery Conditions: Obesity https://clinicaltrials.gov/study/NCT03048578 - NCT03235050 | Phase 2 | COMPLETED | enrolled 834 A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT03235050 - NCT01507389 | Phase 1 | COMPLETED | enrolled 24 Safety of Liraglutide in Subjects With Liver Impairment and in Subjects With Normal Liver Function Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT01507389 - NCT05360147 | Phase 3 | COMPLETED | enrolled 30 Liraglutide Improve Cognitive Function in Patients With Type 2 Diabetes Mellitus Conditions: Type 2 Diabetes Mellitus https://clinicaltrials.gov/study/NCT05360147 - NCT01550653 | Phase 1 | COMPLETED | enrolled 40 Liraglutide Effects on Memory in Healthy Subjects Conditions: Healthy https://clinicaltrials.gov/study/NCT01550653 - NCT02443155 | Phase 2 | COMPLETED | enrolled 308 A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function Conditions: Diabetes, Diabetes Mellitus, Type 1 https://clinicaltrials.gov/study/NCT02443155 - NCT03555994 | Phase 2 | COMPLETED | enrolled 51 A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus. Conditions: Type 2 Diabetes Mellitus https://clinicaltrials.gov/study/NCT03555994 - NCT05444569 | Phase 1 | COMPLETED | enrolled 47 A Study of LY3537021 in Healthy Participants Conditions: Healthy https://clinicaltrials.gov/study/NCT05444569 - NCT01916174 | Phase 1 | COMPLETED | enrolled 50 A Trial to Demonstrate Bioequivalence Between Two Insulin Degludec/Liraglutide Formulations, B5 and V2 in Healthy Subjects Conditions: Diabetes, Diabetes Mellitus, Type 2, Healthy https://clinicaltrials.gov/study/NCT01916174 - NCT03534310 | Not phased | COMPLETED | enrolled 75 Weight Loss With Intensive Lifestyle Modifications Plus Bariatric Surgery Versus Liraglutide 3 mg Conditions: Obesity https://clinicaltrials.gov/study/NCT03534310 - NCT03018028 | Phase 3 | COMPLETED | enrolled 243 Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT03018028 - NCT00620282 | Phase 3 | COMPLETED | enrolled 49 The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT00620282 - NCT03520062 | Not phased | COMPLETED | enrolled 14 The Effect of Liraglutide on Pancreatic Hormones and Its Size Conditions: Obesity https://clinicaltrials.gov/study/NCT03520062 - NCT02473809 | Phase 4 | COMPLETED | enrolled 60 The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function Conditions: Diabetes Complications, Osteoporosis https://clinicaltrials.gov/study/NCT02473809 - NCT01392898 | Not phased | UNKNOWN | enrolled 50 Liraglutide and Insulin Therapy in Patients With Type 2 Diabetes Conditions: Type 2 Diabetes Mellitus https://clinicaltrials.gov/study/NCT01392898 - NCT02654665 | Phase 3 | UNKNOWN | enrolled 36 Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults Conditions: Non-alcoholic Fatty Liver Disease (NAFLD), Weight Loss, Non-alcoholic Steatohepatitis (NASH) https://clinicaltrials.gov/study/NCT02654665 - NCT03671733 | Phase 3 | UNKNOWN | enrolled 150 Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients Conditions: Obesity https://clinicaltrials.gov/study/NCT03671733 - NCT03011008 | Phase 4 | UNKNOWN | enrolled 20 Liraglutide as Additional Treatment to Insulin in Patients With Autoimmune Diabetes Mellitus Conditions: Type 1 Diabetes Mellitus, Autoimmune Diabetes https://clinicaltrials.gov/study/NCT03011008 - NCT00294723 | Phase 3 | TERMINATED | enrolled 746 To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT00294723 - NCT01508897 | Phase 1 | COMPLETED | enrolled 22 Comparison of Two Liraglutide Formulations in Healthy Volunteers Conditions: Diabetes, Healthy https://clinicaltrials.gov/study/NCT01508897 - NCT01232946 | Not phased | COMPLETED | enrolled 30 Cooperation of Insulin and GLP-1 on Myocardial Glucose Uptake Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT01232946 - NCT04575844 | Phase 4 | RECRUITING | enrolled 80 Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome Conditions: Metabolic Syndrome https://clinicaltrials.gov/study/NCT04575844 - NCT01373450 | Phase 1 | COMPLETED | enrolled 12 Evaluation of the Glucoregulatory Effects of Glucagon-like Peptide-1 Receptor (GLP-1 Receptor) Activation in Participants With Type 2 Diabetes Mellitus (MK-0000-222) Conditions: Type 2 Diabetes Mellitus https://clinicaltrials.gov/study/NCT01373450 - NCT04186494 | Not phased | COMPLETED | enrolled 30 Effect of Liraglutide vs CPAP on Cardiometabolic Outcomes in Obstructive Sleep Apnea Conditions: Sleep Apnea, Obstructive https://clinicaltrials.gov/study/NCT04186494 - NCT03279731 | Phase 3 | TERMINATED | enrolled 36 Binge Eating Liraglutide Intervention Conditions: Binge-Eating Disorder https://clinicaltrials.gov/study/NCT03279731 - NCT02953665 | Phase 2 | COMPLETED | enrolled 63 Safety and Efficacy of Liraglutide in Parkinson's Disease Conditions: Parkinson Disease https://clinicaltrials.gov/study/NCT02953665 - NCT02898506 | Phase 2 | COMPLETED | enrolled 13 Incretin-based Therapy in Late Preclinical Type 1 Diabetes Conditions: Type 1 Diabetes https://clinicaltrials.gov/study/NCT02898506 - NCT00333151 | Phase 3 | COMPLETED | enrolled 576 Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT00333151 - NCT01175473 | Phase 2 | COMPLETED | enrolled 148 Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes Conditions: Type 2 Diabetes Mellitus https://clinicaltrials.gov/study/NCT01175473 - NCT01973231 | Phase 4 | COMPLETED | enrolled 404 Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT01973231 - NCT01843075 | Phase 2 | UNKNOWN | enrolled 204 Evaluating Liraglutide in Alzheimer's Disease Conditions: Alzheimer's Disease https://clinicaltrials.gov/study/NCT01843075 - NCT01618162 | Phase 3 | COMPLETED | enrolled 435 The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT01618162 - NCT02501850 | Phase 4 | UNKNOWN | enrolled 40 The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a) Conditions: Diabetes Mellitus Type 2 https://clinicaltrials.gov/study/NCT02501850 - NCT05111912 | Phase 2 | COMPLETED | enrolled 206 Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With Obesity Conditions: Obesity https://clinicaltrials.gov/study/NCT05111912 - NCT02505334 | Phase 3 | COMPLETED | enrolled 635 A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus. Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT02505334 - NCT02743598 | Phase 4 | TERMINATED | enrolled 4 Liraglutide for HIV-associated Neurocognitive Disorder Conditions: HIV Infection, Diabetes Mellitus Type 2, Obesity, Overweight, Metabolic Syndrome https://clinicaltrials.gov/study/NCT02743598 - NCT02147925 | Phase 4 | COMPLETED | enrolled 75 Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects Conditions: Non-alcoholic Fatty Liver Disease https://clinicaltrials.gov/study/NCT02147925 - NCT01541215 | Phase 3 | COMPLETED | enrolled 135 Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT01541215 - NCT02098395 | Phase 3 | COMPLETED | enrolled 835 The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 1 https://clinicaltrials.gov/study/NCT02098395 - NCT01511198 | Phase 2 | COMPLETED | enrolled 223 Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT01511198 - NCT02089256 | Phase 4 | COMPLETED | enrolled 10 Effect of Repeated Administration of Liraglutide on Insulinogenic Indices Conditions: Healthy https://clinicaltrials.gov/study/NCT02089256 - NCT02423824 | Phase 3 | COMPLETED | enrolled 21 Cognitive Dysfunction and Glucagon-like Peptide-1 Agonists Conditions: Bipolar Disorder, Major Depressive Disorder https://clinicaltrials.gov/study/NCT02423824 - NCT01847313 | Phase 3 | COMPLETED | enrolled 20 The Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney Disease Conditions: Diabetic Kidney Disease https://clinicaltrials.gov/study/NCT01847313 - NCT02930265 | Not phased | UNKNOWN | enrolled 400 Clinical Study of Liraglutide in Improving Cardiac Function for Patients With Ischemic Cardiomyopathy Conditions: Ischemic Cardiomyopathy https://clinicaltrials.gov/study/NCT02930265 - NCT01511159 | Phase 1 | COMPLETED | enrolled 32 Comparison of Liraglutide Inhaled Into the Lungs Compared to Liraglutide Injected Under the Skin in Healthy Male Volunteers Conditions: Diabetes, Healthy https://clinicaltrials.gov/study/NCT01511159 - NCT01789086 | Phase 1 | COMPLETED | enrolled 21 A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability and Pharmacokinetics of Liraglutide in Obese Adolescent Subjects Aged 12 to 17 Years Conditions: Metabolism and Nutrition Disorder, Obesity https://clinicaltrials.gov/study/NCT01789086 - NCT00331851 | Phase 3 | COMPLETED | enrolled 584 Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT00331851 - NCT01676116 | Phase 3 | COMPLETED | enrolled 438 The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT01676116 - NCT02036372 | Not phased | COMPLETED | enrolled 150 Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes Mellitus Conditions: Diabetes Mellitus Type II https://clinicaltrials.gov/study/NCT02036372 - NCT02607306 | Phase 3 | COMPLETED | enrolled 819 A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus. Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT02607306 - NCT01473953 | Phase 1 | COMPLETED | enrolled 31 Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects Conditions: Diabetes, Diabetes Mellitus, Type 2, Healthy https://clinicaltrials.gov/study/NCT01473953 - NCT01784965 | Phase 3 | COMPLETED | enrolled 69 Liraglutide and a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and CVD. Conditions: Pre-diabetes, Older Adults https://clinicaltrials.gov/study/NCT01784965 - NCT02483299 | Phase 4 | COMPLETED | enrolled 40 Liraglutide as Add on Therapy on Metformin in Women With Polycystic Ovary Syndrome Conditions: PCOS, Obesity https://clinicaltrials.gov/study/NCT02483299 - NCT01507337 | Phase 1 | COMPLETED | enrolled 32 Comparison of the Effect of Liraglutide in Young Versus Elderly Healthy Volunteers Conditions: Diabetes, Healthy https://clinicaltrials.gov/study/NCT01507337 - NCT07225816 | Phase 1 | RECRUITING | enrolled 71 Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) Conditions: Obesity https://clinicaltrials.gov/study/NCT07225816 - NCT02928614 | Phase 4 | COMPLETED | enrolled 150 Biomarkers in Obese Patients With Knee Osteoarthritis; Weight Maintenance Conditions: Osteoarthritis, Obesity https://clinicaltrials.gov/study/NCT02928614 - NCT03421119 | Phase 3 | UNKNOWN | enrolled 300 Comparing Efficacy and Safety of CinnaGen-liraglutide Versus Victoza® in Patients With Type II Diabetes Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT03421119 - NCT06361238 | Phase 3 | RECRUITING | enrolled 260 Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery Conditions: Delirium, Postoperative https://clinicaltrials.gov/study/NCT06361238 - NCT02944500 | Phase 4 | ACTIVE_NOT_RECRUITING | enrolled 28 Saxenda: Underlying Mechanisms and Clinical Outcomes Conditions: Obesity https://clinicaltrials.gov/study/NCT02944500 - NCT01505673 | Phase 4 | COMPLETED | enrolled 71 Adding Liraglutide to High Dose Insulin: Breaking the Cycle Conditions: Type 2 Diabetes Mellitus, Obesity https://clinicaltrials.gov/study/NCT01505673 - NCT00422058 | Phase 2 | COMPLETED | enrolled 564 The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes Conditions: Metabolism and Nutrition Disorder, Obesity https://clinicaltrials.gov/study/NCT00422058 - NCT01733758 | Phase 3 | COMPLETED | enrolled 494 A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM) Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT01733758 - NCT01753362 | Phase 3 | COMPLETED | enrolled 84 Liraglutide In Overweight Patients With Type 1 Diabetes Conditions: Type 1 Diabetes https://clinicaltrials.gov/study/NCT01753362 - NCT02408705 | Phase 2 | COMPLETED | enrolled 14 Investigating the Effect of Liraglutide on the Endogenous Glucose Production During in Tye 1 Diabetes Subjects Conditions: Type 1 Diabetes Mellitus https://clinicaltrials.gov/study/NCT02408705 - NCT03115099 | Phase 1 | COMPLETED | enrolled 80 A Study of LY3325656 in Healthy Participants and Participants With Type 2 Diabetes Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT03115099 - NCT02655770 | Phase 4 | COMPLETED | enrolled 40 Effect of Liraglutide on Diastolic Dysfunction on Cardiac MRI in Type 2 Diabetes Patients Conditions: Diabetes Mellitus Type 2, Diastolic Dysfunction, Cardiac MRI, Myocardial Perfusion https://clinicaltrials.gov/study/NCT02655770 - NCT04763564 | Phase 2 | TERMINATED | enrolled 8 Efficacy of Liraglutide Therapy in Patients With IPAA Conditions: Pouchitis, Irritable Pouch Syndrome https://clinicaltrials.gov/study/NCT04763564 - NCT02016846 | Phase 3 | UNKNOWN | enrolled 36 Liraglutide Efficacy on Glucocorticoid Induced Hyperglycemia in Patients High Risk for Diabetes Conditions: Glucocorticoid Induced Hyperglycemia https://clinicaltrials.gov/study/NCT02016846 - NCT01572740 | Phase 3 | COMPLETED | enrolled 257 Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Alone in Japanese Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT01572740 - NCT04881110 | Phase 4 | COMPLETED | enrolled 60 Liraglutide and Peripheral Artery Disease Conditions: Type 2 Diabetes, Peripheral Arterial Disease https://clinicaltrials.gov/study/NCT04881110 - NCT01575301 | Not phased | COMPLETED | enrolled 411 DIabetes REsearCh on Patient sTratification (DIRECT): GLP-1R Agonists Conditions: Diabetes https://clinicaltrials.gov/study/NCT01575301 - NCT01542242 | Phase 4 | TERMINATED | enrolled 1 Liraglutide Use in Prader-Willi Syndrome Conditions: Diabetes Mellitus Type 2, Prader Willi Syndrome https://clinicaltrials.gov/study/NCT01542242 - NCT01931982 | Phase 4 | COMPLETED | enrolled 20 Effect of Glucagon-like Peptide 1 (GLP-1) on Microvascular Myocardial Function in Patients With Type 2 Diabetes. Conditions: Type 2 Diabetes, Microvascular Dysfunction https://clinicaltrials.gov/study/NCT01931982 - NCT01511172 | Phase 2 | COMPLETED | enrolled 145 Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT01511172 - NCT02420262 | Phase 3 | COMPLETED | enrolled 506 A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT02420262 - NCT03101930 | Phase 4 | COMPLETED | enrolled 329 Cardiovascular Effects of GLP-1 Receptor Activation Conditions: Obesity, PreDiabetes https://clinicaltrials.gov/study/NCT03101930 - NCT01937598 | Phase 3 | COMPLETED | enrolled 16 Antidiabetic Effects of Adding a DPP-4 Inhibitor to Pre-Existing Treatment With an Incretin Mimetic in Patients With T2D Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT01937598 - NCT01599338 | Not phased | COMPLETED | enrolled 30 Impact of Liraglutide on Sensory Perception, Sensory Specific Satiety, Liking and Wanting in Type 2 Diabetic Patients Conditions: Type 2 Diabetes Mellitus, Overweight https://clinicaltrials.gov/study/NCT01599338 - NCT00978393 | Phase 1 | COMPLETED | enrolled 49 A Trial to Assess the Effect of Liraglutide on Gastric Emptying in Healthy Obese Volunteers Conditions: Metabolism and Nutrition Disorder, Obesity https://clinicaltrials.gov/study/NCT00978393 - NCT02014740 | Phase 4 | COMPLETED | enrolled 100 Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes Conditions: Type 2 Diabetes, Overweight, Obesity https://clinicaltrials.gov/study/NCT02014740 - NCT02235961 | Phase 1 | COMPLETED | enrolled 163 Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects Conditions: Metabolism and Nutrition Disorder, Obesity https://clinicaltrials.gov/study/NCT02235961 - NCT01677104 | Not phased | COMPLETED | enrolled 63 The Microvascular Function of GLP-1 and Its Analogues Conditions: Type 2 Diabetes, Obesity https://clinicaltrials.gov/study/NCT01677104 - NCT04829903 | Not phased | COMPLETED | enrolled 116 Dulaglutide Versus Liraglutide in Obese Type 2 Diabetic Adolescents Using Metformin Conditions: Type 2 Diabetes Treated With Insulin, Obesity, Adolescent Obesity https://clinicaltrials.gov/study/NCT04829903 - NCT03737240 | Phase 3 | COMPLETED | enrolled 145 IDegLira HIGH Trial Conditions: Diabetes Mellitus https://clinicaltrials.gov/study/NCT03737240 - NCT01399645 | Phase 2 | COMPLETED | enrolled 35 Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes Conditions: Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Type 2 Diabetes https://clinicaltrials.gov/study/NCT01399645 - NCT02140983 | Phase 1 | COMPLETED | enrolled 41 Effects of Liraglutide on Hippocampal Structure and Function in Aging Adults With Prediabetes Conditions: Insulin Resistance, Dementia https://clinicaltrials.gov/study/NCT02140983 - NCT01394341 | Phase 4 | COMPLETED | enrolled 40 Liraglutide Treatment to Patients With Severe Renal Insufficiency Conditions: Type 2 Diabetes Mellitus, End-stage Renal Disease https://clinicaltrials.gov/study/NCT01394341 - NCT03986008 | Phase 3 | UNKNOWN | enrolled 60 Effects of Benaglutide on Weight and Gut Microbiota in Obese Patients Conditions: Obesity https://clinicaltrials.gov/study/NCT03986008 - NCT01516476 | Phase 2 | TERMINATED | enrolled 2 Study of RO6807952 in Patients With Diabetes Mellitus Type 2 Conditions: Diabetes Mellitus Type 2 https://clinicaltrials.gov/study/NCT01516476 - NCT02461589 | Phase 2 | COMPLETED | enrolled 706 Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT02461589 - NCT03182426 | Phase 2 | COMPLETED | enrolled 22 Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM) Conditions: Diabetes Mellitus, Type 1 https://clinicaltrials.gov/study/NCT03182426 - NCT00318422 | Phase 3 | COMPLETED | enrolled 1041 Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT00318422 - NCT02492763 | Phase 2 | TERMINATED | enrolled 176 A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004) Conditions: Type II Diabetes Mellitus https://clinicaltrials.gov/study/NCT02492763 - NCT03856632 | Phase 4 | ACTIVE_NOT_RECRUITING | enrolled 60 Liraglutide Effect in Atrial Fibrillation Conditions: Atrial Fibrillation https://clinicaltrials.gov/study/NCT03856632 - NCT01507311 | Phase 1 | COMPLETED | enrolled 11 Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT01507311 - NCT03151005 | Phase 4 | COMPLETED | enrolled 70 The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS Conditions: Polycystic Ovary Syndrome (PCOS), Overweight, Obesity https://clinicaltrials.gov/study/NCT03151005 - NCT02911818 | Phase 4 | COMPLETED | enrolled 150 Lifestyle Modification and Liraglutide Conditions: Obesity https://clinicaltrials.gov/study/NCT02911818 - NCT02315001 | Phase 2 | COMPLETED | enrolled 26 Liraglutide to Improve corONary Haemodynamics During Exercise streSS Conditions: Ischaemic Heart Disease, Coronary Heart Disease, Chronic Stable Angina https://clinicaltrials.gov/study/NCT02315001 - NCT05041673 | Not phased | UNKNOWN | enrolled 120 Anti-diabetic Drugs and Fatty Liver Management Conditions: Fatty Liver, Nonalcoholic, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT05041673 - NCT02113332 | Phase 2 | COMPLETED | enrolled 124 Addition of Liraglutide to Patients With Type 2 Diabetes Treated With Multiple Daily Insulin Injections Conditions: Type 2 Diabetes Mellitus https://clinicaltrials.gov/study/NCT02113332 - NCT05029076 | Phase 1 | COMPLETED | enrolled 28 Human Bioequivalence Test of Liraglutide Injection Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT05029076 - NCT01469351 | Not phased | COMPLETED | enrolled 34 Identifying Potential Effects of Liraglutide on Degenerative Changes Conditions: Alzheimers Disease https://clinicaltrials.gov/study/NCT01469351 - NCT02527993 | Phase 4 | COMPLETED | enrolled 11 Treatment of Hypoglycemia Following Gastric Bypass Surgery Conditions: Hypoglycemia, Obesity, Surgery https://clinicaltrials.gov/study/NCT02527993 - NCT02059564 | Phase 1 | UNKNOWN | enrolled 44 A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus Conditions: Diabetes Mellitus https://clinicaltrials.gov/study/NCT02059564 - NCT01597531 | Phase 4 | TERMINATED | enrolled 1 Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding Conditions: Type 2 Diabetes, Gastric Banding https://clinicaltrials.gov/study/NCT01597531 - NCT02879409 | Not phased | ACTIVE_NOT_RECRUITING | enrolled 150 HbA1c Variability in Type II Diabetes Conditions: Diabetes Mellitus Type 2 https://clinicaltrials.gov/study/NCT02879409 - NCT00614120 | Phase 3 | COMPLETED | enrolled 929 Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT00614120 - NCT01612468 | Phase 4 | COMPLETED | enrolled 100 Liraglutide in Type 1 Diabetes Conditions: Diabetes Mellitus, Type 1, Overweight https://clinicaltrials.gov/study/NCT01612468 - NCT02660047 | Phase 4 | COMPLETED | enrolled 51 Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients of South Asian Descent Conditions: Diabetes Mellitus Type 2, Metabolic Syndrome, Cardiovascular Disease, Diastolic Dysfunction, Fatty Liver https://clinicaltrials.gov/study/NCT02660047 - NCT01508949 | Phase 2 | COMPLETED | enrolled 35 Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT01508949 - NCT04657939 | Phase 4 | COMPLETED | enrolled 57 Targeting Beta-cell Failure in Lean Patients With Type 2 Diabetes Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT04657939 - NCT01899430 | Phase 4 | COMPLETED | enrolled 32 Polycystic Ovary Syndrome and Liraglutide Conditions: PCOS, Obesity https://clinicaltrials.gov/study/NCT01899430 --- ## Semaglutide (Ozempic · Wegovy) URL: https://www.whatsactuallyknown.com/compounds/semaglutide Registered human trials: 547 Currently recruiting or running: 241 FDA approved: Yes — FDA-approved for type 2 diabetes and chronic weight management. Furthest stage reached: phase4 Marketed for: Weight loss; Blood sugar control; Cardiovascular risk Answer: Semaglutide has 547 registered human trials. Trials on record: - NCT02827708 | Phase 3 | COMPLETED | enrolled 324 Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT02827708 - NCT06946628 | Phase 3 | NOT_YET_RECRUITING | enrolled 296 New Triple Therapy in Newly Diagnosed Type 2 Diabetes Conditions: Diabetes Mellitus https://clinicaltrials.gov/study/NCT06946628 - NCT07554417 | Phase 4 | NOT_YET_RECRUITING | enrolled 20 Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1 Conditions: GLP - 1, Obesity & Overweight, Muscle Loss, Exercise Intervention, Dietary Assessment https://clinicaltrials.gov/study/NCT07554417 - NCT03987074 | Phase 2 | COMPLETED | enrolled 109 Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH) Conditions: Nonalcoholic Steatohepatitis https://clinicaltrials.gov/study/NCT03987074 - NCT05173714 | Phase 2 | RECRUITING | enrolled 156 Sit Less, Interact and Move More (SLIMM) 2 Study Conditions: Chronic Kidney Diseases, Obesity https://clinicaltrials.gov/study/NCT05173714 - NCT05895643 | Phase 2 | COMPLETED | enrolled 108 Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity? Conditions: Alcohol Abuse, Alcohol Addiction, Alcohol Dependence, Alcohol Use Disorder https://clinicaltrials.gov/study/NCT05895643 - NCT04560998 | Phase 3 | COMPLETED | enrolled 792 A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes Conditions: Diabetes Mellitus, Type 2, Peripheral Arterial Disease https://clinicaltrials.gov/study/NCT04560998 - NCT06934655 | Phase 3 | NOT_YET_RECRUITING | enrolled 150 Early Re-Initiation of Semaglutide Post Sleeve Gastrectomy in Youth Conditions: Pediatric Obesity, Metabolic and Bariatric Surgery, Semaglutide https://clinicaltrials.gov/study/NCT06934655 - NCT04216589 | Phase 2 | COMPLETED | enrolled 51 Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study) Conditions: HIV Infections, Non-Alcoholic Fatty Liver Disease https://clinicaltrials.gov/study/NCT04216589 - NCT07073053 | Phase 4 | NOT_YET_RECRUITING | enrolled 60 The Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential Mechanisms Conditions: Glucagon-Like Peptide-1 Receptor Agonists, Type 2 Diabetes, Coronary Arterial Disease (CAD) https://clinicaltrials.gov/study/NCT07073053 - NCT06461377 | Phase 4 | RECRUITING | enrolled 50 The Ameliorative Effects of GLP-1RA on Diabetic Cardiac Autonomatic Neuropathy Conditions: Type 2 Diabetes, Diabetes With Diabetic Autonomic Neuropathy (Diagnosis) https://clinicaltrials.gov/study/NCT06461377 - NCT05813249 | Phase 4 | COMPLETED | enrolled 180 Semaglutide in Nonalcoholic Fatty Liver Disease Conditions: Non-alcoholic Fatty Liver Disease https://clinicaltrials.gov/study/NCT05813249 - NCT06409130 | Phase 2 | COMPLETED | enrolled 270 Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease Conditions: Alcohol-related Liver Disease https://clinicaltrials.gov/study/NCT06409130 - NCT07446998 | Phase 2 | RECRUITING | enrolled 200 Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss Conditions: Obesity & Overweight, Mobility Disability, HOMA-IR https://clinicaltrials.gov/study/NCT07446998 - NCT05073835 | Phase 3 | ACTIVE_NOT_RECRUITING | enrolled 70 Semaglutide 2.4 mg in Patients With Poor Weight-loss Conditions: Obesity, Diabetes, Metabolic Syndrome https://clinicaltrials.gov/study/NCT05073835 - NCT07293325 | Not phased | RECRUITING | enrolled 66 Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity Conditions: Adults With Simple Obesity https://clinicaltrials.gov/study/NCT07293325 - NCT07570810 | Not phased | NOT_YET_RECRUITING | enrolled 30 Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM Conditions: Type 2 Diabetes, Obesity, Non-alcoholic Fatty Liver Disease https://clinicaltrials.gov/study/NCT07570810 - NCT07271251 | Phase 3 | ACTIVE_NOT_RECRUITING | enrolled 264 A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 Diabetes Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT07271251 - NCT06045221 | Phase 3 | COMPLETED | enrolled 1698 A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT06045221 - NCT05646706 | Phase 3 | COMPLETED | enrolled 1407 A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP) Conditions: Obesity https://clinicaltrials.gov/study/NCT05646706 - NCT06764056 | Not phased | NOT_YET_RECRUITING | enrolled 120 Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Conditions: Metabolic Associated Fatty Liver Disease, Metabolic Associated-dysfunction Steatohepatitis (MASH), Obesity https://clinicaltrials.gov/study/NCT06764056 - NCT07325435 | Phase 4 | ACTIVE_NOT_RECRUITING | enrolled 60 Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists Conditions: Type 2 Diabetes (T2DM) https://clinicaltrials.gov/study/NCT07325435 - NCT06913023 | Phase 3 | NOT_YET_RECRUITING | enrolled 74 Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus Conditions: Kidney Transplant Recipient https://clinicaltrials.gov/study/NCT06913023 - NCT06778967 | Phase 3 | ACTIVE_NOT_RECRUITING | enrolled 1100 A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus Conditions: Type 2 Diabetes Mellitus (T2DM) https://clinicaltrials.gov/study/NCT06778967 - NCT03015220 | Phase 3 | COMPLETED | enrolled 458 Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT03015220 - NCT05132088 | Phase 3 | COMPLETED | enrolled 201 Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity Conditions: Overweight and Obesity https://clinicaltrials.gov/study/NCT05132088 - NCT06292065 | Not phased | COMPLETED | enrolled 88 Gastric Ultrasound To Assess Gastric Contents In Patients On Semaglutide Therapy Conditions: Gastroparesis https://clinicaltrials.gov/study/NCT06292065 - NCT03191396 | Phase 3 | COMPLETED | enrolled 577 Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT03191396 - NCT07187856 | Phase 2 | NOT_YET_RECRUITING | enrolled 80 Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes Mellitus Conditions: Type 2 Diabetes Mellitus (T2DM) https://clinicaltrials.gov/study/NCT07187856 - NCT01885208 | Phase 3 | COMPLETED | enrolled 813 Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT01885208 - NCT04878406 | Phase 1 | COMPLETED | enrolled 24 A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Japanese Men Conditions: Healthy Volunteers Type 2 Diabetes https://clinicaltrials.gov/study/NCT04878406 - NCT07325500 | Phase 2 | RECRUITING | enrolled 30 Incretin Microdosing for Cardiometabolic Health in People With HIV Conditions: Weight Gain https://clinicaltrials.gov/study/NCT07325500 - NCT03819153 | Phase 3 | COMPLETED | enrolled 3533 A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT03819153 - NCT01930188 | Phase 3 | COMPLETED | enrolled 1231 Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT01930188 - NCT04596631 | Phase 3 | COMPLETED | enrolled 132 A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT04596631 - NCT04109508 | Phase 1 | COMPLETED | enrolled 278 A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (C) Semaglutide Tablets Conditions: Healthy Volunteers, Type 2 Diabetes https://clinicaltrials.gov/study/NCT04109508 - NCT05514535 | Phase 3 | COMPLETED | enrolled 573 A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE) Conditions: Diabetes Mellitus, Type 2, Obesity https://clinicaltrials.gov/study/NCT05514535 - NCT06827002 | Phase 2 | ACTIVE_NOT_RECRUITING | enrolled 248 Effect of Aqueous Extracts of Cissus Quadrangularis and Dichrostachys Glomerata on GLP-1 Concentration and DPP-4 Activity in Overweight and Obese Adults Conditions: Obesity and Overweight, Appetite Regulation https://clinicaltrials.gov/study/NCT06827002 - NCT00833716 | Phase 1 | COMPLETED | enrolled 62 Effect of Renal Impairment on the Pharmacokinetics of NN9535 Conditions: Diabetes, Diabetes Mellitus, Type 2, Renal Impairment https://clinicaltrials.gov/study/NCT00833716 - NCT06548490 | Phase 2 | RECRUITING | enrolled 200 GLP-1R Agonist Treatment for Opioid Use Disorder Conditions: Opioid Use Disorder, Opioid Abuse and Addiction, Narcotic-Related Disorders, Substance-Related Disorders, Chemically-Induced Disorders, Mental Disorder, Opioid https://clinicaltrials.gov/study/NCT06548490 - NCT03466567 | Phase 1 | COMPLETED | enrolled 21 A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy Subjects Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT03466567 - NCT06908694 | Phase 4 | RECRUITING | enrolled 20 Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy Conditions: Prostate Cancer https://clinicaltrials.gov/study/NCT06908694 - NCT05441267 | Phase 4 | ACTIVE_NOT_RECRUITING | enrolled 21296 A Study of Cardiovascular Events iN Diabetes Plus Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT05441267 - NCT05040971 | Phase 3 | COMPLETED | enrolled 207 Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes Conditions: Obesity https://clinicaltrials.gov/study/NCT05040971 - NCT06387199 | Phase 3 | RECRUITING | enrolled 26 Alleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide Conditions: Type 1 Diabetes, Diabetes Mellitus https://clinicaltrials.gov/study/NCT06387199 - NCT01324505 | Phase 1 | COMPLETED | enrolled 43 Effect of Oral Contraceptives After Administration of Semaglutide in Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT01324505 - NCT07242534 | Phase 4 | RECRUITING | enrolled 62 Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization. Conditions: Infertility, Obesity https://clinicaltrials.gov/study/NCT07242534 - NCT07430332 | Phase 2 | NOT_YET_RECRUITING | enrolled 15 GLP-1 RA for Stage 1 Type 1 Diabetes Conditions: Stage 1 Diabetes Mellitus, Type 1 https://clinicaltrials.gov/study/NCT07430332 - NCT02014259 | Phase 1 | COMPLETED | enrolled 71 Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function Conditions: Diabetes, Diabetes Mellitus, Type 2, Healthy https://clinicaltrials.gov/study/NCT02014259 - NCT05784402 | Phase 1 | COMPLETED | enrolled 264 A Research Study to Compare How Much Semaglutide is Found in the Blood With Different Tablets of Oral Semaglutide in Healthy Participants Conditions: Healthy Participants https://clinicaltrials.gov/study/NCT05784402 - NCT05533632 | Phase 4 | COMPLETED | enrolled 104 Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT05533632 - NCT06977438 | Phase 4 | NOT_YET_RECRUITING | enrolled 1020 GLP-1 Plus Lifestyle for Overall Wellness: Find Your Way Forward Conditions: Obesity, Childhood https://clinicaltrials.gov/study/NCT06977438 - NCT07628985 | Phase 3 | NOT_YET_RECRUITING | enrolled 374 BALANCE-DM2 Study of Bofanglutide in Adults With Type 2 Diabetes Conditions: Type 2 Diabetes Mellitus (T2DM) https://clinicaltrials.gov/study/NCT07628985 - NCT06974825 | Phase 2 | COMPLETED | enrolled 67 A Study of BGM0504 in Chinese Patients With Type 2 Diabetes Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT06974825 - NCT06896981 | Phase 3 | RECRUITING | enrolled 30 Semaglutide in Women With Polycystic Ovary Syndrome and Obesity Conditions: Polycystic Ovary Syndrome (PCOS) Women, Obesity https://clinicaltrials.gov/study/NCT06896981 - NCT06634927 | Phase 1 | COMPLETED | enrolled 68 Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects. Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT06634927 - NCT04061200 | Phase 4 | UNKNOWN | enrolled 80 Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and Albuminuria Conditions: Type 2 Diabetes With Renal Manifestations https://clinicaltrials.gov/study/NCT04061200 - NCT06400615 | Phase 2 | COMPLETED | enrolled 40 Study That Tests AD109 in Patients Taking GLP-1 Drugs Conditions: OSA https://clinicaltrials.gov/study/NCT06400615 - NCT05822830 | Phase 3 | COMPLETED | enrolled 751 A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities Conditions: Obesity, Overweight https://clinicaltrials.gov/study/NCT05822830 - NCT06801015 | Phase 4 | ACTIVE_NOT_RECRUITING | enrolled 30 Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions Conditions: Obesity https://clinicaltrials.gov/study/NCT06801015 - NCT05920889 | Phase 2 | COMPLETED | enrolled 140 Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies Conditions: Stroke, Stroke, Acute, Stroke, Ischemic, Brain Diseases https://clinicaltrials.gov/study/NCT05920889 - NCT05813925 | Phase 3 | COMPLETED | enrolled 331 A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight Conditions: Obesity or Overweight https://clinicaltrials.gov/study/NCT05813925 - NCT07184086 | Phase 1 | RECRUITING | enrolled 80 A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet Conditions: Obesity https://clinicaltrials.gov/study/NCT07184086 - NCT06149260 | Phase 1 | UNKNOWN | enrolled 10 Subcutaneous Semaglutide in Systemic Scleroderma Conditions: Scleroderma, Systemic, Fibrosis, Semaglutide https://clinicaltrials.gov/study/NCT06149260 - NCT04916470 | Phase 3 | COMPLETED | enrolled 617 Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT04916470 - NCT04990024 | Not phased | RECRUITING | enrolled 60 The Effect of Different Diets on Arterial Stiffness in Obese Patients on Semaglutide Conditions: Obesity, Weight Loss https://clinicaltrials.gov/study/NCT04990024 - NCT07513168 | Phase 4 | RECRUITING | enrolled 60 Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults Conditions: Obesity, Weight Reduction, Cardiometabolic Risk Factors https://clinicaltrials.gov/study/NCT07513168 - NCT06541509 | Phase 2 | UNKNOWN | enrolled 10 Mechanisms of Semaglutide Therapy in Heart Failure Patients Conditions: Heart Failure, Obesity https://clinicaltrials.gov/study/NCT06541509 - NCT06475586 | Phase 4 | COMPLETED | enrolled 30 Effect of Semaglutide on the Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus Conditions: Psoriasis Vulgaris, Diabetes Type 2 https://clinicaltrials.gov/study/NCT06475586 - NCT06604624 | Phase 3 | COMPLETED | enrolled 462 Semaglutide in Treatment of Obesity Conditions: Weight Management https://clinicaltrials.gov/study/NCT06604624 - NCT07401992 | Phase 4 | RECRUITING | enrolled 62 Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis Conditions: Psoriasis (PsO), Obesity & Overweight, Diabetes Mellitus - Type 2 https://clinicaltrials.gov/study/NCT07401992 - NCT07294950 | Phase 3 | RECRUITING | enrolled 98 Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide Termination Conditions: Obesity (Disorder), Weight Change, Blood Pressure Monitoring, Appetite Regulation https://clinicaltrials.gov/study/NCT07294950 - NCT05751226 | Phase 1 | COMPLETED | enrolled 88 A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906 Conditions: Healthy, Obesity https://clinicaltrials.gov/study/NCT05751226 - NCT07317115 | Not phased | RECRUITING | enrolled 20 Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes Conditions: Obesity (Disorder), Obesity & Overweight, Type 2 Diabetes (T2DM) https://clinicaltrials.gov/study/NCT07317115 - NCT06851962 | Phase 4 | ACTIVE_NOT_RECRUITING | enrolled 504 Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. Conditions: Diabetes Mellitus Type 2 https://clinicaltrials.gov/study/NCT06851962 - NCT04639414 | Phase 4 | COMPLETED | enrolled 192 Combined Active Treatment in Type 2 Diabetes With NASH Conditions: Type 2 Diabetes, Non-alcoholic Steatohepatitis (NASH), Non-alcoholic Fatty Liver Disease (NAFLD) https://clinicaltrials.gov/study/NCT04639414 - NCT05371496 | Phase 4 | ENROLLING_BY_INVITATION | enrolled 81 Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Conditions: Cardiomyopathy, Heart Failure With Preserved Ejection Fraction (HFpEF), Obesity https://clinicaltrials.gov/study/NCT05371496 - NCT06739044 | Phase 3 | COMPLETED | enrolled 494 Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 Diabetes Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT06739044 - NCT06287307 | Phase 4 | NOT_YET_RECRUITING | enrolled 152 Semaglutide 2.4mg for Low Responders After Bariatric Surgery Conditions: Obesity, Obesity, Morbid, Weight Gain https://clinicaltrials.gov/study/NCT06287307 - NCT02305381 | Phase 3 | COMPLETED | enrolled 397 Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT02305381 - NCT06954090 | Phase 4 | ENROLLING_BY_INVITATION | enrolled 50 Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study Conditions: Type 2 DM, Type 2 DM /Diabetic Nephropathy, Albuminuria https://clinicaltrials.gov/study/NCT06954090 - NCT03693430 | Phase 3 | COMPLETED | enrolled 304 Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity Conditions: Overweight, Obesity https://clinicaltrials.gov/study/NCT03693430 - NCT05444153 | Phase 3 | WITHDRAWN | enrolled 0 Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT05444153 - NCT05579249 | Phase 4 | COMPLETED | enrolled 500 A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America Conditions: Obesity https://clinicaltrials.gov/study/NCT05579249 - NCT07163624 | Phase 2 | COMPLETED | enrolled 211 UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study Conditions: Type 2 Diabetes Mellitus (T2DM) https://clinicaltrials.gov/study/NCT07163624 - NCT06027567 | Phase 4 | COMPLETED | enrolled 38 The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure Conditions: Idiopathic Intracranial Hypertension, Intracranial Pressure, Obesity, Pseudotumor Cerebri Syndrome, Papilledema, Weight Loss https://clinicaltrials.gov/study/NCT06027567 - NCT07136714 | Phase 4 | RECRUITING | enrolled 116 Does Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity Conditions: Major Depressive Disorder https://clinicaltrials.gov/study/NCT07136714 - NCT02016911 | Phase 1 | COMPLETED | enrolled 56 Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment Conditions: Diabetes, Diabetes Mellitus, Type 2, Healthy https://clinicaltrials.gov/study/NCT02016911 - NCT06616961 | Phase 3 | NOT_YET_RECRUITING | enrolled 480 Efficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh With or Without Type 2 Diabetes Mellitus Conditions: Obesity, Type 2 Diabetes Mellitus (T2DM) https://clinicaltrials.gov/study/NCT06616961 - NCT07361874 | Not phased | RECRUITING | enrolled 75 IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion Conditions: Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS), Subclinical Cushing's, Mild Autonomous Cortisol Excess https://clinicaltrials.gov/study/NCT07361874 - NCT01572753 | Phase 1 | COMPLETED | enrolled 161 Investigation of Optimal Dosing Conditions for a Long Acting GLP-1 Analogue in Healthy Male Subjects Conditions: Diabetes, Diabetes Mellitus, Type 2, Healthy https://clinicaltrials.gov/study/NCT01572753 - NCT07745504 | Phase 3 | NOT_YET_RECRUITING | enrolled 285 A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight Conditions: Overweight, Obesity https://clinicaltrials.gov/study/NCT07745504 - NCT07280403 | Not phased | COMPLETED | enrolled 60 Effect of a Low-carbohydrate Diet on Weight Loss in People Using the Injectable GLP-1 Agonist Semaglutide for Weight Loss Conditions: Weight Loss https://clinicaltrials.gov/study/NCT07280403 - NCT07091500 | Not phased | RECRUITING | enrolled 40 Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With Obesity Conditions: Obesity, Skeletal Muscle, Brain Connectivity https://clinicaltrials.gov/study/NCT07091500 - NCT06534411 | Phase 3 | COMPLETED | enrolled 1023 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT06534411 - NCT07713992 | Not phased | NOT_YET_RECRUITING | enrolled 72 Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide Conditions: Type 2 Diabetes Mellitus (T2DM), Nonalcoholic Fatty Liver Disease (NAFLD) With History of Diabetes Melitus https://clinicaltrials.gov/study/NCT07713992 - NCT03914326 | Phase 3 | COMPLETED | enrolled 9651 A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT03914326 - NCT06762314 | Phase 2 | RECRUITING | enrolled 105 Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes Conditions: Diabetes https://clinicaltrials.gov/study/NCT06762314 - NCT07668414 | Phase 3 | NOT_YET_RECRUITING | enrolled 650 A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide Conditions: Overweight, Obesity https://clinicaltrials.gov/study/NCT07668414 - NCT05302596 | Phase 2 | COMPLETED | enrolled 16 Semaglutide Use in Elderly Obese Patients Conditions: Obesity, Aging https://clinicaltrials.gov/study/NCT05302596 - NCT07547878 | Phase 4 | NOT_YET_RECRUITING | enrolled 64 Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) Conditions: Chronic Kidney Disease, Type 2 Diabetes https://clinicaltrials.gov/study/NCT07547878 - NCT02648204 | Phase 3 | COMPLETED | enrolled 1201 Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes. Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT02648204 - NCT07112872 | Phase 2 | ACTIVE_NOT_RECRUITING | enrolled 240 A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes Conditions: Type 2 Diabetes Mellitus https://clinicaltrials.gov/study/NCT07112872 - NCT06396416 | Phase 4 | RECRUITING | enrolled 60 Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2 Conditions: Obesity, Chronic Kidney Disease https://clinicaltrials.gov/study/NCT06396416 - NCT03707990 | Phase 1 | COMPLETED | enrolled 88 A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese Conditions: Obesity and Overweight https://clinicaltrials.gov/study/NCT03707990 - NCT07171723 | Phase 2 | RECRUITING | enrolled 24 Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment Conditions: Obesity &Amp; Overweight https://clinicaltrials.gov/study/NCT07171723 - NCT07731256 | Phase 2 | NOT_YET_RECRUITING | enrolled 250 Semaglutide for Low Back Pain Conditions: Lower Back Pain, Obesity (BMI>30), Chronic Lower Back Pain, glp1 Agonist https://clinicaltrials.gov/study/NCT07731256 - NCT07478653 | Not phased | NOT_YET_RECRUITING | enrolled 50 MODERN-Dental: Pediatric Obesity, Cardiometabolic Risks, And Periodontal Disease Conditions: Obesity, Dental Care for Children https://clinicaltrials.gov/study/NCT07478653 - NCT07483801 | Phase 4 | NOT_YET_RECRUITING | enrolled 112 DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies Conditions: Cardiovascular Diseases https://clinicaltrials.gov/study/NCT07483801 - NCT07253285 | Phase 3 | RECRUITING | enrolled 460 A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight Conditions: Overweight, Obesity https://clinicaltrials.gov/study/NCT07253285 - NCT05322200 | Phase 4 | UNKNOWN | enrolled 140 The POST-ACS Study Conditions: Diabetes Mellitus, Acute Coronary Syndrome, Coronary Artery Disease https://clinicaltrials.gov/study/NCT05322200 - NCT05996848 | Phase 3 | COMPLETED | enrolled 300 A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight Conditions: Obesity or Overweight https://clinicaltrials.gov/study/NCT05996848 - NCT07092605 | Phase 1 | ENROLLING_BY_INVITATION | enrolled 150 Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures Conditions: Longevity, Quality of Life, Mood, Inflammation, Immune Health, Pain Management, Weight Management, Alertness https://clinicaltrials.gov/study/NCT07092605 - NCT04007107 | Phase 2 | COMPLETED | enrolled 103 A Study Comparing the Injection Site Pain Experience After the Injection of 2 Different Solutions of Semaglutide With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity Conditions: Healthy Volunteers Diabetes Mellitus, Type 2, Healthy Volunteers Overweight, Healthy Volunteers Obesity https://clinicaltrials.gov/study/NCT04007107 - NCT07218354 | Phase 3 | RECRUITING | enrolled 622 Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of a GLP-1 Receptor Agonist Semaglutide in U.S. Veterans With Alcohol Use Disorder Conditions: Alcohol Use Disorder https://clinicaltrials.gov/study/NCT07218354 - NCT07485062 | Phase 4 | NOT_YET_RECRUITING | enrolled 164 Exercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 Diabetes Conditions: Type 2 Diabetes, Cognitive Decline in Older Adults https://clinicaltrials.gov/study/NCT07485062 - NCT06173778 | Phase 2 | RECRUITING | enrolled 197 Semaglutide for Post-Smoking Cessation Weight Management Conditions: Obesity, Overweight, Cigarette Smoking https://clinicaltrials.gov/study/NCT06173778 - NCT05630586 | Phase 2 | RECRUITING | enrolled 380 Acute Subcutaneous SemaglutidE in Acute Ischemic sTroke Conditions: Acute Ischemic Stroke https://clinicaltrials.gov/study/NCT05630586 - NCT06546384 | Not phased | NOT_YET_RECRUITING | enrolled 64 GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease Conditions: Adiposity, Fatty Liver, Alcohol Use Disorder https://clinicaltrials.gov/study/NCT06546384 - NCT06836284 | Not phased | RECRUITING | enrolled 40 The Evira Study: Additional Support During Obesity Treatment Conditions: Childhood Obesity, Treatment Adherence https://clinicaltrials.gov/study/NCT06836284 - NCT05390307 | Not phased | COMPLETED | enrolled 60 Obesity Treatment to Improve Diabetes Conditions: Type 1 Diabetes https://clinicaltrials.gov/study/NCT05390307 - NCT02453711 | Phase 2 | COMPLETED | enrolled 957 Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus Conditions: Metabolism and Nutrition Disorder, Obesity https://clinicaltrials.gov/study/NCT02453711 - NCT07284979 | Phase 3 | RECRUITING | enrolled 1200 Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes Conditions: Obesity https://clinicaltrials.gov/study/NCT07284979 - NCT06363487 | Not phased | COMPLETED | enrolled 70 Semaglutide and Cognition in Healthy Volunteers Conditions: Cognitive Change https://clinicaltrials.gov/study/NCT06363487 - NCT04126603 | Phase 4 | COMPLETED | enrolled 10 Impact of Semaglutide on CD34+ EPC and Fat Derived MSC Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT04126603 - NCT07011667 | Phase 3 | ACTIVE_NOT_RECRUITING | enrolled 609 A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term Conditions: Obesity https://clinicaltrials.gov/study/NCT07011667 - NCT07564414 | Phase 3 | RECRUITING | enrolled 2500 A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight Conditions: Obesity, Type 2 Diabetes https://clinicaltrials.gov/study/NCT07564414 - NCT06797869 | Phase 2 | ACTIVE_NOT_RECRUITING | enrolled 142 A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy Conditions: Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy https://clinicaltrials.gov/study/NCT06797869 - NCT07059377 | Phase 3 | RECRUITING | enrolled 100 Semaglutide for Smoking Cessation in Patients With Diabetes Conditions: Diabetes Mellitus, Type 2, Nicotine Addiction, Tobacco Dependence https://clinicaltrials.gov/study/NCT07059377 - NCT07195994 | Not phased | RECRUITING | enrolled 90 A Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 Diabetes Conditions: Prediabetes / Type 2 Diabetes https://clinicaltrials.gov/study/NCT07195994 - NCT04817644 | Phase 1 | COMPLETED | enrolled 14 A Research Study to See How Much Semaglutide and SNAC is in the Milk of Healthy, Breastfeeding Women Taking Semaglutide Tablets Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT04817644 - NCT06909006 | Phase 3 | NOT_YET_RECRUITING | enrolled 122 Semaglutide Treatment in Type 1 Diabetes Conditions: Obesity in Diabetes, Obesity/Therapy, Type 1 Diabetes Mellitus (T1DM), Insulin Sensitivity/Resistance, Semaglutide, Lipidomics, Metabolomics, Weight Loss, Glycemic Control for Diabetes Mellitus https://clinicaltrials.gov/study/NCT06909006 - NCT07668388 | Phase 2 | RECRUITING | enrolled 300 A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT07668388 - NCT06975111 | Phase 3 | RECRUITING | enrolled 200 Focusing on the Menopausal Transition to Improve Mid-Life Women's Health Conditions: Menopause, Menopause Hot Flashes, Menopause Related Conditions, Cardiovascular https://clinicaltrials.gov/study/NCT06975111 - NCT06131372 | Phase 2 | COMPLETED | enrolled 626 A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo Conditions: Chronic Kidney Disease, Type 2 Diabetes, Obesity https://clinicaltrials.gov/study/NCT06131372 - NCT05569772 | Phase 3 | RECRUITING | enrolled 252 Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes Conditions: Glucose Intolerance After a Recent History of Gestational Diabetes https://clinicaltrials.gov/study/NCT05569772 - NCT03548935 | Phase 3 | COMPLETED | enrolled 1961 STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity Conditions: Metabolism and Nutrition Disorder, Overweight or Obesity https://clinicaltrials.gov/study/NCT03548935 - NCT03811574 | Phase 3 | COMPLETED | enrolled 401 STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity Conditions: Overweight, Obesity https://clinicaltrials.gov/study/NCT03811574 - NCT07651319 | Phase 2 | RECRUITING | enrolled 30 Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease Conditions: Alzheimer Dementia (AD) https://clinicaltrials.gov/study/NCT07651319 - NCT06344247 | Not phased | UNKNOWN | enrolled 48 Comparison of the Efficacy and Safety of SGLT2i and GLP-1 Receptor Agonists in Obese Patients With Kidney Disease Conditions: Obesity, Chronic Kidney Diseases https://clinicaltrials.gov/study/NCT06344247 - NCT06449625 | Phase 2 | NOT_YET_RECRUITING | enrolled 40 Semaglutide in Auto-HSCT Conditions: Intestinal Mucositis, Inflammation, Chemotherapeutic Toxicity https://clinicaltrials.gov/study/NCT06449625 - NCT02161588 | Phase 1 | COMPLETED | enrolled 48 A Trial to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Male Japanese and Caucasian Subjects Conditions: Diabetes, Diabetes Mellitus, Type 2, Healthy https://clinicaltrials.gov/study/NCT02161588 - NCT06318442 | Not phased | RECRUITING | enrolled 60 The GAPSID Study - How GLP-1 Analogues Prevent Steroid-Induced Diabetes Conditions: Steroid-Induced Diabetes, Steroid Induced Hyperglycemia https://clinicaltrials.gov/study/NCT06318442 - NCT07073417 | Phase 2 | ACTIVE_NOT_RECRUITING | enrolled 163 A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH) Conditions: Obesity, Weight Management https://clinicaltrials.gov/study/NCT07073417 - NCT07586150 | Not phased | NOT_YET_RECRUITING | enrolled 140 Personalized Pharmaco-Lifestyle Interventions for Severe Mental Illnesses (LIFETRAIN) Conditions: Severe Mental Illness, Depression / Major Depressive Disorder, Bipolar Disorder (BD), Schizophrenia https://clinicaltrials.gov/study/NCT07586150 - NCT06716216 | Phase 3 | RECRUITING | enrolled 537 A Study of BGM0504 in Participants with Type 2 Diabetes Conditions: Type 2 Diabetes Mellitus (T2DM) https://clinicaltrials.gov/study/NCT06716216 - NCT06269107 | Phase 3 | COMPLETED | enrolled 485 A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4) Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT06269107 - NCT04263415 | Phase 4 | COMPLETED | enrolled 30 The Effects of Semaglutide on Taste, Tongue Tissue Transcriptome, Gastric Emptying and Central Neural Response in Women With PCOS and Obesity Conditions: PCOS, Semaglutide, Taste, Altered, Tongue Tissue Transcriptome, Gastric Emptying, Central Neural Response https://clinicaltrials.gov/study/NCT04263415 - NCT04109547 | Phase 3 | COMPLETED | enrolled 521 A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT04109547 - NCT04259801 | Phase 1 | COMPLETED | enrolled 152 First Research Study to Look at How Two Medicines, NNC0480-0389 and Semaglutide, Work Together in Healthy People, in People With High Body Weight and in People With Diabetes Conditions: Healthy Volunteers, Overweight, Obesity, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT04259801 - NCT06468748 | Phase 4 | WITHDRAWN | enrolled 0 The Effects of Semaglutide on Body Composition and Performance in Military Personnel Conditions: Obesity https://clinicaltrials.gov/study/NCT06468748 - NCT07505303 | Phase 2 | ACTIVE_NOT_RECRUITING | enrolled 151 MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial Conditions: Adult Obesity, Weight Management https://clinicaltrials.gov/study/NCT07505303 - NCT06083675 | Phase 3 | WITHDRAWN | enrolled 0 Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT06083675 - NCT06557811 | Phase 4 | NOT_YET_RECRUITING | enrolled 88 Effect of Oral Semaglutide on Epicardial and Pericoronary Adipose Tissues in Type 2 Diabetes After Myocardial Infarction Conditions: Diabetic Patients, Acute Myocardial Infarction https://clinicaltrials.gov/study/NCT06557811 - NCT07220629 | Phase 2 | ACTIVE_NOT_RECRUITING | enrolled 82 Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2) Conditions: Obesity https://clinicaltrials.gov/study/NCT07220629 - NCT06131437 | Phase 3 | COMPLETED | enrolled 809 A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight Conditions: Obesity https://clinicaltrials.gov/study/NCT06131437 - NCT06754163 | Phase 4 | ACTIVE_NOT_RECRUITING | enrolled 20 Evaluating the Effect of the STEP@STAH Semaglutide Protocol on the Physical Health Measures of Atypical Antipsychotic-Treated Patients Conditions: Obesity and Obesity-related Medical Conditions, Psychiatric Disorders https://clinicaltrials.gov/study/NCT06754163 - NCT07673900 | Phase 1 | RECRUITING | enrolled 62 Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants Conditions: Overweight and/or Obesity https://clinicaltrials.gov/study/NCT07673900 - NCT03899402 | Phase 3 | ACTIVE_NOT_RECRUITING | enrolled 78 Triple Therapy in T1DM Conditions: Type 1 Diabetes Mellitus https://clinicaltrials.gov/study/NCT03899402 - NCT02128932 | Phase 3 | COMPLETED | enrolled 1089 Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT02128932 - NCT07428746 | Phase 3 | RECRUITING | enrolled 20 Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT07428746 - NCT06989203 | Not phased | RECRUITING | enrolled 140 Protein Supplementation Intervention on Body Weight Conditions: Obesity, Weight Loss, Protein Supplementation https://clinicaltrials.gov/study/NCT06989203 - NCT07065383 | Not phased | RECRUITING | enrolled 60 Rebalancing the Fat Content of the Heart and Muscles Conditions: Diabetes Mellitus Type 2 https://clinicaltrials.gov/study/NCT07065383 - NCT07064486 | Phase 3 | RECRUITING | enrolled 477 A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia Conditions: Type 2 Diabetes (T2DM) https://clinicaltrials.gov/study/NCT07064486 - NCT01766245 | Phase 1 | COMPLETED | enrolled 28 A Randomised, Single Centre, Double-blind, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Subcutaneous Injections of Semaglutide Produced by Two Manufacturing Processes Conditions: Diabetes, Healthy https://clinicaltrials.gov/study/NCT01766245 - NCT02906930 | Phase 3 | COMPLETED | enrolled 703 Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT02906930 - NCT06072963 | Phase 2 | RECRUITING | enrolled 80 COMMETS- Combination MCI Metabolic Syndrome Conditions: Alzheimer Disease, Mild Cognitive Impairment, Metabolic Syndrome https://clinicaltrials.gov/study/NCT06072963 - NCT07254715 | Phase 4 | RECRUITING | enrolled 60 Effect of Itopride on Semaglutide Gastroparesis Conditions: Semaglutide-Induced Gastric Motility, Anesthesia https://clinicaltrials.gov/study/NCT07254715 - NCT07642635 | Phase 2 | NOT_YET_RECRUITING | enrolled 30 Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy Conditions: Duchenne Muscular Dystrophy (DMD) https://clinicaltrials.gov/study/NCT07642635 - NCT05567796 | Phase 3 | ACTIVE_NOT_RECRUITING | enrolled 3400 A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight Conditions: Obesity https://clinicaltrials.gov/study/NCT05567796 - NCT05829460 | Phase 2 | WITHDRAWN | enrolled 0 Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia Conditions: Endometrial Hyperplasia https://clinicaltrials.gov/study/NCT05829460 - NCT03144271 | Phase 1 | COMPLETED | enrolled 58 Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects Conditions: Diabetes, Diabetes Mellitus, Type 2, Healthy https://clinicaltrials.gov/study/NCT03144271 - NCT05071898 | Phase 1 | RECRUITING | enrolled 600 Pharmacogenetics of Response to GLP1R Agonists Conditions: Obesity, Diabetes Type 2 https://clinicaltrials.gov/study/NCT05071898 - NCT07462663 | Phase 4 | NOT_YET_RECRUITING | enrolled 80 SHAPE-ENDO: Pilot Randomized Trial of Multimodal Pre-Surgical Optimization Versus Standard Surgery in Patients With Obesity and Early-Stage Endometrial Cancer Conditions: Endometrial Cancer, Endometrial Cancer Stage I, Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I, Atypical Endometrial Hyperplasia, Endometrial Intraepithelial Neoplasia, Obesity & Overweight, BMI>40, Obesity, Obesity Grade III https://clinicaltrials.gov/study/NCT07462663 - NCT05984238 | Not phased | COMPLETED | enrolled 33 A Trial to Evaluate Safety, Feasibility and Efficacy of the ReCET Procedure (EMINENT-2) Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT05984238 - NCT06885736 | Not phased | RECRUITING | enrolled 232 LEAN Mass Preservation With Resistance Exercise and Protein During Semaglutide/Tirzepatide Therapy Conditions: Obesity https://clinicaltrials.gov/study/NCT06885736 - NCT01923181 | Phase 2 | COMPLETED | enrolled 632 Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT01923181 - NCT03600480 | Phase 1 | COMPLETED | enrolled 96 A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese Conditions: Obesity, Overweight https://clinicaltrials.gov/study/NCT03600480 - NCT05209165 | Phase 4 | SUSPENDED | enrolled 132 Semaglutide to Reduce Atrial Fibrillation Burden Conditions: Atrial Fibrillation, Obesity, Overweight https://clinicaltrials.gov/study/NCT05209165 - NCT07239570 | Phase 4 | RECRUITING | enrolled 125 A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease Conditions: Chronic Kidney Disease(CKD) https://clinicaltrials.gov/study/NCT07239570 - NCT04019197 | Phase 2 | ACTIVE_NOT_RECRUITING | enrolled 108 Effects of Semaglutide in HIV-Associated Lipohypertrophy Conditions: HIV/AIDS, Lipohypertrophy, Obesity https://clinicaltrials.gov/study/NCT04019197 - NCT01619345 | Phase 1 | COMPLETED | enrolled 27 Pharmacoscintigraphic Investigation of NN9924 in Healthy Male Subjects Conditions: Diabetes, Healthy https://clinicaltrials.gov/study/NCT01619345 - NCT06716307 | Phase 1 | COMPLETED | enrolled 18 A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity Conditions: Obesity https://clinicaltrials.gov/study/NCT06716307 - NCT07466017 | Phase 2 | RECRUITING | enrolled 120 A Study of CS060380 Tablets in Patients With MASH and Obesity Conditions: Metabolic Dysfunction-associated Steatohepatitis (MASH), Obesity https://clinicaltrials.gov/study/NCT07466017 - NCT03021187 | Phase 3 | COMPLETED | enrolled 731 Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT03021187 - NCT06161844 | Phase 3 | COMPLETED | enrolled 506 Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus Conditions: Type 2 Diabetes Mellitus https://clinicaltrials.gov/study/NCT06161844 - NCT06986993 | Phase 4 | RECRUITING | enrolled 40 Impact of Semaglutide on Tobacco Use and Related Health Behaviors Conditions: Tobacco Use https://clinicaltrials.gov/study/NCT06986993 - NCT05548647 | Phase 4 | COMPLETED | enrolled 120 Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects Conditions: Obesity https://clinicaltrials.gov/study/NCT05548647 - NCT03548987 | Phase 3 | COMPLETED | enrolled 902 Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity Conditions: Metabolism and Nutrition Disorder, Obesity https://clinicaltrials.gov/study/NCT03548987 - NCT05891587 | Phase 2 | COMPLETED | enrolled 80 Semaglutide Therapy for Alcohol Reduction - Tulsa Conditions: Alcohol Use Disorder https://clinicaltrials.gov/study/NCT05891587 - NCT06771115 | Phase 2 | COMPLETED | enrolled 176 Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity Conditions: Obesity https://clinicaltrials.gov/study/NCT06771115 - NCT05819138 | Phase 3 | RECRUITING | enrolled 60 Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes Conditions: Diabetes Mellitus, Type 1 https://clinicaltrials.gov/study/NCT05819138 - NCT07617155 | Phase 4 | NOT_YET_RECRUITING | enrolled 396 GLP-1 Agonists for Prevention of Recurrent Hypertriglyceridemic Acute Pancreatitis Conditions: Hypertriglyceridemia Induced Acute Pancreatitis, Recurrent Acute Pancreatitis, Pancreatitis Relapsing, Hypertriglyceridemia https://clinicaltrials.gov/study/NCT07617155 - NCT05822609 | Phase 2 | RECRUITING | enrolled 60 Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes Conditions: Diabetic Kidney Disease, Type 1 Diabetes https://clinicaltrials.gov/study/NCT05822609 - NCT05352815 | Phase 3 | COMPLETED | enrolled 1291 A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT05352815 - NCT05891496 | Phase 3 | COMPLETED | enrolled 23 A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease Conditions: Alzheimers Disease https://clinicaltrials.gov/study/NCT05891496 - NCT06792422 | Phase 4 | RECRUITING | enrolled 126 A Study Investigating Oral Semaglutide in People with Open-Angle Glaucoma Conditions: Primary Open Angle Glaucoma (POAG), Open-Angle Glaucoma, Glaucoma https://clinicaltrials.gov/study/NCT06792422 - NCT03789578 | Phase 1 | COMPLETED | enrolled 30 A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or Together Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT03789578 - NCT06852391 | Phase 4 | RECRUITING | enrolled 74 JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity Conditions: Obesity (Disorder) https://clinicaltrials.gov/study/NCT06852391 - NCT07223983 | Phase 1 | RECRUITING | enrolled 10 Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS) Conditions: Alcohol Use Disorder, Weight Loss, Bariatric Surgery Patients https://clinicaltrials.gov/study/NCT07223983 - NCT06613854 | Phase 4 | RECRUITING | enrolled 90 Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes Conditions: Type 2 Diabetes Mellitus (T2DM) https://clinicaltrials.gov/study/NCT06613854 - NCT07251556 | Phase 4 | NOT_YET_RECRUITING | enrolled 40 GLP-1 Receptor Agonists in Non-diabetic Patients With Psoriatic Arthritis Conditions: Psoriasis Arthritis https://clinicaltrials.gov/study/NCT07251556 - NCT03724981 | Phase 4 | COMPLETED | enrolled 312 A Study Comparing the Dulaglutide Pen and the Semaglutide Pen Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT03724981 - NCT06082063 | Phase 3 | RECRUITING | enrolled 2000 Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes Conditions: Cardiovascular Diseases, Heart Failure, Type 1 Diabetes, Kidney Failure https://clinicaltrials.gov/study/NCT06082063 - NCT02970942 | Phase 2 | COMPLETED | enrolled 320 Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis. Conditions: Hepatobiliary Disorders, Non-alcoholic Steatohepatitis https://clinicaltrials.gov/study/NCT02970942 - NCT07622810 | Phase 3 | NOT_YET_RECRUITING | enrolled 352 BALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or Obesity Conditions: Obesity & Overweight https://clinicaltrials.gov/study/NCT07622810 - NCT05586802 | Phase 3 | RECRUITING | enrolled 150 Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome Conditions: Klinefelter Syndrome https://clinicaltrials.gov/study/NCT05586802 - NCT01272973 | Phase 1 | COMPLETED | enrolled 96 Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9924 in Healthy Male Subjects Conditions: Diabetes, Diabetes Mellitus, Type 2, Healthy https://clinicaltrials.gov/study/NCT01272973 - NCT06446531 | Phase 1 | RECRUITING | enrolled 64 Prevention of Progression of Prediabetes, Obesity and CV Risk Conditions: Pre-Diabetes, Weight, Body, Cardiovascular Diseases https://clinicaltrials.gov/study/NCT06446531 - NCT07728383 | Phase 4 | RECRUITING | enrolled 40 A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity Conditions: Obesity & Overweight https://clinicaltrials.gov/study/NCT07728383 - NCT04451837 | Phase 2 | ACTIVE_NOT_RECRUITING | enrolled 200 Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology Conditions: Type2 Diabetes https://clinicaltrials.gov/study/NCT04451837 - NCT05129891 | Phase 1 | COMPLETED | enrolled 384 A Research Study Looking at New Protein-based Tablets in Healthy Male Participants Conditions: Healthy Volunteers, High Blood Cholesterol Levels, Type 2 Diabetes https://clinicaltrials.gov/study/NCT05129891 - NCT07653477 | Phase 3 | NOT_YET_RECRUITING | enrolled 956 Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2) Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT07653477 - NCT04251156 | Phase 3 | COMPLETED | enrolled 375 Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity. Conditions: Overweight, Obesity, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT04251156 - NCT07017270 | Phase 4 | RECRUITING | enrolled 100 Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis Conditions: Kidney Disease, Chronic, Diabetes, Dialysis, End Stage Kidney Disease (ESRD) https://clinicaltrials.gov/study/NCT07017270 - NCT04979130 | Phase 4 | COMPLETED | enrolled 69 Comparing Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus (SIB) Conditions: Type 2 Diabetes, Chronic Inflammation, Intestinal Permeability https://clinicaltrials.gov/study/NCT04979130 - NCT07227948 | Phase 2 | RECRUITING | enrolled 75 Repurposing Semaglutide for the Treatment of Cocaine Use Disorder Conditions: Cocaine Use Disorder https://clinicaltrials.gov/study/NCT07227948 - NCT05259033 | Phase 3 | COMPLETED | enrolled 683 A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2) Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT05259033 - NCT07204249 | Phase 2 | RECRUITING | enrolled 162 Glutide for Ending Methamphetamine Conditions: Methamphetamine-dependence https://clinicaltrials.gov/study/NCT07204249 - NCT02022254 | Phase 1 | COMPLETED | enrolled 24 Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects Conditions: Diabetes, Diabetes Mellitus, Type 2, Healthy https://clinicaltrials.gov/study/NCT02022254 - NCT04238962 | Phase 1 | COMPLETED | enrolled 111 A Research Study to Compare Two Different Forms of Once-weekly Semaglutide in Two Different Injection Pens Conditions: Overweight, Obesity https://clinicaltrials.gov/study/NCT04238962 - NCT06639464 | Phase 2 | RECRUITING | enrolled 46 Semaglutide for Helping Opioid Recovery Conditions: Opioid Use Disorder https://clinicaltrials.gov/study/NCT06639464 - NCT07213466 | Phase 4 | RECRUITING | enrolled 100 Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder Conditions: Bipolar I Disorder, Bipolar II Disorder, Schizo Affective Disorder, Obesity, Weight Loss, GLP - 1 https://clinicaltrials.gov/study/NCT07213466 - NCT02607865 | Phase 3 | COMPLETED | enrolled 1864 Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT02607865 - NCT03989232 | Phase 3 | COMPLETED | enrolled 961 A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT03989232 - NCT02773381 | Phase 1 | COMPLETED | enrolled 15 A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT02773381 - NCT02146079 | Phase 1 | COMPLETED | enrolled 44 A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects Conditions: Diabetes, Diabetes Mellitus, Type 2, Healthy https://clinicaltrials.gov/study/NCT02146079 - NCT06699329 | Phase 1 | COMPLETED | enrolled 38 A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023) Conditions: Healthy https://clinicaltrials.gov/study/NCT06699329 - NCT04865744 | Phase 4 | COMPLETED | enrolled 10 The Effect of Semaglutide on Pituitary Function Conditions: Healthy https://clinicaltrials.gov/study/NCT04865744 - NCT07592546 | Phase 4 | NOT_YET_RECRUITING | enrolled 240 Translational Health Research Into Vascular and Neurocognitive Effects of Weight Loss Conditions: Class I/II Obesity https://clinicaltrials.gov/study/NCT07592546 - NCT06289504 | Phase 1 | COMPLETED | enrolled 34 A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight Conditions: Obesity https://clinicaltrials.gov/study/NCT06289504 - NCT04938388 | Phase 4 | TERMINATED | enrolled 12 Comparison of Oral Semaglutide w/ Placebo- Treatment for Latino Adults w/T2 Diabetes Receiving Enhanced Lifestyle Care Conditions: Diabetes Mellitus, Type 2, Glucose Metabolism Disorders (Including Diabetes Mellitus) https://clinicaltrials.gov/study/NCT04938388 - NCT07400107 | Phase 3 | NOT_YET_RECRUITING | enrolled 1000 AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight Conditions: Obesity, Overweight, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT07400107 - NCT06184633 | Phase 4 | RECRUITING | enrolled 280 DUTCH Weight Control in Atrial Fibrillation Study Conditions: Atrial Fibrillation, Obesity, Weight Loss https://clinicaltrials.gov/study/NCT06184633 - NCT05890976 | Phase 3 | COMPLETED | enrolled 200 Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3) Conditions: Overweight, Obesity https://clinicaltrials.gov/study/NCT05890976 - NCT06780449 | Phase 3 | ACTIVE_NOT_RECRUITING | enrolled 400 A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity Conditions: Obesity https://clinicaltrials.gov/study/NCT06780449 - NCT02079870 | Phase 1 | COMPLETED | enrolled 30 Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo Conditions: Diabetes, Metabolism and Nutrition Disorder, Obesity https://clinicaltrials.gov/study/NCT02079870 - NCT06894784 | Phase 3 | RECRUITING | enrolled 36 A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes Conditions: Diabetes Type 1 https://clinicaltrials.gov/study/NCT06894784 - NCT07319975 | Not phased | NOT_YET_RECRUITING | enrolled 48 Effect of Semaglutide and Tirzepatide Combined With Exercise in Obesity Conditions: Obesity https://clinicaltrials.gov/study/NCT07319975 - NCT05394519 | Phase 3 | COMPLETED | enrolled 1200 A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight Conditions: Overweight, Obesity, Type 2 Diabetes Mellitus https://clinicaltrials.gov/study/NCT05394519 - NCT05857085 | Phase 4 | COMPLETED | enrolled 90 Novel Therapeutics and Endothelial Dysfunction in T1DM Patients Conditions: Endothelial Dysfunction, Diabetes Mellitus, Type 1, Biomarkers, Endothelial Progenitor Cells, SGLT 2 Inhibitors, Incretins, Glucose Excursions, FMD, FPF, Arterial Stiffness https://clinicaltrials.gov/study/NCT05857085 - NCT06555146 | Not phased | NOT_YET_RECRUITING | enrolled 15 Semaglutide's Effect on Renal Hemodynamics and Function in Patients With Type 2 Diabetes Mellitus and Nephropathy Conditions: Diabetes Mellitus, Type 2, Kidney Disease, Chronic https://clinicaltrials.gov/study/NCT06555146 - NCT04097600 | Phase 1 | COMPLETED | enrolled 274 A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets Conditions: Healthy Volunteers, Type 2 Diabetes https://clinicaltrials.gov/study/NCT04097600 - NCT04865770 | Phase 3 | COMPLETED | enrolled 106 A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial) Conditions: Diabetes Mellitus, Type 2, Chronic Kidney Disease https://clinicaltrials.gov/study/NCT04865770 - NCT03136484 | Phase 3 | COMPLETED | enrolled 788 Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT03136484 - NCT05498610 | Phase 1 | COMPLETED | enrolled 24 A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Chinese Men Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT05498610 - NCT07610174 | Phase 2 | COMPLETED | enrolled 160 Effects of Dapagliflozin, Semaglutide, and Their Combination in Heart Failure Patients With Prosthetic Heart Valves Conditions: Heart Failure, Heart Valve Prosthesis https://clinicaltrials.gov/study/NCT07610174 - NCT07732218 | Phase 4 | COMPLETED | enrolled 95 Efficacy of Once Weekly Semaglutide in Patients With Type 2 Diabetes: a Non Randomized Clinical Trial Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT07732218 - NCT07021937 | Phase 3 | NOT_YET_RECRUITING | enrolled 120 Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity Conditions: Obesity/Therapy https://clinicaltrials.gov/study/NCT07021937 - NCT07179120 | Phase 2 | NOT_YET_RECRUITING | enrolled 180 Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health Conditions: Obesity-related Male Infertility https://clinicaltrials.gov/study/NCT07179120 - NCT04971785 | Phase 2 | COMPLETED | enrolled 457 Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) Conditions: Nonalcoholic Steatohepatitis https://clinicaltrials.gov/study/NCT04971785 - NCT07430059 | Phase 1 | NOT_YET_RECRUITING | enrolled 20 Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant Conditions: Obesity & Overweight https://clinicaltrials.gov/study/NCT07430059 - NCT07677995 | Not phased | ENROLLING_BY_INVITATION | enrolled 60 Free Fatty Acid Effects In Type 2 Diabetes Conditions: Type 2 Diabetes, Cardiovascular Disease, Omega-3 Fatty Acids https://clinicaltrials.gov/study/NCT07677995 - NCT02692716 | Phase 3 | COMPLETED | enrolled 3183 A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT02692716 - NCT06619015 | Phase 3 | WITHDRAWN | enrolled 0 Tailoring Obesity Treatment Trial Conditions: Obesity, Appetite Regulation, PreDiabetes https://clinicaltrials.gov/study/NCT06619015 - NCT05333003 | Not phased | ACTIVE_NOT_RECRUITING | enrolled 92 Semaglutide in Comorbid Schizophrenia Spectrum Disorder and Obesity Conditions: Schizophrenia Spectrum Disorders https://clinicaltrials.gov/study/NCT05333003 - NCT07465965 | Phase 1 | RECRUITING | enrolled 60 A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults Conditions: Overweight, Obesity https://clinicaltrials.gov/study/NCT07465965 - NCT06648031 | Phase 1 | COMPLETED | enrolled 148 Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants Conditions: Type2diabetes https://clinicaltrials.gov/study/NCT06648031 - NCT05779644 | Not phased | UNKNOWN | enrolled 300 Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus Conditions: Metformin, Obesity, Abdominal, Diabetes Mellitus, Type 2, Abdominal Fat, Non-Alcoholic Fatty Liver Disease, Metabolism Disorder, Glucose, Metabolism Disorder, Lipid https://clinicaltrials.gov/study/NCT05779644 - NCT04143945 | Phase 2 | COMPLETED | enrolled 104 A Study Comparing the Injection Site Pain Experience After the Injection of Semaglutide B and Semaglutide D With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity Conditions: Healthy Volunteers Diabetes Mellitus, Type 2, Healthy Volunteers Overweight, Healthy Volunteers Obesity https://clinicaltrials.gov/study/NCT04143945 - NCT06050577 | Phase 2 | ACTIVE_NOT_RECRUITING | enrolled 64 The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical Trial Conditions: Type 2 Diabetes, Osteopenia https://clinicaltrials.gov/study/NCT06050577 - NCT07597018 | Phase 1 | RECRUITING | enrolled 234 A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity Conditions: Obesity, Overweight https://clinicaltrials.gov/study/NCT07597018 - NCT05501483 | Not phased | RECRUITING | enrolled 60 Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT05501483 - NCT05254314 | Phase 2 | ACTIVE_NOT_RECRUITING | enrolled 100 Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3) Conditions: Asthma https://clinicaltrials.gov/study/NCT05254314 - NCT06410352 | Phase 4 | RECRUITING | enrolled 220 Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome Conditions: Metabolic Syndrome https://clinicaltrials.gov/study/NCT06410352 - NCT05816057 | Phase 3 | COMPLETED | enrolled 476 A Study of the Efficacy and Safety of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT05816057 - NCT06361823 | Phase 3 | UNKNOWN | enrolled 74 Exploratory Study on the Efficacy and Safety of Semaglutide for Idiopathic Intracranial Hypertension Treatment Conditions: Idiopathic Intracranial Hypertension https://clinicaltrials.gov/study/NCT06361823 - NCT06499857 | Phase 3 | RECRUITING | enrolled 200 Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation Conditions: Overweight or Obesity, Atrial Fibrillation https://clinicaltrials.gov/study/NCT06499857 - NCT04940078 | Phase 1 | COMPLETED | enrolled 40 A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity Conditions: Obesity & Overweight https://clinicaltrials.gov/study/NCT04940078 - NCT07633639 | Not phased | RECRUITING | enrolled 200 GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity Conditions: Obesity https://clinicaltrials.gov/study/NCT07633639 - NCT03919929 | Phase 3 | COMPLETED | enrolled 60 Treating PCOS With Semaglutide vs Active Lifestyle Intervention Conditions: PCOS, Adolescent Obesity, NAFLD https://clinicaltrials.gov/study/NCT03919929 - NCT07662213 | Phase 3 | RECRUITING | enrolled 1200 A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus Conditions: Type 2 Diabetes Mellitus https://clinicaltrials.gov/study/NCT07662213 - NCT06715514 | Not phased | ACTIVE_NOT_RECRUITING | enrolled 96 Menopausal Hormone Therapy, GLP-1 Agonists, and Glucose and Energy Homeostasis in Postmenopausal Women With Diabetes Conditions: Menopause, Type 2 Diabetes https://clinicaltrials.gov/study/NCT06715514 - NCT06260722 | Phase 3 | ACTIVE_NOT_RECRUITING | enrolled 1250 Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT06260722 - NCT06390501 | Not phased | COMPLETED | enrolled 60 The Effect of Weekly Semaglutide Treatment on Energy Expenditure Conditions: Obesity; Drug https://clinicaltrials.gov/study/NCT06390501 - NCT04524832 | Phase 1 | COMPLETED | enrolled 290 Research Study Comparing New Tablets of Semaglutide in New Doses, in Healthy People Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT04524832 - NCT05078255 | Not phased | COMPLETED | enrolled 61 The Separate and Combined Effects of Long-term GIP and GLP-1 Receptor Activation in Patients with Type 2 Diabetes Conditions: Type 2 Diabetes, Obesity https://clinicaltrials.gov/study/NCT05078255 - NCT04892199 | Phase 4 | ACTIVE_NOT_RECRUITING | enrolled 104 Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication? Conditions: Metabolic Disturbance, Schizophrenia, Type 2 Diabetes, Clozapine, GLP-1, Olanzapine https://clinicaltrials.gov/study/NCT04892199 - NCT07389941 | Phase 4 | NOT_YET_RECRUITING | enrolled 240 Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation Conditions: Atrial Fibrillation (AF) https://clinicaltrials.gov/study/NCT07389941 - NCT02064348 | Phase 1 | COMPLETED | enrolled 168 A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects Conditions: Diabetes, Healthy https://clinicaltrials.gov/study/NCT02064348 - NCT07724340 | Phase 2 | RECRUITING | enrolled 150 A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity Conditions: Adults With Overweight/Obesity and Type 2 Diabetes https://clinicaltrials.gov/study/NCT07724340 - NCT07411378 | Phase 2 | NOT_YET_RECRUITING | enrolled 164 Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss. Conditions: Muscle Wasting, Obesity & Overweight, Obesity https://clinicaltrials.gov/study/NCT07411378 - NCT05232708 | Phase 1 | COMPLETED | enrolled 18 A Clinical Trial Looking at the Comparability of 2 Different Forms of Semaglutide Conditions: Healthy Volunteers (Diabetes Mellitus, Type 2) https://clinicaltrials.gov/study/NCT05232708 - NCT06738979 | Phase 3 | NOT_YET_RECRUITING | enrolled 408 A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects Conditions: Obesity https://clinicaltrials.gov/study/NCT06738979 - NCT03061214 | Phase 3 | COMPLETED | enrolled 868 Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT) Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT03061214 - NCT06814938 | Phase 4 | ACTIVE_NOT_RECRUITING | enrolled 135 A Study of a Novel Precision Medicine Approach For Obesity Conditions: Obesity https://clinicaltrials.gov/study/NCT06814938 - NCT01866748 | Phase 1 | COMPLETED | enrolled 170 Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male Subjects Conditions: Diabetes, Diabetes Mellitus, Type 2, Healthy https://clinicaltrials.gov/study/NCT01866748 - NCT06691243 | Phase 2 | RECRUITING | enrolled 40 Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV Conditions: Cocaine Use Disorder, HIV https://clinicaltrials.gov/study/NCT06691243 - NCT03951753 | Phase 1 | COMPLETED | enrolled 117 A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM) Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT03951753 - NCT07727473 | Phase 1 | NOT_YET_RECRUITING | enrolled 20 Preoperative Semaglutide Prior to Radical Prostatectomy Conditions: Prostate Cancer https://clinicaltrials.gov/study/NCT07727473 - NCT03086330 | Phase 3 | COMPLETED | enrolled 302 Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT03086330 - NCT04187300 | Phase 1 | COMPLETED | enrolled 68 A Research Study Looking at the Comparability (Bioequivalence) of Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity Conditions: Overweight, Obesity https://clinicaltrials.gov/study/NCT04187300 - NCT05579977 | Phase 2 | TERMINATED | enrolled 902 Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity Conditions: Diabetes Mellitus, Obesity https://clinicaltrials.gov/study/NCT05579977 - NCT07249554 | Phase 2 | NOT_YET_RECRUITING | enrolled 45 Combination Therapy for Alcohol Use Disorder Conditions: Alcohol Use Disorder https://clinicaltrials.gov/study/NCT07249554 - NCT07621640 | Not phased | NOT_YET_RECRUITING | enrolled 80 Brown Adipose Tissue as a Mechanistic Determinant of Semaglutide Treatment Response in Obesity (BAT-Sema Study) Conditions: Obesity, Metabolic Syndrome, Brown Adipose Tissue https://clinicaltrials.gov/study/NCT07621640 - NCT06215196 | Not phased | COMPLETED | enrolled 81 Effectiveness and Safety of Semaglutide Combined With Dietary Fiber (Soloways) in Adults With Overweight or Obesity Conditions: Overweight and Obesity https://clinicaltrials.gov/study/NCT06215196 - NCT05870462 | Phase 4 | UNKNOWN | enrolled 100 Semaglutide and Vascular Regeneration Conditions: Atherosclerosis, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Obesity https://clinicaltrials.gov/study/NCT05870462 - NCT02557620 | Phase 1 | COMPLETED | enrolled 113 Comparing Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly Conditions: Diabetes, Healthy https://clinicaltrials.gov/study/NCT02557620 - NCT02070510 | Phase 1 | COMPLETED | enrolled 52 A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Lisinopril and Warfarin in Healthy Subjects Conditions: Diabetes, Healthy https://clinicaltrials.gov/study/NCT02070510 - NCT05780905 | Phase 4 | RECRUITING | enrolled 50 Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes Conditions: Diabetes Mellitus, Type 2, Stroke (CVA) or Transient Ischemic Attack https://clinicaltrials.gov/study/NCT05780905 - NCT06041217 | Phase 3 | COMPLETED | enrolled 242 A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range Conditions: Overweight, Obesity https://clinicaltrials.gov/study/NCT06041217 - NCT05671653 | Phase 1 | TERMINATED | enrolled 32 A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range Conditions: Obesity https://clinicaltrials.gov/study/NCT05671653 - NCT07743983 | Phase 3 | RECRUITING | enrolled 372 A Study of BGM0504 in Early T2DM With Obesity Conditions: Type 2 Diabetes (T2DM) https://clinicaltrials.gov/study/NCT07743983 - NCT04189848 | Phase 4 | COMPLETED | enrolled 104 Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc Conditions: Healthy Volunteers, Diabetes Mellitus, Type 2, Overweight, Obesity https://clinicaltrials.gov/study/NCT04189848 - NCT07096739 | Not phased | COMPLETED | enrolled 20 Tolerance of a High Protein Nutrition Shake in Individuals on GLP-1 Conditions: GLP-1 Concentration https://clinicaltrials.gov/study/NCT07096739 - NCT04538352 | Phase 4 | COMPLETED | enrolled 60 Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT04538352 - NCT07391267 | Not phased | NOT_YET_RECRUITING | enrolled 90 Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide. Conditions: Chronic Kidney Diseases, MAFLD https://clinicaltrials.gov/study/NCT07391267 - NCT06745284 | Phase 1 | ACTIVE_NOT_RECRUITING | enrolled 64 A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity Conditions: Obesity https://clinicaltrials.gov/study/NCT06745284 - NCT05035095 | Phase 3 | COMPLETED | enrolled 667 Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1) Conditions: Obesity, Overweight https://clinicaltrials.gov/study/NCT05035095 - NCT07732426 | Not phased | RECRUITING | enrolled 30 Effects of Semaglutide on Brain Dopamine Responses to Food Cues in Adults With Obesity and Food Addiction Tendencies Conditions: Food Addiction Tendency, Obesity, Overweight https://clinicaltrials.gov/study/NCT07732426 - NCT00696657 | Phase 2 | COMPLETED | enrolled 415 A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT00696657 - NCT07135245 | Phase 2 | NOT_YET_RECRUITING | enrolled 180 Improved Treatment and Monitoring of Alzheimer's Disease Conditions: Alzheimer Disease (AD) https://clinicaltrials.gov/study/NCT07135245 - NCT04032197 | Phase 1 | COMPLETED | enrolled 101 A Research Study of How Semaglutide Works in People With Disease Affecting the Heart and/or Blood Vessels and Type 2 Diabetes Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT04032197 - NCT06579105 | Phase 2 | COMPLETED | enrolled 406 Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus. Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT06579105 - NCT07202247 | Phase 2 | RECRUITING | enrolled 60 Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial Conditions: Prostate Carcinoma, Recurrent Prostate Carcinoma https://clinicaltrials.gov/study/NCT07202247 - NCT03689374 | Phase 3 | COMPLETED | enrolled 2274 A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT03689374 - NCT05616013 | Phase 2 | COMPLETED | enrolled 507 Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese Conditions: Obesity, Obese, Overweight or Obesity https://clinicaltrials.gov/study/NCT05616013 - NCT07087795 | Phase 1 | ACTIVE_NOT_RECRUITING | enrolled 96 A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 Diabetes Conditions: Diabetes Mellitus, Type 1 https://clinicaltrials.gov/study/NCT07087795 - NCT05892432 | Phase 2 | COMPLETED | enrolled 50 Clinical Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder (AUD) Conditions: Alcohol Use Disorder https://clinicaltrials.gov/study/NCT05892432 - NCT06533527 | Phase 4 | COMPLETED | enrolled 69 Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy Conditions: Diabetes Mellitus, Type 2, Obesity, Gastroparesis https://clinicaltrials.gov/study/NCT06533527 - NCT06500429 | Phase 2 | COMPLETED | enrolled 120 A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist Conditions: Overweight and Obesity, Healthy https://clinicaltrials.gov/study/NCT06500429 - NCT02249871 | Phase 1 | COMPLETED | enrolled 54 Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects Conditions: Diabetes, Healthy https://clinicaltrials.gov/study/NCT02249871 - NCT05766709 | Phase 1 | COMPLETED | enrolled 53 A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations Conditions: Non-alcoholic Steatohepatitis https://clinicaltrials.gov/study/NCT05766709 - NCT06629688 | Not phased | COMPLETED | enrolled 51 Semaglutide and Intestinal Iron Absorption Conditions: Diabetes Mellitus Type 2, Iron Absorption https://clinicaltrials.gov/study/NCT06629688 - NCT07150975 | Phase 3 | RECRUITING | enrolled 420 Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects Conditions: Obesity/Overweight in Adult https://clinicaltrials.gov/study/NCT07150975 - NCT04969939 | Phase 2 | COMPLETED | enrolled 120 A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity Conditions: Obesity https://clinicaltrials.gov/study/NCT04969939 - NCT02863419 | Phase 3 | COMPLETED | enrolled 711 Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT02863419 - NCT07272343 | Phase 4 | RECRUITING | enrolled 100 The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes Conditions: Type 2 Diabetes Mellitus (T2DM), Semaglutide, Caloric Restriction https://clinicaltrials.gov/study/NCT07272343 - NCT05938712 | Phase 2 | RECRUITING | enrolled 20 The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients Conditions: Kidney Transplant Recipients https://clinicaltrials.gov/study/NCT05938712 - NCT04515849 | Phase 2 | COMPLETED | enrolled 248 A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus Conditions: Type 2 Diabetes Mellitus, Chronic Kidney Diseases https://clinicaltrials.gov/study/NCT04515849 - NCT06608433 | Not phased | COMPLETED | enrolled 22 Glucagon-like Peptide-1 Receptor Agnoists for the Assessment of Adrenal Function Conditions: Healthy Volunteer Study, HPA, Cortisol Deficiency, Adrenal Insufficiency https://clinicaltrials.gov/study/NCT06608433 - NCT05486065 | Phase 2 | COMPLETED | enrolled 245 A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT05486065 - NCT05788965 | Phase 3 | COMPLETED | enrolled 8 Semaglutide in CFRD Conditions: Cystic Fibrosis, Cystic Fibrosis-related Diabetes https://clinicaltrials.gov/study/NCT05788965 - NCT02254291 | Phase 3 | COMPLETED | enrolled 308 A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT02254291 - NCT07040592 | Phase 2 | RECRUITING | enrolled 30 Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide Conditions: Alcohol Use Disorder (AUD), HIV https://clinicaltrials.gov/study/NCT07040592 - NCT04702516 | Phase 2 | UNKNOWN | enrolled 64 The Effect of Semaglutide on Bone Turnover in Patients With Increased Risk of Bone Fracture Conditions: Osteopenia https://clinicaltrials.gov/study/NCT04702516 - NCT07639021 | Phase 2 | RECRUITING | enrolled 230 A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity Conditions: Obesity https://clinicaltrials.gov/study/NCT07639021 - NCT07254572 | Phase 4 | RECRUITING | enrolled 300 Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes Conditions: Coronary Artery Disease, PreDiabetes https://clinicaltrials.gov/study/NCT07254572 - NCT05195944 | Phase 4 | ENROLLING_BY_INVITATION | enrolled 58 Semaglutide vs Sitagliptin Conditions: Liver Transplant; Complications, Diabetes Mellitus, NASH - Nonalcoholic Steatohepatitis, NAFLD https://clinicaltrials.gov/study/NCT05195944 - NCT04228354 | Phase 1 | COMPLETED | enrolled 28 A Research Study Looking at the Comparability (Bioequivalence) of Two Versions of Semaglutide Conditions: Healthy Volunteers, Overweight, Obesity https://clinicaltrials.gov/study/NCT04228354 - NCT05202353 | Phase 1 | ACTIVE_NOT_RECRUITING | enrolled 29 A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver Conditions: Obesity https://clinicaltrials.gov/study/NCT05202353 - NCT03611582 | Phase 3 | COMPLETED | enrolled 611 Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program Conditions: Overweight, Obesity https://clinicaltrials.gov/study/NCT03611582 - NCT05478252 | Phase 3 | COMPLETED | enrolled 388 A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT05478252 - NCT01686945 | Phase 1 | COMPLETED | enrolled 107 Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2, Healthy https://clinicaltrials.gov/study/NCT01686945 - NCT05813912 | Phase 3 | COMPLETED | enrolled 148 A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT05813912 - NCT05520775 | Phase 2 | COMPLETED | enrolled 48 Semaglutide for Alcohol Use Disorder Conditions: Alcohol Use Disorder, Cigarette Smoking https://clinicaltrials.gov/study/NCT05520775 - NCT07581145 | Phase 3 | RECRUITING | enrolled 52 Effect of Semaglutide on Healing of Foot Ulcers in Type 2 Diabetes Patients Conditions: Foot Ulcer Due to Type 2 Diabetes Mellitus https://clinicaltrials.gov/study/NCT07581145 - NCT03811561 | Phase 3 | ACTIVE_NOT_RECRUITING | enrolled 1500 A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT03811561 - NCT06642584 | Phase 1 | COMPLETED | enrolled 90 A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IV Conditions: Healthy Volunteers Type 2 Diabetes https://clinicaltrials.gov/study/NCT06642584 - NCT06959784 | Phase 4 | ENROLLING_BY_INVITATION | enrolled 142 Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study) Conditions: Diabetes Mellitus, Cardiovascular Diseases, Cerebrovascular Disease https://clinicaltrials.gov/study/NCT06959784 - NCT07010432 | Phase 1 | RECRUITING | enrolled 144 The Role of the Amylin Analogue Cagrilintide in Bone Metabolism Conditions: Obesity https://clinicaltrials.gov/study/NCT07010432 - NCT04779697 | Phase 1 | COMPLETED | enrolled 96 GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight Conditions: Obesity https://clinicaltrials.gov/study/NCT04779697 - NCT04982575 | Phase 2 | COMPLETED | enrolled 92 Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT04982575 - NCT06267092 | Phase 1 | COMPLETED | enrolled 164 A Study of How CagriSema Works on Appetite in People With Excess Body Weight Conditions: Overweight, Obesity https://clinicaltrials.gov/study/NCT06267092 - NCT05424003 | Phase 2 | RECRUITING | enrolled 50 Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant Conditions: NAFLD https://clinicaltrials.gov/study/NCT05424003 - NCT06863363 | Phase 4 | NOT_YET_RECRUITING | enrolled 212 PEG-rhGH and Semaglutide Combination Therapy in Non-Diabetic Obese Adults Conditions: Non-diabetic Obesity https://clinicaltrials.gov/study/NCT06863363 - NCT06388187 | Phase 3 | COMPLETED | enrolled 300 A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight Conditions: Obesity https://clinicaltrials.gov/study/NCT06388187 - NCT05786521 | Phase 4 | COMPLETED | enrolled 20 Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults Conditions: Aging, Diabetes Mellitus, Type 2, PreDiabetes, Overweight and Obesity https://clinicaltrials.gov/study/NCT05786521 - NCT04287179 | Phase 3 | WITHDRAWN | enrolled 0 SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT04287179 - NCT05897372 | Phase 2 | TERMINATED | enrolled 1 Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study Conditions: Diabetic Kidney Disease https://clinicaltrials.gov/study/NCT05897372 - NCT07200622 | Phase 2 | NOT_YET_RECRUITING | enrolled 60 Oral Semaglutide in Patients With Alzheimer's Disease Conditions: Alzheimer Disease https://clinicaltrials.gov/study/NCT07200622 - NCT04152915 | Phase 1 | COMPLETED | enrolled 68 A Research Study Looking at Similarity Between Once-weekly Semaglutide Versions for Different Injection Pens Conditions: Healthy Volunteers, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT04152915 - NCT05067621 | Phase 2 | ACTIVE_NOT_RECRUITING | enrolled 60 Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease Conditions: Type 2 Diabetes Mellitus, Impaired Glucose Tolerance, Non-Alcoholic Fatty Liver Disease, Obesity, Childhood https://clinicaltrials.gov/study/NCT05067621 - NCT06057077 | Phase 2 | UNKNOWN | enrolled 120 Semaglutide GLP1 Agonists With Degludec Basal-bolus Insulin in Early Type 1 Diabetes to Basal-bolus Conditions: Type 1 Diabetes https://clinicaltrials.gov/study/NCT06057077 - NCT05537233 | Phase 2 | COMPLETED | enrolled 115 ADJUnct Semaglutide Treatment in Type 1 Diabetes Conditions: Type 1 Diabetes, Obesity https://clinicaltrials.gov/study/NCT05537233 - NCT05702931 | Phase 4 | RECRUITING | enrolled 104 Semaglutide Treatment for Hyperglycaemia After Renal Transplantation Conditions: Hyperglycemia, Renal Transplant Complication Primary Non-Function, Diabetes https://clinicaltrials.gov/study/NCT05702931 - NCT03288740 | Phase 1 | COMPLETED | enrolled 36 A Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese Subjects Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT03288740 - NCT06423599 | Phase 3 | RECRUITING | enrolled 100 Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure Conditions: Heart Failure With Reduced Ejection Fraction, Obesity, Weight Loss, Chronic Heart Failure https://clinicaltrials.gov/study/NCT06423599 - NCT07523633 | Phase 2 | RECRUITING | enrolled 100 Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder Conditions: Cannabis Use Disorder, Cannabis Use Disorders, Cannabis Abuse, Cannabis Dependence, Cannabis Addiction https://clinicaltrials.gov/study/NCT07523633 - NCT05819853 | Phase 3 | RECRUITING | enrolled 80 Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome Conditions: PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, Obese https://clinicaltrials.gov/study/NCT05819853 - NCT06897475 | Phase 2 | RECRUITING | enrolled 240 A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT06897475 - NCT02920385 | Phase 1 | COMPLETED | enrolled 45 A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Levothyroxine and the Influence of Co-administered Tablets on the Pharmacokinetics of Semaglutide Administered Orally in Healthy Subjects. Conditions: Diabetes, Healthy https://clinicaltrials.gov/study/NCT02920385 - NCT06005012 | Phase 2 | ACTIVE_NOT_RECRUITING | enrolled 120 Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM Conditions: Fibrosis, Liver, Type 2 Diabetes Mellitus in Obese, Non-Alcoholic Fatty Liver Disease https://clinicaltrials.gov/study/NCT06005012 - NCT03596450 | Phase 4 | COMPLETED | enrolled 1278 Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT03596450 - NCT06497049 | Phase 1 | COMPLETED | enrolled 120 Open Randomized Study of Comparative Pharmacokinetics and Biosimilarity of GP40221 (GEROPHARM LLC, Russia) and Ozempic®. Conditions: Pharmacokinetics, Safety Issues, Bioequivalence https://clinicaltrials.gov/study/NCT06497049 - NCT06706284 | Phase 4 | RECRUITING | enrolled 50 Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes Conditions: Spinal Cord Injuries, Type 2 Diabetes https://clinicaltrials.gov/study/NCT06706284 - NCT07172867 | Phase 2 | WITHDRAWN | enrolled 0 A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM Conditions: Diabetes Mellitus, Type 2, Obesity https://clinicaltrials.gov/study/NCT07172867 - NCT04998136 | Phase 3 | COMPLETED | enrolled 150 Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity Conditions: Obesity https://clinicaltrials.gov/study/NCT04998136 - NCT06633783 | Phase 3 | NOT_YET_RECRUITING | enrolled 370 A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy® Conditions: Obesity https://clinicaltrials.gov/study/NCT06633783 - NCT03292315 | Phase 4 | COMPLETED | enrolled 5 Once Weekly GLP-1 in Persons With Spinal Cord Injury Conditions: Spinal Cord Injuries, Insulin Resistance, Pre Diabetes, Obesity https://clinicaltrials.gov/study/NCT03292315 - NCT06339086 | Phase 3 | UNKNOWN | enrolled 478 Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes Conditions: Type 2 Diabetes Mellitus https://clinicaltrials.gov/study/NCT06339086 - NCT05646199 | Phase 3 | UNKNOWN | enrolled 60 Semaglutide vs Metformin in Polycystic Ovary Syndrome (PCOS) Conditions: Polycystic Ovary Syndrome https://clinicaltrials.gov/study/NCT05646199 - NCT03842202 | Phase 1 | COMPLETED | enrolled 72 A Research Study to Look at How Semaglutide Affects Gastric Emptying in People With Obesity Conditions: Overweight, Obesity https://clinicaltrials.gov/study/NCT03842202 - NCT04074161 | Phase 3 | COMPLETED | enrolled 338 Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity Conditions: Overweight, Obesity https://clinicaltrials.gov/study/NCT04074161 - NCT00851773 | Phase 1 | COMPLETED | enrolled 84 Safety, Tolerability, and Profile of Action of Drug in the Body of NN9535 in Healthy Male Japanese and Caucasian Subjects Conditions: Diabetes, Healthy https://clinicaltrials.gov/study/NCT00851773 - NCT04513704 | Phase 1 | COMPLETED | enrolled 156 A Clinical Trial Comparing Semaglutide in Healthy People Who Eat and Take the Medicine at Different Times Conditions: Healthy Volunteers Type 2 Diabetes https://clinicaltrials.gov/study/NCT04513704 - NCT07282769 | Phase 2 | NOT_YET_RECRUITING | enrolled 10 Semaglutide (Wegovy) Treatment for Trichotillomania Conditions: Trichotillomania (Hair-Pulling Disorder), Trichotillomania, Hair Pulling Disorder, Hair Pulling, Hair-Pulling Disorder https://clinicaltrials.gov/study/NCT07282769 - NCT04615871 | Phase 2 | UNKNOWN | enrolled 400 Semaglutide to Reduce Myocardial Injury in PATIents With COVID-19 Conditions: Covid19, Myocardial Injury https://clinicaltrials.gov/study/NCT04615871 - NCT06207877 | Phase 1 | COMPLETED | enrolled 62 A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight Conditions: Obesity https://clinicaltrials.gov/study/NCT06207877 - NCT07599046 | Not phased | NOT_YET_RECRUITING | enrolled 20 Fecal Microbiota Transplantation (FMT) Combined With Calorie-Restricted Diet and Semaglutide in Patients With Obesity and Type 2 Diabetes Conditions: Obesity Type 2 Diabetes Mellitus https://clinicaltrials.gov/study/NCT07599046 - NCT04624672 | Phase 4 | TERMINATED | enrolled 3 Treatment of GLP-1 for Diabetic Bariatric Patients Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT04624672 - NCT05071417 | Phase 3 | UNKNOWN | enrolled 120 Effect Of Semaglutide In Coronary Atheroma Plaque Conditions: Atheroscleroses, Coronary https://clinicaltrials.gov/study/NCT05071417 - NCT07101939 | Phase 2 | RECRUITING | enrolled 120 A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2) Conditions: Obesity, Muscle Loss https://clinicaltrials.gov/study/NCT07101939 - NCT05205928 | Phase 3 | COMPLETED | enrolled 28 Weekly Subcutaneous Semaglutide as Adjunct to Closed-loop Therapy in Type 1 Diabetes Care Conditions: Type 1 Diabetes, Diabetes Mellitus, Type 1 https://clinicaltrials.gov/study/NCT05205928 - NCT04944992 | Phase 2 | COMPLETED | enrolled 145 A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001) Conditions: Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis https://clinicaltrials.gov/study/NCT04944992 - NCT03987919 | Phase 3 | COMPLETED | enrolled 1879 A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT03987919 - NCT07297589 | Phase 3 | RECRUITING | enrolled 136 Epicardial Cardiac Fat-CT (EPIC-CT) Conditions: STEMI - ST Elevation Myocardial Infarction, Epicardial Fat https://clinicaltrials.gov/study/NCT07297589 - NCT02212067 | Phase 1 | COMPLETED | enrolled 87 A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT02212067 - NCT02147431 | Phase 1 | COMPLETED | enrolled 38 A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT02147431 - NCT04466345 | Phase 2 | COMPLETED | enrolled 72 Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder Conditions: Major Depressive Disorder https://clinicaltrials.gov/study/NCT04466345 - NCT06003153 | Phase 4 | RECRUITING | enrolled 125 GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH Conditions: Genetic Predisposition, Metabolic Diseases, Type 2 Diabetes https://clinicaltrials.gov/study/NCT06003153 - NCT06640972 | Phase 2 | COMPLETED | enrolled 68 Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists Conditions: Triglycerides, Weight Gain Trajectory, Cholesterol, Elevated https://clinicaltrials.gov/study/NCT06640972 - NCT05227196 | Phase 1 | COMPLETED | enrolled 546 A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People Conditions: Healthy Volunteers, Type 2 Diabetes https://clinicaltrials.gov/study/NCT05227196 - NCT06575738 | Phase 1 | RECRUITING | enrolled 40 Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents Conditions: Obesity, Adolescent Obesity, Body-Weight Trajectory, Weight Loss Trajectory, Bariatric Surgery, Anti-obesity Agents https://clinicaltrials.gov/study/NCT06575738 - NCT04102189 | Phase 3 | COMPLETED | enrolled 201 A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity Conditions: Overweight, Obesity https://clinicaltrials.gov/study/NCT04102189 - NCT05702905 | Phase 4 | UNKNOWN | enrolled 75 Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome Conditions: PCOS (Polycystic Ovary Syndrome), Semaglutide https://clinicaltrials.gov/study/NCT05702905 - NCT04447859 | Phase 3 | UNKNOWN | enrolled 100 16-week Flexible vs. 8-week Semaglutide Titration Conditions: Diabetes type2 https://clinicaltrials.gov/study/NCT04447859 - NCT05236517 | Phase 1 | COMPLETED | enrolled 60 A Research Study Looking at How 50 mg Semaglutide Daily Affects Food Intake and Emptying of the Stomach in People With Obesity Conditions: Obesity https://clinicaltrials.gov/study/NCT05236517 - NCT06097390 | Phase 1 | COMPLETED | enrolled 121 A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III Conditions: Healthy Participants https://clinicaltrials.gov/study/NCT06097390 - NCT06989177 | Not phased | RECRUITING | enrolled 140 Probiotic Intervention on Body Weight Conditions: Obesity, Homeostasis, Weight Loss, Probiotic Intervention https://clinicaltrials.gov/study/NCT06989177 - NCT06982859 | Phase 1 | ACTIVE_NOT_RECRUITING | enrolled 95 A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus Conditions: Diabetes Mellitus, Insulin Sensitivity https://clinicaltrials.gov/study/NCT06982859 - NCT03018028 | Phase 3 | COMPLETED | enrolled 243 Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT03018028 - NCT06221969 | Phase 3 | COMPLETED | enrolled 1024 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT06221969 - NCT06803888 | Phase 4 | ACTIVE_NOT_RECRUITING | enrolled 125 Bariatric Surgery vs. Semaglutide vs. Tirzepatide Conditions: Obesity and Obesity-related Medical Conditions https://clinicaltrials.gov/study/NCT06803888 - NCT04707469 | Phase 3 | COMPLETED | enrolled 1606 Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT04707469 - NCT04012255 | Phase 1 | TERMINATED | enrolled 29 A Research Study to Compare Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity Conditions: Overweight, Obesity https://clinicaltrials.gov/study/NCT04012255 - NCT05670379 | Phase 1 | COMPLETED | enrolled 24 Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant Conditions: Overweight and Obesity, Type2diabetes https://clinicaltrials.gov/study/NCT05670379 - NCT05429593 | Phase 1 | COMPLETED | enrolled 152 A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One Tablet Conditions: Healthy Volunteers https://clinicaltrials.gov/study/NCT05429593 - NCT01720446 | Phase 3 | COMPLETED | enrolled 3297 Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT01720446 - NCT04017832 | Phase 3 | COMPLETED | enrolled 1441 A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT04017832 - NCT06222437 | Phase 1 | WITHDRAWN | enrolled 0 Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy Conditions: Polycystic Ovary Syndrome https://clinicaltrials.gov/study/NCT06222437 - NCT05564117 | Phase 3 | COMPLETED | enrolled 307 Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range Conditions: Overweight, Obesity https://clinicaltrials.gov/study/NCT05564117 - NCT04854083 | Phase 4 | UNKNOWN | enrolled 50 Semaglutide as an Adjunct to Dieting in the Treatment of Type 2 Diabetes Conditions: Type2 Diabetes https://clinicaltrials.gov/study/NCT04854083 - NCT07282613 | Phase 3 | NOT_YET_RECRUITING | enrolled 80 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT07282613 - NCT04016974 | Phase 1 | COMPLETED | enrolled 32 A Research Study of How Oral Semaglutide Tablets Work in Healthy People Who Are Chinese Conditions: Healthy Volunteers, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT04016974 - NCT06403761 | Phase 1 | COMPLETED | enrolled 158 Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT06403761 - NCT06717698 | Phase 2 | RECRUITING | enrolled 465 A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease Conditions: Chronic Kidney Disease https://clinicaltrials.gov/study/NCT06717698 - NCT06363747 | Phase 3 | ACTIVE_NOT_RECRUITING | enrolled 50 The Medically Reproducing Bariatric Surgery (MRB) II Study Conditions: Type 2 Diabetes, Obesity https://clinicaltrials.gov/study/NCT06363747 - NCT05153564 | Phase 1 | COMPLETED | enrolled 27 A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After Menopause Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT05153564 - NCT07221214 | Phase 2 | RECRUITING | enrolled 200 GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV Conditions: HIV, Alcohol, Smoking Cigarette, Cardiovascular Disease Prevention https://clinicaltrials.gov/study/NCT07221214 - NCT04889183 | Phase 3 | COMPLETED | enrolled 125 SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes Conditions: Obesity, Albuminuria https://clinicaltrials.gov/study/NCT04889183 - NCT05119179 | Phase 4 | RECRUITING | enrolled 300 Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes Conditions: PreDiabetes https://clinicaltrials.gov/study/NCT05119179 - NCT06323174 | Phase 3 | COMPLETED | enrolled 189 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT06323174 - NCT06649344 | Phase 3 | COMPLETED | enrolled 884 A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT06649344 - NCT07527195 | Phase 1 | RECRUITING | enrolled 100 Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health) Conditions: Obesity https://clinicaltrials.gov/study/NCT07527195 - NCT06282458 | Phase 2 | COMPLETED | enrolled 168 Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt Conditions: Muscle Loss, Obesity https://clinicaltrials.gov/study/NCT06282458 - NCT05303857 | Phase 4 | COMPLETED | enrolled 107 Analyse the Effect of Semaglutide on Vascular Structure and Function in Patients With Early Type 2 Diabetes Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT05303857 - NCT05144984 | Phase 2 | COMPLETED | enrolled 500 A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT05144984 - NCT07589322 | Not phased | RECRUITING | enrolled 120 Comparative Observation of Metabolic and Pharmacologic Adipose Remodeling With Enhanced Incretin AgonisTs Conditions: Obesity and Metabolic Syndrome https://clinicaltrials.gov/study/NCT07589322 - NCT03357380 | Phase 1 | COMPLETED | enrolled 67 A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the Liver Conditions: Hepatobiliary Disorders, Non-alcoholic Fatty Liver Disease https://clinicaltrials.gov/study/NCT03357380 - NCT05435677 | Phase 1 | COMPLETED | enrolled 20 A Research Study to Look at How Insulin Icodec and Semaglutide Work in the Body of People From China With Type 2 Diabetes When Given Alone or Together Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT05435677 - NCT03638778 | Phase 1 | COMPLETED | enrolled 105 Research Study Comparing Different Tablets With the Study Medicine Semaglutide in Healthy Men Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT03638778 - NCT06972992 | Phase 1 | COMPLETED | enrolled 28 A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With Semaglutide Conditions: Chronic Weight Management https://clinicaltrials.gov/study/NCT06972992 - NCT05996874 | Phase 1 | COMPLETED | enrolled 121 A Research Study Comparing the Effect of Different Dosing Conditions on Blood Levels of Semaglutide in a New Tablet Composition in Healthy Participants Conditions: Healthy Participants https://clinicaltrials.gov/study/NCT05996874 - NCT05606471 | Phase 4 | UNKNOWN | enrolled 45 Glucagon-like Peptide-1 Agonism With Very Low Calorie Diets Conditions: Type 2 Diabetes Mellitus in Obese https://clinicaltrials.gov/study/NCT05606471 - NCT07057310 | Phase 4 | ENROLLING_BY_INVITATION | enrolled 30 Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women Conditions: Obesity, Menopause https://clinicaltrials.gov/study/NCT07057310 - NCT00813020 | Phase 1 | COMPLETED | enrolled 44 A Clinical Trial Investigating the Comparison of Three Different Concentrations of NN9535 in Healthy Male Subjects Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT00813020 - NCT05064735 | Phase 3 | COMPLETED | enrolled 407 Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis Conditions: Obesity https://clinicaltrials.gov/study/NCT05064735 - NCT03598621 | Phase 1 | COMPLETED | enrolled 68 A Research Study to Look at Similarity Between Semaglutide Versions in Different Injection Tools Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT03598621 - NCT05046873 | Phase 1 | COMPLETED | enrolled 16 A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT05046873 - NCT06937060 | Phase 3 | RECRUITING | enrolled 14 Effect of Semaglutide in Patients With Psoriasis and Obesity Conditions: Psoriasis (PsO), Obesity and Overweight https://clinicaltrials.gov/study/NCT06937060 - NCT05340868 | Not phased | RECRUITING | enrolled 1000 Genetics of the Acute Response to Oral Semaglutide Conditions: PreDiabetes, Prediabetic State, Obesity https://clinicaltrials.gov/study/NCT05340868 - NCT07165158 | Phase 4 | NOT_YET_RECRUITING | enrolled 150 The Effect of Semaglutide on Bone Health Conditions: Osteoporosis, Osteoporosis Fracture, T2DM https://clinicaltrials.gov/study/NCT07165158 - NCT04873050 | Phase 4 | RECRUITING | enrolled 102 Treatment to Regress to Normoglycemia in Women with a Recent History of GDM Conditions: Pre Diabetes, Postpartum Disorder https://clinicaltrials.gov/study/NCT04873050 - NCT06571383 | Phase 4 | ACTIVE_NOT_RECRUITING | enrolled 500 STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss Conditions: Obesity https://clinicaltrials.gov/study/NCT06571383 - NCT07563699 | Phase 2 | NOT_YET_RECRUITING | enrolled 24 Safety, Tolerability and Efficacy of Semaglutide Depot in Subjects With Type-2 Diabetes Mellitus Conditions: Diabete Type 2 https://clinicaltrials.gov/study/NCT07563699 - NCT05616052 | Phase 4 | UNKNOWN | enrolled 80 Comparison of Body Weight Change Through Different Smeglutide Administration Methods Conditions: Weight Change, Body https://clinicaltrials.gov/study/NCT05616052 - NCT02172313 | Phase 1 | COMPLETED | enrolled 78 Effect of Food on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects Conditions: Diabetes, Healthy https://clinicaltrials.gov/study/NCT02172313 - NCT07275697 | Phase 4 | NOT_YET_RECRUITING | enrolled 200 Waiting on Atrial Fibrillation Intervention Therapy (WAIT) Study Conditions: Atrial Fibrillation (AF), Obesity & Overweight https://clinicaltrials.gov/study/NCT07275697 - NCT05689099 | Phase 1 | COMPLETED | enrolled 20 A Research Trial Looking at the Comparability of 2 Different Concentrations of Semaglutide for the 0.5 Milligram (mg) Dose Conditions: Diabetes Mellitus, Type 2, Healthy Participants https://clinicaltrials.gov/study/NCT05689099 - NCT06065540 | Phase 3 | COMPLETED | enrolled 2734 A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor Conditions: Type 2 Diabetes Mellitus https://clinicaltrials.gov/study/NCT06065540 - NCT06422624 | Phase 1 | UNKNOWN | enrolled 14 A Study to Evaluate Safety, Tolerability and pK of Semaglutide ER Injectable Suspension in Healthy, Adult Human Subjects Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT06422624 - NCT03987451 | Phase 2 | COMPLETED | enrolled 71 A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage Conditions: Non-alcoholic Steatohepatitis https://clinicaltrials.gov/study/NCT03987451 - NCT06489457 | Phase 3 | COMPLETED | enrolled 25 The Effects of Semaglutide vs Testosterone Replacement Therapy on Functional Hypogonadism and Sperm Quality in Men With Type 2 Diabetes Mellitus and Obesity Conditions: Type 2 Diabetes Mellitus, Obesity, Functional Hypogonadism https://clinicaltrials.gov/study/NCT06489457 - NCT05442450 | Phase 4 | UNKNOWN | enrolled 116 Efficacy of Oral Semaglutide in Overweight or Obesity Conditions: Obesity, Weight Loss https://clinicaltrials.gov/study/NCT05442450 - NCT02054897 | Phase 3 | COMPLETED | enrolled 388 Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT02054897 - NCT06184568 | Phase 3 | COMPLETED | enrolled 349 A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity Conditions: Type 2 Diabetes, Obesity https://clinicaltrials.gov/study/NCT06184568 - NCT04777409 | Phase 3 | COMPLETED | enrolled 1840 A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) Conditions: Early Alzheimer´s Disease https://clinicaltrials.gov/study/NCT04777409 - NCT07225816 | Phase 1 | RECRUITING | enrolled 71 Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) Conditions: Obesity https://clinicaltrials.gov/study/NCT07225816 - NCT07285902 | Phase 3 | ACTIVE_NOT_RECRUITING | enrolled 572 A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity Conditions: Obesity https://clinicaltrials.gov/study/NCT07285902 - NCT04174755 | Not phased | RECRUITING | enrolled 80 Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV Conditions: Obesity, HIV-1-infection https://clinicaltrials.gov/study/NCT04174755 - NCT05035082 | Phase 4 | COMPLETED | enrolled 1020 A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE) Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT05035082 - NCT04788511 | Phase 3 | COMPLETED | enrolled 529 Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity Conditions: Obesity https://clinicaltrials.gov/study/NCT04788511 - NCT04153929 | Phase 2 | COMPLETED | enrolled 413 A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes. Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT04153929 - NCT02249910 | Phase 1 | COMPLETED | enrolled 32 Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Metformin and Digoxin in Healthy Subjects Conditions: Diabetes, Healthy https://clinicaltrials.gov/study/NCT02249910 - NCT06323161 | Phase 3 | COMPLETED | enrolled 274 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT06323161 - NCT07509112 | Phase 2 | NOT_YET_RECRUITING | enrolled 40 Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study Conditions: Methamphetamine Use Disorder https://clinicaltrials.gov/study/NCT07509112 - NCT05305794 | Phase 3 | RECRUITING | enrolled 76 Effect of Weekly GLP1 Agonist Treatment in "Double Diabetes" Conditions: Double Diabetes https://clinicaltrials.gov/study/NCT05305794 - NCT06492330 | Not phased | COMPLETED | enrolled 62 Efficacy and Safety of CS0159 Combined With Semaglutide in MASH Patients With Obesity and T2DM Conditions: Metabolic Dysfunction-Associated Steatohepatitis (MASH), Obesity, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT06492330 - NCT04885634 | Phase 3 | WITHDRAWN | enrolled 0 Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF Patients Conditions: Atrial Fibrillation, Overweight and Obesity https://clinicaltrials.gov/study/NCT04885634 - NCT06577090 | Phase 2 | ACTIVE_NOT_RECRUITING | enrolled 136 Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo Conditions: Obesity https://clinicaltrials.gov/study/NCT06577090 - NCT07090343 | Phase 3 | NOT_YET_RECRUITING | enrolled 826 Semaglutide in Patients Undergoing Transcatether Aortic Valve Replacement Conditions: Aortic Stenosis, Heart Failure https://clinicaltrials.gov/study/NCT07090343 - NCT06605703 | Phase 4 | COMPLETED | enrolled 226 A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial) Conditions: Obesity, Overweight https://clinicaltrials.gov/study/NCT06605703 - NCT05087342 | Phase 3 | COMPLETED | enrolled 119 Latino Semaglutide Study Conditions: Obesity, Obesity; Drug, Overweight or Obesity, Weight Loss, Weight Loss Trajectory, Weight, Body https://clinicaltrials.gov/study/NCT05087342 - NCT07036172 | Phase 3 | RECRUITING | enrolled 460 Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients Conditions: Obesity Control https://clinicaltrials.gov/study/NCT07036172 - NCT06497595 | Not phased | RECRUITING | enrolled 60 Lifestyle Intervention to Reduce the Risk of Sarcopenia in Adults With Diabetes & Obesity Treated With Semaglutide Conditions: Type 2 Diabetes Mellitus in Obese https://clinicaltrials.gov/study/NCT06497595 - NCT07613437 | Phase 2 | NOT_YET_RECRUITING | enrolled 200 GLP-1 Receptor Agonist in Primary Intracerebral Hemorrhage: A Phase 2 Randomized Trial Conditions: Intracerebral Hemorrhage https://clinicaltrials.gov/study/NCT07613437 - NCT02877355 | Phase 1 | COMPLETED | enrolled 55 Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes. Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT02877355 - NCT07295223 | Phase 3 | RECRUITING | enrolled 44 Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial) Conditions: Acute Myocardial Infarction With ST Elevation https://clinicaltrials.gov/study/NCT07295223 - NCT05597202 | Phase 4 | UNKNOWN | enrolled 22 Does the Hematopoietic Stem Cell Govern Residual Inflammatory Cardiovascular Risk in Type 2 Diabetes Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT05597202 - NCT05990374 | Not phased | UNKNOWN | enrolled 100 Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years Conditions: Diabetes https://clinicaltrials.gov/study/NCT05990374 - NCT03611322 | Phase 1 | COMPLETED | enrolled 54 A Trial to Compare Blood Concentration Levels of Semaglutide Following Subcutaneous Injections of Semaglutide 1 mg by 2 Different Devices (the DV3372 Device and by the PDS290 Semaglutide Pen-injector) Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT03611322 - NCT05726227 | Phase 3 | ACTIVE_NOT_RECRUITING | enrolled 210 A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight Conditions: Obesity https://clinicaltrials.gov/study/NCT05726227 - NCT06015893 | Phase 2 | ACTIVE_NOT_RECRUITING | enrolled 63 Semaglutide Therapy for Alcohol Reduction (STAR) Conditions: Addiction, Alcohol Use Disorder https://clinicaltrials.gov/study/NCT06015893 - NCT05950516 | Phase 3 | UNKNOWN | enrolled 478 Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT05950516 - NCT05649137 | Phase 3 | COMPLETED | enrolled 512 A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight Conditions: Obesity, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT05649137 - NCT03574584 | Phase 1 | COMPLETED | enrolled 37 A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese Conditions: Metabolism and Nutrition Disorders, Overweight or Obesity https://clinicaltrials.gov/study/NCT03574584 - NCT02231684 | Phase 1 | COMPLETED | enrolled 42 Investigating the Pharmacokinetics of Subcutaneous Injections With 1 mg/mL, 3 mg/mL, and 10 mg/mL Semaglutide Strengths and the Absolute Bioavailability of Semaglutide Conditions: Diabetes, Healthy https://clinicaltrials.gov/study/NCT02231684 - NCT04383197 | Not phased | UNKNOWN | enrolled 30 Exercise and GLP-1 RA on Insulin Secretion Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT04383197 - NCT06788626 | Phase 3 | NOT_YET_RECRUITING | enrolled 390 Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment Conditions: Acute Ischemic Stroke, Large Vessel Occlusion, Neuroprotective Drugs, Endovascular Treatment https://clinicaltrials.gov/study/NCT06788626 - NCT07046273 | Phase 3 | NOT_YET_RECRUITING | enrolled 496 Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes Conditions: Type 2 Diabetes (T2DM) https://clinicaltrials.gov/study/NCT07046273 - NCT03659682 | Phase 2 | UNKNOWN | enrolled 120 GLP1R in Parkinson's Disease Conditions: Parkinson Disease https://clinicaltrials.gov/study/NCT03659682 - NCT02863328 | Phase 3 | COMPLETED | enrolled 822 Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT02863328 - NCT03884075 | Phase 2 | RECRUITING | enrolled 104 Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES) Conditions: Non-Alcoholic Steatohepatitis, Non-Alcoholic Fatty Liver Disease https://clinicaltrials.gov/study/NCT03884075 - NCT06884293 | Phase 3 | ACTIVE_NOT_RECRUITING | enrolled 479 A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD） Conditions: Overweight, Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) https://clinicaltrials.gov/study/NCT06884293 - NCT02207374 | Phase 3 | COMPLETED | enrolled 601 A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT02207374 - NCT05147896 | Not phased | UNKNOWN | enrolled 100 Semaglutide Anti-Atherosclerotic Mechanisms of Action Study in Type 2 Diabetes Patients Conditions: Diabetes Mellitus, Type 2, Atherosclerosis https://clinicaltrials.gov/study/NCT05147896 - NCT02461589 | Phase 2 | COMPLETED | enrolled 706 Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT02461589 - NCT05574439 | Phase 4 | COMPLETED | enrolled 246 Young Adults With Early-onset Obesity Treated With Semaglutide Conditions: Obesity, Adolescent https://clinicaltrials.gov/study/NCT05574439 - NCT07614412 | Phase 2 | NOT_YET_RECRUITING | enrolled 240 SHIELD-T1D: Shingrix and GLP-1 Agonist for Beta-Cell Preservation in Recent-Onset Type 1 Diabetes. Conditions: Type 1 Diabetes Mellitus https://clinicaltrials.gov/study/NCT07614412 - NCT05249881 | Phase 1 | UNKNOWN | enrolled 300 "Efficacy of Once Weekly GLP 1 Analogue: Semaglutide. A Multicenter Experience From Pakistan." Conditions: Diabetes Mellitus, Type 2, Weight Change, Body https://clinicaltrials.gov/study/NCT05249881 - NCT07511543 | Phase 3 | NOT_YET_RECRUITING | enrolled 826 Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy Conditions: Ischemic Stroke https://clinicaltrials.gov/study/NCT07511543 - NCT06411210 | Phase 2 | RECRUITING | enrolled 54 Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment Conditions: Diabetes type1, Obesity https://clinicaltrials.gov/study/NCT06411210 - NCT05193578 | Phase 2 | COMPLETED | enrolled 154 Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes Conditions: Schizophrenia, Prediabetic State https://clinicaltrials.gov/study/NCT05193578 - NCT03985384 | Phase 4 | COMPLETED | enrolled 140 Semaglutide Treatment On Coronary Progression Conditions: Type 2 Diabetes, Coronary Artery Disease https://clinicaltrials.gov/study/NCT03985384 - NCT02849080 | Phase 3 | COMPLETED | enrolled 504 Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus. Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT02849080 - NCT07374328 | Phase 2 | RECRUITING | enrolled 240 Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT07374328 - NCT06060392 | Not phased | RECRUITING | enrolled 50 Effect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus Conditions: Liver Transplant; Complications, Diabete Mellitus https://clinicaltrials.gov/study/NCT06060392 - NCT05530577 | Phase 2 | COMPLETED | enrolled 24 Effects of Semaglutide on Nicotine Intake Conditions: Tobacco Use Disorder, Nicotine Addiction https://clinicaltrials.gov/study/NCT05530577 - NCT06299098 | Phase 2 | ACTIVE_NOT_RECRUITING | enrolled 1005 A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation Conditions: Obesity https://clinicaltrials.gov/study/NCT06299098 - NCT04822181 | Phase 3 | ACTIVE_NOT_RECRUITING | enrolled 1205 Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) Conditions: Non-alcoholic Steatohepatitis https://clinicaltrials.gov/study/NCT04822181 - NCT05746039 | Phase 2 | RECRUITING | enrolled 8 Feasibility of Semaglutide in Advanced Lung Disease Conditions: Obesity, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, Sarcoidosis, Pulmonary, Pulmonary Hypertension https://clinicaltrials.gov/study/NCT05746039 - NCT04741074 | Phase 3 | TERMINATED | enrolled 15 Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy Conditions: CKD, Diabetic Kidney Disease, Type 2 Diabetes Mellitus in Obese, Obesity, Severe Obesity https://clinicaltrials.gov/study/NCT04741074 - NCT06338553 | Phase 1 | RECRUITING | enrolled 24 GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab Conditions: Type 1 Diabetes https://clinicaltrials.gov/study/NCT06338553 - NCT04777396 | Phase 3 | COMPLETED | enrolled 1840 A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) Conditions: Early Alzheimer's Disease https://clinicaltrials.gov/study/NCT04777396 - NCT04873245 | Phase 2 | COMPLETED | enrolled 120 Lifestyle Counseling and Medication for Adolescent Weight Management Conditions: Obesity, Childhood https://clinicaltrials.gov/study/NCT04873245 - NCT06221696 | Not phased | COMPLETED | enrolled 160 Preventing Weight Regain Post-Semaglutide Treatment With Active Fiber Supplement (Soloways) Conditions: Overweight and Obesity https://clinicaltrials.gov/study/NCT06221696 - NCT05016882 | Phase 2 | COMPLETED | enrolled 698 Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH) Conditions: Non-alcoholic Steatohepatitis https://clinicaltrials.gov/study/NCT05016882 - NCT07139548 | Phase 3 | NOT_YET_RECRUITING | enrolled 600 A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes Conditions: T2DM https://clinicaltrials.gov/study/NCT07139548 - NCT07627191 | Phase 1 | NOT_YET_RECRUITING | enrolled 30 GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer Conditions: Pancreatic Cancer, Colorectal Cancer, Hepatocellular Carcinoma https://clinicaltrials.gov/study/NCT07627191 - NCT06825793 | Not phased | NOT_YET_RECRUITING | enrolled 56 Semaglutide's Weight Loss Effects in Obesity Conditions: Obesity https://clinicaltrials.gov/study/NCT06825793 - NCT06243536 | Phase 4 | UNKNOWN | enrolled 60 The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients Conditions: Type 2 Diabetes, Overweight, Disordered Eating Behaviors https://clinicaltrials.gov/study/NCT06243536 - NCT05669755 | Phase 3 | ACTIVE_NOT_RECRUITING | enrolled 7101 REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels Conditions: Cardiovascular Disease https://clinicaltrials.gov/study/NCT05669755 - NCT02060266 | Phase 1 | COMPLETED | enrolled 7 Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects Conditions: Diabetes, Healthy https://clinicaltrials.gov/study/NCT02060266 - NCT02210871 | Phase 1 | COMPLETED | enrolled 44 Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function Conditions: Diabetes, Diabetes Mellitus, Type 2, Hepatic Impaired https://clinicaltrials.gov/study/NCT02210871 - NCT05877547 | Phase 2 | COMPLETED | enrolled 381 A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013) Conditions: Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, NAFLD, Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis https://clinicaltrials.gov/study/NCT05877547 - NCT06256549 | Phase 2 | UNKNOWN | enrolled 272 A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus Conditions: Type 2 Diabetes https://clinicaltrials.gov/study/NCT06256549 - NCT05013229 | Phase 3 | COMPLETED | enrolled 679 A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3) Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT05013229 - NCT02845219 | Phase 1 | COMPLETED | enrolled 25 A Trial Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug in Healthy Postmenopausal Females Conditions: Diabetes, Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT02845219 - NCT07030621 | Phase 3 | NOT_YET_RECRUITING | enrolled 436 Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial Conditions: Acute Ischemic Stroke https://clinicaltrials.gov/study/NCT07030621 - NCT03574597 | Phase 3 | COMPLETED | enrolled 17604 Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity Conditions: Overweight, Obesity https://clinicaltrials.gov/study/NCT03574597 - NCT07314684 | Phase 4 | RECRUITING | enrolled 80 GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM Conditions: T2DM (Type 2 Diabetes Mellitus) https://clinicaltrials.gov/study/NCT07314684 - NCT07415954 | Phase 2 | RECRUITING | enrolled 270 A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes Conditions: Diabetes Mellitus, Type 2 https://clinicaltrials.gov/study/NCT07415954 - NCT06042153 | Phase 4 | ACTIVE_NOT_RECRUITING | enrolled 43 DIALYSIS-TIR Study Conditions: Type 2 Diabetes, End Stage Renal Disease on Dialysis https://clinicaltrials.gov/study/NCT06042153 - NCT03010475 | Phase 1 | COMPLETED | enrolled 41 A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects Conditions: Diabetes, Healthy https://clinicaltrials.gov/study/NCT03010475 - NCT03552757 | Phase 3 | COMPLETED | enrolled 1210 Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity Conditions: Obesity, Overweight https://clinicaltrials.gov/study/NCT03552757 - NCT02243098 | Phase 1 | COMPLETED | enrolled 31 Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects Conditions: Diabetes, Healthy https://clinicaltrials.gov/study/NCT02243098